BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 780] [Cited by in F6Publishing: 644] [Article Influence: 195.0] [Reference Citation Analysis]
Number Citing Articles
1 Dipasquale V, Deganello Saccomani M, Di Giorgio A, Oliva S, Salvatore S, Strisciuglio C, Tambucci R, Lionetti P, Romano C. Pediatric Gastroenterology and Hepatology in Italy before and after the COVID-19: Lessons learned and management changes by SIGENP. Ital J Pediatr 2023;49:15. [PMID: 36698148 DOI: 10.1186/s13052-023-01418-7] [Reference Citation Analysis]
2 Budzinskaya AA, Belousova EA, Orlova LP, Vakurova ES. Differential diagnosis of inflammatory bowel diseases by endoscopic ultrasound. Almanac of Clinical Medicine 2023;50:400-407. [DOI: 10.18786/2072-0505-2022-50-055] [Reference Citation Analysis]
3 Glyn T, Lightner AL. Inflammatory Bowel Disease and Colorectal Cancer. Digestive Disease Interventions 2023. [DOI: 10.1055/s-0042-1760425] [Reference Citation Analysis]
4 Armuzzi A, Hart A, Cappelleri JC, Mammar N, Hur P, Hoskin B, Hennessy F, Milligan G, Dignass A. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries. BMC Gastroenterol 2023;23:17. [PMID: 36658481 DOI: 10.1186/s12876-023-02640-7] [Reference Citation Analysis]
5 Wu J, Cui S, Tang X, Zhang Q, Jin Y, Zhao J, Mao B, Zhang H. Bifidobacterium longum CCFM1206 Promotes the Biotransformation of Glucoraphanin to Sulforaphane That Contributes to Amelioration of Dextran-Sulfate-Sodium-Induced Colitis in Mice. J Agric Food Chem 2023;71:1100-12. [PMID: 36604158 DOI: 10.1021/acs.jafc.2c07090] [Reference Citation Analysis]
6 Guo J, Wang F, Hu Y, Luo Y, Wei Y, Xu K, Zhang H, Liu H, Bo L, Lv S, Sheng S, Zhuang X, Zhang T, Xu C, Chen X, Su J. Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases. Cell Rep Med 2023;4:100881. [PMID: 36603578 DOI: 10.1016/j.xcrm.2022.100881] [Reference Citation Analysis]
7 Simpson N, Seenan JP, Patel R, Kipgen D. Republished: Acute interstitial nephritis secondary to vedolizumab. Drug Ther Bull 2023:dtb. [PMID: 36649975 DOI: 10.1136/dtb.2022.243568.rep] [Reference Citation Analysis]
8 Ferretti F, Cannatelli R, Maconi G, Ardizzone S. Therapeutic Management of Adults with Inflammatory Bowel Disease and Malignancies: A Clinical Challenge. Cancers (Basel) 2023;15. [PMID: 36672491 DOI: 10.3390/cancers15020542] [Reference Citation Analysis]
9 Caron B, Jairath V, D'Amico F, Al Awadhi S, Dignass A, Hart AL, Kobayashi T, Kotze PG, Magro F, Siegmund B, Paridaens K, Danese S, Peyrin-Biroulet L. International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. Medicina (Kaunas) 2023;59:183. [PMID: 36676807 DOI: 10.3390/medicina59010183] [Reference Citation Analysis]
10 Güney Coşkun M, Kolay E, Basaranoglu M. Telenutrition for the management of inflammatory bowel disease: Benefits, limits, and future perspectives. World J Clin Cases 2023; 11(2): 308-315 [DOI: 10.12998/wjcc.v11.i2.308] [Reference Citation Analysis]
11 Rosiou K, Selinger CP. Obstetric Considerations in Pregnant Women with Crohn's Disease. J Clin Med 2023;12. [PMID: 36675613 DOI: 10.3390/jcm12020684] [Reference Citation Analysis]
12 Nakase H. Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy. Gut Liver 2023;17:49-57. [PMID: 36375793 DOI: 10.5009/gnl220017] [Reference Citation Analysis]
13 Dua A, Corson M, Sauk JS, Jaffe N, Limketkai BN. Impact of malnutrition and nutrition support in hospitalised patients with inflammatory bowel disease. Aliment Pharmacol Ther 2023. [PMID: 36638118 DOI: 10.1111/apt.17389] [Reference Citation Analysis]
14 Mohan LJ, Daly JS, Ryan BM, Ramtoola Z. Oral Infliximab Nanomedicines for Targeted Treatment of Inflammatory Bowel Diseases. Eur J Pharm Sci 2023;:106379. [PMID: 36646154 DOI: 10.1016/j.ejps.2023.106379] [Reference Citation Analysis]
15 Rizzello F, Gionchetti P, Spisni E, Saracino IM, Bellocchio I, Spigarelli R, Collini N, Imbesi V, Dervieux T, Alvisi P, Valerii MC. Dietary Habits and Nutrient Deficiencies in a Cohort of European Crohn's Disease Adult Patients. Int J Mol Sci 2023;24. [PMID: 36675009 DOI: 10.3390/ijms24021494] [Reference Citation Analysis]
16 Ishige T, Shimizu T, Watanabe K, Arai K, Kamei K, Kudo T, Kunisaki R, Tokuhara D, Naganuma M, Mizuochi T, Murashima A, Inoki Y, Iwata N, Iwama I, Koinuma S, Shimizu H, Jimbo K, Takaki Y, Takahashi S, Cho Y, Nambu R, Nishida D, Hagiwara SI, Hikita N, Fujikawa H, Hosoi K, Hosomi S, Mikami Y, Miyoshi J, Yagi R, Yokoyama Y, Hisamatsu T. Expert consensus on vaccination in patients with inflammatory bowel disease in Japan. J Gastroenterol 2023;58:135-57. [PMID: 36629948 DOI: 10.1007/s00535-022-01953-w] [Reference Citation Analysis]
17 Opdam MAA, Vriezekolk JE, Broen J, den Broeder AA, Verhoef LM. Exploring the perspective of patients with immune-mediated inflammatory diseases and care providers on the use of immunomodulatory drugs in infections: an interview study. Rheumatol Adv Pract 2023;7:rkad003. [PMID: 36685994 DOI: 10.1093/rap/rkad003] [Reference Citation Analysis]
18 Ratajczak AE, Festa S, Aratari A, Papi C, Dobrowolska A, Krela-kaźmierczak I. Should the Mediterranean diet be recommended for inflammatory bowel diseases patients? A narrative review. Front Nutr 2023;9. [DOI: 10.3389/fnut.2022.1088693] [Reference Citation Analysis]
19 Seishima R, Okabayashi K, Ikeuchi H, Uchino M, Futami K, Noguchi T, Ohge H, Iseki Y, Watanabe K, Itabashi M, Okamoto K, Toiyama Y, Ogino T, Nakamura M, Yamada K, Wakai T, Sato Y, Kimura H, Takahashi K, Hida K, Kinugasa Y, Ishida F, Okuda J, Daito K, Koyama F, Ueno H, Yamamoto T, Yamamoto S, Hanai T, Maemoto A, Arakaki J, Komori K, Akagi Y, Shida D, Yamaguchi S, Matsuda K, Maeda K, Noake T, Nezu R, Sasaki S, Hasegawa J, Sunami E, Kanemitsu Y, Katsumata K, Uehara K, Kiyomatsu T, Suto T, Kazama S, Yamada T, Goi T, Ishihara S, Ajioka Y, Sugihara K. Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study. Am J Gastroenterol 2023. [PMID: 36622356 DOI: 10.14309/ajg.0000000000002149] [Reference Citation Analysis]
20 Kammermeier J, Lamb CA, Jones KDJ, Anderson CA, Baple EL, Bolton C, Braggins H, Coulter TI, Gilmour KC, Gregory V, Hambleton S, Hartley D, Hawthorne AB, Hearn S, Laurence A, Parkes M, Russell RK, Speight RA, Travis S, Wilson DC, Uhlig HH. Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition. Lancet Gastroenterol Hepatol 2023:S2468-1253(22)00337-5. [PMID: 36634696 DOI: 10.1016/S2468-1253(22)00337-5] [Reference Citation Analysis]
21 Liu Z, Sun J, Yang H, Lin H, Li M, Liu Z, Kurban M, Gao X, Zhang N, Guo Q. Long-term Efficacy of Endoscopic Balloon Dilatation in Patients with Small bowel Strictures Secondary to Crohn’s Disease.. [DOI: 10.21203/rs.3.rs-2441897/v1] [Reference Citation Analysis]
22 Khosravi B, Salehnia A, Pak N, Montazeri SA, Sima AR, Vahedi H, Malekzadeh R, Radmard AR. A Practical Index to Distinguish Backwash Ileitis From Crohn's Terminal Ileitis in MR Enterography. Inflamm Bowel Dis 2023;29:42-50. [PMID: 35259254 DOI: 10.1093/ibd/izac040] [Reference Citation Analysis]
23 Zudeh G, Franca R, Lucafò M, Bonten EJ, Bramuzzo M, Sgarra R, Lagatolla C, Franzin M, Evans WE, Decorti G, Stocco G. PACSIN2 as a modulator of autophagy and mercaptopurine cytotoxicity: mechanisms in lymphoid and intestinal cells. Life Sci Alliance 2023;6. [PMID: 36596605 DOI: 10.26508/lsa.202201610] [Reference Citation Analysis]
24 Ajabnoor SM, Attar A, BinJahlan N, Almutairi N, Bashmail S, Hashim A, Forbes A, Jawa H. Enteral Nutrition Prescription in Children and Adults with Inflammatory Bowel Diseases: Gaps in Current Gastroenterology Practice in Saudi Arabia. Nutrients 2023;15. [PMID: 36615890 DOI: 10.3390/nu15010232] [Reference Citation Analysis]
25 Bjørlykke KH, Jahnsen J, Brynskov J, Molander P, Eberhardson M, Davidsdottir LG, Sipponen T, Hjortswang H, Goll GL, Syversen SW, Langholz E, Jørgensen KK, Steenholdt C. Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia. Scand J Gastroenterol 2023;58:25-33. [PMID: 35996928 DOI: 10.1080/00365521.2022.2108684] [Reference Citation Analysis]
26 Kienle P. Chirurgische Therapieprinzipien, Abszesse und chirurgische Fistelversorgung. Pflege bei chronisch-entzündlichen Darmerkrankungen 2023. [DOI: 10.1007/978-3-662-64938-1_14] [Reference Citation Analysis]
27 Furtado FS, Suarez-weiss KE, Amorim BJ, Clark JW, Picchio M, Harisinghani M, Catalano OA. Gastrointestinal imaging. Clinical PET/MRI 2023. [DOI: 10.1016/b978-0-323-88537-9.00015-5] [Reference Citation Analysis]
28 Khorasaniha R, Olof H, Voisin A, Armstrong K, Wine E, Vasanthan T, Armstrong H. Diversity of fibers in common foods: Key to advancing dietary research. Food Hydrocolloids 2023. [DOI: 10.1016/j.foodhyd.2023.108495] [Reference Citation Analysis]
29 Yamawaka T, Kitamoto H, Nojima M, Kazama T, Wagatsuma K, Ishigami K, Yamamoto S, Honzawa Y, Matsuura M, Seno H, Nakase H. The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection. J Gastroenterol 2023;58:44-52. [PMID: 36287269 DOI: 10.1007/s00535-022-01931-2] [Reference Citation Analysis]
30 Din S, Selinger CP, Black CJ, Ford AC. Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther 2022. [PMID: 36585944 DOI: 10.1111/apt.17379] [Reference Citation Analysis]
31 Wang Y, Zhu X, Liang Y, Li X, Wang Y, Li J. Sishen Wan Treats Ulcerative Colitis in Rats by Regulating Gut Microbiota and Restoring the Treg/Th17 Balance. Evid Based Complement Alternat Med 2022;2022:1432816. [PMID: 36619196 DOI: 10.1155/2022/1432816] [Reference Citation Analysis]
32 Joustra V, Li Yim AYF, Hageman I, Levin E, Adams A, Satsangi J, de Jonge WJ, Henneman P, D'Haens G. Long-term Temporal Stability of Peripheral Blood DNA Methylation Profiles in Patients With Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol 2022:S2352-345X(22)00262-4. [PMID: 36581079 DOI: 10.1016/j.jcmgh.2022.12.011] [Reference Citation Analysis]
33 Saha A, Dreyfuss I, Sarfraz H, Friedman M, Markowitz J. Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. Cancers (Basel) 2022;15. [PMID: 36612082 DOI: 10.3390/cancers15010084] [Reference Citation Analysis]
34 Te Groen M, Derks M, den Broeder N, Peters C, Dijkstra G, de Vries A, Romkens T, Horjus C, de Boer N, de Jong M, Nagtegaal I, Derikx L, Hoentjen F. Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control Study. Clin Gastroenterol Hepatol 2022:S1542-3565(22)01177-6. [PMID: 36572110 DOI: 10.1016/j.cgh.2022.12.010] [Reference Citation Analysis]
35 Barrett R, Barrett R, Lin SX, Culliford D, Fraser S, Edwards CJ. Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset. BMJ Open 2022;12:e051936. [PMID: 36564115 DOI: 10.1136/bmjopen-2021-051936] [Reference Citation Analysis]
36 Echarri A, Pérez-calle JL, Calvo M, Molina G, Sierra-ausín M, Morete-pérez MC, Manceñido N, Botella B, Cano N, Castro B, Martín-rodríguez D, Sánchez-ortega Y, Corsino P, Cañas M, López-calleja AM, Nos P, Muñiz J, on behalf of the G-Educainflamatoria—GETECCU Group. Should Inflammatory Bowel Disease Clinicians Provide Their Patients with e-Health Resources? Patients' and Professionals' Perspectives. Telemedicine and e-Health 2022. [DOI: 10.1089/tmj.2022.0425] [Reference Citation Analysis]
37 Ayeni AA, Waterland P, Evans M, Singhal S, Patel RK, Akingboye A. Case Report: Multiple colorectal cancers in a patient with Ulcerative colitis and Lynch syndrome: Is there a role for prophylactic colectomy? A short report and review of literature. Front Oncol 2022;12:1031606. [PMID: 36620534 DOI: 10.3389/fonc.2022.1031606] [Reference Citation Analysis]
38 Haskey N, Shim RCK, Davidson-Hunt A, Ye J, Singh S, Dieleman LA, Jacobson K, Ghosh S, Gibson DL. Dietary adherence to the Mediterranean diet pattern in a randomized clinical trial of patients with quiescent ulcerative colitis. Front Nutr 2022;9:1080156. [PMID: 36618690 DOI: 10.3389/fnut.2022.1080156] [Reference Citation Analysis]
39 Shah R, Kelley J, Amundsen T, Coggins K, Edwards A, Johnson CM. Medical and social determinants of health as predictors of adverse outcomes in patients with inflammatory bowel disease. Baylor University Medical Center Proceedings 2022. [DOI: 10.1080/08998280.2022.2156025] [Reference Citation Analysis]
40 Akbulut S. An assessment of serum vitamin B12 and folate in patients with Crohn's disease. Medicine (Baltimore) 2022;101:e31892. [PMID: 36550821 DOI: 10.1097/MD.0000000000031892] [Reference Citation Analysis]
41 Vidhya CS, Loganathan M, Bhuvana S, Baskaran N, Meenatchi R. Evaluation of Phytochemicals and Anticancer Potential of <i>C. maxima</i>: An <i>In-silico</i> Molecular Docking Approach. JNR 2022. [DOI: 10.18311/jnr/2022/29923] [Reference Citation Analysis]
42 Hanrahan TP, Chan R, Tassone D, Ding NS, Basnayake C, Schulberg J, Vasudevan A, Kamm M, De Gregorio M, van Langenberg DR, Niewiadomski O. Persistence of Second and Third-Line Biologics in Inflammatory Bowel Disease: A Multi-Centre Cohort Study. Future Pharmacology 2022;2:669-680. [DOI: 10.3390/futurepharmacol2040041] [Reference Citation Analysis]
43 Barcina Lacosta T, Vulto AG, Huys I, Simoens S. Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis. Front Pharmacol 2022;13:1031910. [PMID: 36588696 DOI: 10.3389/fphar.2022.1031910] [Reference Citation Analysis]
44 Burger A, Baldock R, Adams DJ, Din S, Papatheodorou I, Glinka M, Hill B, Houghton D, Sharghi M, Wicks M, Arends MJ. Towards a Clinically-based Common Coordinate Framework for the Human Gut Cell Atlas - The Gut Models.. [DOI: 10.1101/2022.12.08.519665] [Reference Citation Analysis]
45 Karachaliou A, Yannakoulia M, Bletsa M, Mantzaris GJ, Archavlis E, Karampekos G, Tzouvala M, Bamias G, Kokkotis G, Kontogianni MD. Assessment of Dietary Adequacy and Quality in a Sample of Patients with Crohn's Disease. Nutrients 2022;14. [PMID: 36558412 DOI: 10.3390/nu14245254] [Reference Citation Analysis]
46 Chen SL, Faye AS, Chang S. Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment. Curr Treat Options Gastro 2022;20:564-581. [DOI: 10.1007/s11938-022-00405-x] [Reference Citation Analysis]
47 Zhou W, Zhan L, Xu H, Zhang L. Structural Alteration of Gut Microbiota During the Amelioration of Chronic Psychological Stress-Aggravated Diabetes-Associated Cognitive Decline by a Traditional Chinese Herbal Formula, ZiBu PiYin Recipe. J Alzheimers Dis 2022;90:1465-83. [PMID: 36278351 DOI: 10.3233/JAD-220692] [Reference Citation Analysis]
48 Pellino G, Rottoli M, Mineccia M, Frontali A, Celentano V, Colombo F, Baldi C, Ardizzone S, Martí Gallostra M, Espín-Basany E, Ferrero A, Panis Y, Poggioli G, Sampietro GM. Segmental Versus Total Colectomy for Crohn's Disease in the Biologic Era: Results From The SCOTCH International, Multicentric Study. J Crohns Colitis 2022;16:1853-61. [PMID: 35819368 DOI: 10.1093/ecco-jcc/jjac096] [Reference Citation Analysis]
49 Desai DC, Dherai AJ, Strik A, Mould DR. Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring. J Clin Pharmacol 2022. [PMID: 36458468 DOI: 10.1002/jcph.2189] [Reference Citation Analysis]
50 Han H, Liu L, Zhang J, Zhang M, Chen X, Huang Y, Ma W, Qin H, Shen L, Zhang J, Yang W. New Lactobacillus plantarum membrane proteins (LpMPs) towards oral anti-inflammatory agents against dextran sulfate sodium-induced colitis. International Immunopharmacology 2022;113:109416. [DOI: 10.1016/j.intimp.2022.109416] [Reference Citation Analysis]
51 Lian MQ, Chng WH, Liang J, Yeo HQ, Lee CK, Belaid M, Tollemeto M, Wacker MG, Czarny B, Pastorin G. Plant-derived extracellular vesicles: Recent advancements and current challenges on their use for biomedical applications. J Extracell Vesicles 2022;11:e12283. [PMID: 36519808 DOI: 10.1002/jev2.12283] [Reference Citation Analysis]
52 Adolph TE, Zhang J. Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts. Gut 2022;71:2574-86. [PMID: 36113981 DOI: 10.1136/gutjnl-2021-326575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Dawson R, Wands DIF, Logan M, Bremner G, Efklides S, Benn L, Henderson P, Grant H, Meredith J, Armstrong K, Wilson DC, Gerasimidis K, Alex G, Russell RK. Comparing Effectiveness of a Generic Oral Nutritional Supplement With Specialized Formula in the Treatment of Active Pediatric Crohn's Disease. Inflamm Bowel Dis 2022;28:1859-64. [PMID: 35259266 DOI: 10.1093/ibd/izac039] [Reference Citation Analysis]
54 Janoušek J, Pilařová V, Macáková K, Nomura A, Veiga-Matos J, Silva DDD, Remião F, Saso L, Malá-Ládová K, Malý J, Nováková L, Mladěnka P. Vitamin D: sources, physiological role, biokinetics, deficiency, therapeutic use, toxicity, and overview of analytical methods for detection of vitamin D and its metabolites. Crit Rev Clin Lab Sci 2022;59:517-54. [PMID: 35575431 DOI: 10.1080/10408363.2022.2070595] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
55 Ding N, Zhao L, Zhu L, Sun W, Li D, Li J, Zhang J, Zhang S. Management of biologics in pregnant, lactating patients with inflammatory bowel disease and the impact on neonatal vaccination: A systematic review of clinical practice guidelines and consensus statements. J Clin Pharm Ther 2022;47:1952-65. [PMID: 36452989 DOI: 10.1111/jcpt.13817] [Reference Citation Analysis]
56 Ben-Horin S, Har-Noy O, Katsanos KH, Roblin X, Chen M, Gao X, Schwartz D, Cheon JH, Cesarini M, Bojic D, Protic M, Theodoropoulou A, Abu-Kaf H, Engel T, Tang J, Veyrard P, Lin X, Mao R, Christodoulou D, Karmiris K, Knezevic-Ivanovski T; ComboMesa investigators. Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial. Clin Gastroenterol Hepatol 2022;20:2868-2875.e1. [PMID: 35272029 DOI: 10.1016/j.cgh.2022.02.055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Dohos D, Farkas N, Váradi A, Erőss B, Párniczky A, Szentesi A, Hegyi P, Sarlós P; Hungarian Pancreatic Study Group. Inflammatory bowel disease does not alter the clinical features and the management of acute pancreatitis: A prospective, multicentre, exact-matched cohort analysis. Pancreatology 2022;22:1071-8. [PMID: 36202731 DOI: 10.1016/j.pan.2022.09.241] [Reference Citation Analysis]
58 Agrawal M, Allin KH, Iversen AT, Mehandru S, Colombel JF, Jess T. Early-Life Mebendazole Exposure Increases the Risk of Adult-Onset Ulcerative Colitis: A Population-Based Cohort Study. Am J Gastroenterol 2022;117:2025-32. [PMID: 36040420 DOI: 10.14309/ajg.0000000000001933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Kim HS, Hernaez R, Sansgiry S, Waljee AK, Scott FI, Lewis JD, El-Serag HB, Hou JK. Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2022;20:2848-2857.e2. [PMID: 35240331 DOI: 10.1016/j.cgh.2022.02.048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Bartoška P, Paluch Z. Treatment of Crohn's disease. Gazz Med Ital - Arch Sci Med 2022;181. [DOI: 10.23736/s0393-3660.22.04819-7] [Reference Citation Analysis]
61 Rusiñol L, Camiña-Conforto G, Puig L. Biologic treatment of psoriasis in oncologic patients. Expert Opin Biol Ther 2022;22:1567-78. [PMID: 36422998 DOI: 10.1080/14712598.2022.2152322] [Reference Citation Analysis]
62 Fairbrass KM, Guthrie EA, Black CJ, Selinger CP, Gracie DJ, Ford AC. Characteristics and Effect of Anxiety and Depression Trajectories in Inflammatory Bowel Disease. Am J Gastroenterol 2022. [PMID: 36227779 DOI: 10.14309/ajg.0000000000002063] [Reference Citation Analysis]
63 Kennel KB, Burmeister J, Radhakrishnan P, Giese NA, Giese T, Salfenmoser M, Gebhardt JM, Strowitzki MJ, Taylor CT, Wielockx B, Schneider M, Harnoss JM. The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancer. JCI Insight 2022;7:e153337. [PMID: 36509284 DOI: 10.1172/jci.insight.153337] [Reference Citation Analysis]
64 Thapaliya G, Eldeghaidy S, Asghar M, Mcging J, Radford S, Francis S, Moran GW. The relationship between Central Nervous System morphometry changes and key symptoms in Crohn’s disease. Brain Imaging and Behavior 2022. [DOI: 10.1007/s11682-022-00742-6] [Reference Citation Analysis]
65 Wang H, Hu Y, Chen F, Shen M. Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis. BMC Pregnancy Childbirth 2022;22:854. [DOI: 10.1186/s12884-022-05191-z] [Reference Citation Analysis]
66 Hanzel J, Drobne D. Contemporary Management of Postoperative Crohn's Disease after Ileocolonic Resection. J Clin Med 2022;11. [PMID: 36431223 DOI: 10.3390/jcm11226746] [Reference Citation Analysis]
67 Ahmed M, Oyibo ST, Dalvi S, Cowell R. Hydrocortisone-induced symptomatic sinus bradycardia. BMJ Case Rep 2022;15:e252878. [PMID: 36375852 DOI: 10.1136/bcr-2022-252878] [Reference Citation Analysis]
68 Regueiro M, Hunter T, Lukanova R, Shan M, Wild R, Knight H, Bannikoppa P, Naegeli AN. Burden of Fatigue Among Patients with Ulcerative Colitis and Crohn’s Disease: Results from a Global Survey of Patients and Gastroenterologists. Adv Ther 2022. [DOI: 10.1007/s12325-022-02364-2] [Reference Citation Analysis]
69 Di Rosa C, Altomare A, Imperia E, Spiezia C, Khazrai YM, Guarino MPL. The Role of Dietary Fibers in the Management of IBD Symptoms. Nutrients 2022;14. [PMID: 36432460 DOI: 10.3390/nu14224775] [Reference Citation Analysis]
70 Quera R, Núñez P, Sicilia B, Flores L, Gomollón F. Corticosteroids in inflammatory bowel disease: Are they still a therapeutic option? Gastroenterol Hepatol 2022:S0210-5705(22)00263-1. [PMID: 36375697 DOI: 10.1016/j.gastrohep.2022.10.017] [Reference Citation Analysis]
71 Wang JS, Liu JC. Intestinal microbiota in the treatment of metabolically associated fatty liver disease. World J Clin Cases 2022; 10(31): 11240-11251 [DOI: 10.12998/wjcc.v10.i31.11240] [Reference Citation Analysis]
72 Zambrano-sánchez R, Alvarez-mena P, Hidalgo D, Liquitay CME, Franco JVA, Vernooij RWM, Simancas-racines D, Viteri-garcía A, Montesinos-guevara C. Quality assessment of Clinical Practice Guidelines (CPG) for the diagnosis and treatment of inflammatory bowel disease using the AGREE II instrument: a systematic review. BMC Gastroenterol 2022;22:447. [DOI: 10.1186/s12876-022-02539-9] [Reference Citation Analysis]
73 Yoo HK, Byun HG, Caprioli F, Fumery M, Peyrin-biroulet L, Sreedhar S, Potter J, Jang M. Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. BMC Health Serv Res 2022;22:1319. [DOI: 10.1186/s12913-022-08683-y] [Reference Citation Analysis]
74 Na SY, Moon W. Recent advances in surveillance colonoscopy for dysplasia in inflammatory bowel disease. Clin Endosc 2022;55:726-35. [PMID: 36397275 DOI: 10.5946/ce.2022.132] [Reference Citation Analysis]
75 Yamamoto H, Yano T, Araki A, Esaki M, Ohtsuka K, Ohmiya N, Oka S, Nakase H, Bamba S, Hirai F, Hosoe N, Matsuda T, Mitsui K, Watanabe K, Ogata H, Katsuki S, Matsumoto T, Fujishiro M, Fujimoto K, Inoue H. Guidelines for endoscopic balloon dilation in treating Crohn's disease-associated small intestinal strictures (supplement to the Clinical Practice Guidelines for Enteroscopy). Dig Endosc 2022;34:1278-96. [PMID: 36073310 DOI: 10.1111/den.14429] [Reference Citation Analysis]
76 Goetgebuer RL, van der Woude CJ, Bakker L, van der Eijk AA, de Ridder L, de Vries AC. The diagnosis and management of CMV colitis in IBD patients shows high practice variation: a national survey among gastroenterologists. Scand J Gastroenterol 2022;57:1321-6. [PMID: 35771203 DOI: 10.1080/00365521.2022.2088244] [Reference Citation Analysis]
77 Vuyyuru SK, Kedia S, Ahuja V. Considerations when starting patients on multiple biologics and small molecules. Curr Opin Gastroenterol 2022;38:562-9. [PMID: 36165042 DOI: 10.1097/MOG.0000000000000886] [Reference Citation Analysis]
78 Huang C, Zhao Q, Zhou X, Huang R, Duan Y, Haybaeck J, Yang Z. The progress of protein synthesis factors eIFs, eEFs and eRFs in inflammatory bowel disease and colorectal cancer pathogenesis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.898966] [Reference Citation Analysis]
79 West J, Stilwell P, Liu H, Ban L, Bythell M, Card TR, Lanyon P, Nanduri V, Rankin J, Bishton MJ, Crooks CJ. Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003-2018. Hemasphere 2022;6:e797. [PMID: 36340911 DOI: 10.1097/HS9.0000000000000797] [Reference Citation Analysis]
80 Kandel R, Merlano M, Tan P, Brar G, Mallick R, Macdonald B, Dubé C, Murthy S, Stiell I, Mccurdy JD. Persistently High Rates of Abdominal Computed Tomography Imaging Among Patients With Inflammatory Bowel Disease Who Present to the Emergency Department. Journal of the Canadian Association of Gastroenterology 2022. [DOI: 10.1093/jcag/gwac029] [Reference Citation Analysis]
81 Magrì S, Demurtas M, Onidi MF, Picchio M, Elisei W, Marzo M, Miculan F, Manca R, Dore MP, Quarta Colosso BM, Cicu A, Cugia L, Carta M, Binaghi L, Usai P, Lai M, Chicco F, Fantini MC, Armuzzi A, Mocci G. Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study. World J Clin Cases 2022; 10(30): 10921-10930 [DOI: 10.12998/wjcc.v10.i30.10921] [Reference Citation Analysis]
82 Yang M, Zhang Q, Taha R, Abdelmotalab MI, Wen Q, Yuan Y, Zhao Y, Li Q, Liao C, Huang X, Jiang Z, Chu C, Jiao C, Sun L. Polysaccharide from Atractylodes macrocephala Koidz. ameliorates DSS-induced colitis in mice by regulating the Th17/Treg cell balance. Front Immunol 2022;13:1021695. [DOI: 10.3389/fimmu.2022.1021695] [Reference Citation Analysis]
83 Blunck D, Kastner L, Nissen M, Winkler J. The Effectiveness of Patient Training in Inflammatory Bowel Disease Knowledge via Instagram: Randomized Controlled Trial. J Med Internet Res 2022;24:e36767. [PMID: 36260385 DOI: 10.2196/36767] [Reference Citation Analysis]
84 Shiga H, Takahashi T, Shiraki M, Kojima Y, Tsuji T, Takagi S, Hiramoto K, Yokoyama N, Sugimura M, Iwabuchi M, Endo K, Onodera M, Sato Y, Shimodaira Y, Nomura E, Kikuchi T, Chiba H, Oomori S, Kudo H, Kumada K, Nagaie S, Ogishima S, Nagami F, Shimoyama Y, Moroi R, Kuroha M, Kakuta Y, Ishige T, Kinouchi Y, Masamune A. Reduced antiviral seropositivity among patients with inflammatory bowel disease treated with immunosuppressive agents. Scand J Gastroenterol 2022;:1-8. [PMID: 36222610 DOI: 10.1080/00365521.2022.2132831] [Reference Citation Analysis]
85 Bikbavova GR, Livzan MA, Fedorin MM. Risk factors for colorectal cancer in IBD patients. jour 2022. [DOI: 10.31146/1682-8658-ecg-205-9-140-146] [Reference Citation Analysis]
86 Shapina MV. Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-15-90-97] [Reference Citation Analysis]
87 Albayrak B, Sebin E. A novel inflammatory indicator in extensive ulcerative colitis; Endocan?. [DOI: 10.21203/rs.3.rs-2101979/v1] [Reference Citation Analysis]
88 Christensen IE, Jyssum I, Tveter AT, Sexton J, Tran TT, Mjaaland S, Kro GB, Kvien TK, Warren DJ, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Grødeland G, Lund-Johansen F, Jørgensen KK, Syversen SW, Goll GL, Provan SA. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study. BMC Med 2022;20:378. [PMID: 36199139 DOI: 10.1186/s12916-022-02587-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Kjeldsen S, Nielsen J, Mertz Nørgård B, Kjeldsen J. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data. Inflamm Bowel Dis 2022;28:1513-9. [PMID: 34849917 DOI: 10.1093/ibd/izab299] [Reference Citation Analysis]
90 Ziv Y, Swaminath A, Sultan K. Patient With Ulcerative Colitis and Failure of Ustekinumab Responds to Risankizumab: Similar Is Not Identical. Inflamm Bowel Dis 2022;28:e140-1. [PMID: 35416978 DOI: 10.1093/ibd/izac072] [Reference Citation Analysis]
91 Kumar S, Plumb A, Mallett S, Bhatnagar G, Bloom S, Clarke CS, Hamlin J, Hart AL, Jacobs I, Travis S, Vega R, Halligan S, Taylor SA. METRIC-EF: magnetic resonance enterography to predict disabling disease in newly diagnosed Crohn's disease-protocol for a multicentre, non-randomised, single-arm, prospective study. BMJ Open 2022;12:e067265. [PMID: 36192092 DOI: 10.1136/bmjopen-2022-067265] [Reference Citation Analysis]
92 Ludlow H. Shaping inflammatory bowel disease care through patient choice and joint decision-making. Gastrointestinal Nursing 2022;20:20-27. [DOI: 10.12968/gasn.2022.20.8.20] [Reference Citation Analysis]
93 Sriranganathan D, Vinci D, Pellino G, Segal JP. Ileoanal pouch cancers in ulcerative colitis and familial adenomatous polyposis: A systematic review and meta-analysis. Dig Liver Dis 2022;54:1328-34. [PMID: 35817683 DOI: 10.1016/j.dld.2022.06.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Coates E, Wickramasekera N, Barr A, Shackley P, Lee M, Hind D, Probert C, Sebastian S, Totton N, Blackwell S, Bedford H, Dames N, Lobo A. Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study. Health Technol Assess 2022;26:1-118. [DOI: 10.3310/rhxr5192] [Reference Citation Analysis]
95 Fitzpatrick JA, Melton SL, Yao CK, Gibson PR, Halmos EP. Dietary management of adults with IBD - the emerging role of dietary therapy. Nat Rev Gastroenterol Hepatol 2022;19:652-69. [PMID: 35577903 DOI: 10.1038/s41575-022-00619-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
96 Lightner AL, Mathis KL. Surgery in Pregnancy. Am J Gastroenterol 2022;117:53-9. [PMID: 36194034 DOI: 10.14309/ajg.0000000000001961] [Reference Citation Analysis]
97 Wu H, Zhang Y, Shao X, Wu X. CT-based body composition parameters predict the loss of response to infliximab in patients with Crohn’s disease.. [DOI: 10.21203/rs.3.rs-2096551/v1] [Reference Citation Analysis]
98 Démaris A, Widigson ESK, Ilvemark JFKF, Steenholdt C, Seidelin JB, Huisinga W, Michelet R, Aulin LBS, Kloft C. Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review. Pharmaceutics 2022;14:2095. [PMID: 36297530 DOI: 10.3390/pharmaceutics14102095] [Reference Citation Analysis]
99 Adams A, Gupta V, Mohsen W, Chapman TP, Subhaharan D, Kakkadasam Ramaswamy P, Kumar S, Kedia S, McGregor CG, Ambrose T, George BD, Palmer R, Brain O, Walsh A, Ahuja V, Travis SPL, Satsangi J. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut 2022:gutjnl-2022-327533. [PMID: 36171080 DOI: 10.1136/gutjnl-2022-327533] [Reference Citation Analysis]
100 Burdge G, Hardman A, Carbery I, Broglio G, Greer D, Selinger CP. Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations. JCM 2022;11:5669. [DOI: 10.3390/jcm11195669] [Reference Citation Analysis]
101 Wang H, Hu Y, Chen F, Shen M. Comparative safety of infliximab and adalimumab on pregnancy outcomes of Women with Inflammatory Bowel Diseases: A Systematic Review &amp; Meta-Analysis.. [DOI: 10.21203/rs.3.rs-2067249/v1] [Reference Citation Analysis]
102 Winters C, Subramanian V, Valdastri P. Robotic, self-propelled, self-steerable, and disposable colonoscopes: Reality or pipe dream? A state of the art review. World J Gastroenterol 2022; 28(35): 5093-5110 [DOI: 10.3748/wjg.v28.i35.5093] [Reference Citation Analysis]
103 Wang Z, Wang X, Zhao X, Hu Z, Sun D, Wu D, Xing Y. Causal relationship between bipolar disorder and inflammatory bowel disease: A bidirectional two-sample mendelian randomization study. Front Genet 2022;13:970933. [DOI: 10.3389/fgene.2022.970933] [Reference Citation Analysis]
104 Bianchi R, Mamadou-pathé B, von Känel R, Roth R, Schreiner P, Rossel J, Burk S, Dora B, Kloth P, Rickenbacher A, Turina M, Greuter T, Misselwitz B, Scharl M, Rogler G, Biedermann L, on behalf of the or the Swiss IBD cohort study. Effect of closed and permanent stoma on disease course, psychological well-being and working capacity in Swiss IBD cohort study patients. PLoS ONE 2022;17:e0274665. [DOI: 10.1371/journal.pone.0274665] [Reference Citation Analysis]
105 Li X, Zhong Y, Yuan C, Lin J, Shen X, Guo M, Lu B, Meng J, Wang Y, Zhang N, Luo Z, Hu G, Mao R, Chen M, Sun C, Li Z, Cao Q, Chen B, Chen Z, Huang B, Feng S. Identifying patients with Crohn's disease at high risk of primary nonresponse to infliximab using a radiomic‐clinical model. Int J of Intelligent Sys. [DOI: 10.1002/int.23066] [Reference Citation Analysis]
106 Joustra VW, Li Yim AYF, de Bruyn JR, Duijvestein M, Hageman IL, de Jonge WJ, Henneman P, Wildenberg M, D'Haens G. Peripheral Blood DNA Methylation Profiles Do Not Predict Endoscopic Post-Operative Recurrence in Crohn's Disease Patients. Int J Mol Sci 2022;23:10467. [PMID: 36142381 DOI: 10.3390/ijms231810467] [Reference Citation Analysis]
107 Ali S, Paul S, Yakkali S, Teresa Selvin S, Thomas S, Bikeyeva V, Abdullah A, Radivojevic A, Abu Jad AA, Ravanavena A, Ravindra C, Igweonu-nwakile EO, Hamid P. Glucocorticoids-Induced Neuropsychiatric Disorders in Patients With Inflammatory Bowel Disease: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.28981] [Reference Citation Analysis]
108 Gao J, Li L, Zhao D, Wang X, Xia Y, Li B, Liu C, Zuo X. Tilapia skin peptides, a by-product of fish processing, ameliorate DSS-induced colitis by regulating inflammation and inhibiting apoptosis. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.988758] [Reference Citation Analysis]
109 Zhang Y, Liu J, Han X, Jiang H, Zhang L, Hu J, Shi L, Li J. Long-term trends in the burden of inflammatory bowel disease in China over three decades: A joinpoint regression and age-period-cohort analysis based on GBD 2019. Front Public Health 2022;10:994619. [PMID: 36159285 DOI: 10.3389/fpubh.2022.994619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Bertani L. Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices. JCM 2022;11:5267. [DOI: 10.3390/jcm11185267] [Reference Citation Analysis]
111 Aldiabat M, Aljabiri Y, Kilani Y, Yusuf MH, Al-khateeb MH, Horoub A, Farukhuddin F, Mahfouz R, Obeidat AE. The Impact of Inflammatory Bowel Disease on Mortality and Other Outcomes of Hospitalized Patients With Diabetic Ketoacidosis: An Observational Study of the United States National Inpatient Sample. Cureus 2022. [DOI: 10.7759/cureus.28697] [Reference Citation Analysis]
112 Lovinfosse P, Hustinx R. The role of PET imaging in inflammatory bowel diseases: state-of-the-art review. Q J Nucl Med Mol Imaging 2022;66. [DOI: 10.23736/s1824-4785.22.03467-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Chen B, Collen LV, Mowat C, Isaacs KL, Singh S, Kane SV, Loftus EV Jr, Farraye FA, Snapper S, Jneid H, Lavie CJ, Krittanawong C. Inflammatory bowel disease and cardiovascular diseases. Am J Med 2022:S0002-9343(22)00633-7. [PMID: 36058305 DOI: 10.1016/j.amjmed.2022.08.012] [Reference Citation Analysis]
114 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 2022;77:761-806. [PMID: 35738507 DOI: 10.1016/j.jhep.2022.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
115 Amiot A, Laharie D, Malamut G, Serrero M, Poullenot F; educational committee of the GETAID. Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID. Dig Liver Dis 2022;54:1162-7. [PMID: 35842365 DOI: 10.1016/j.dld.2022.06.020] [Reference Citation Analysis]
116 Ohnishi Y, Okada S, Kawakami-Miyake A, Furuta T, Fukano R, Yasudo H, Shimokawa M, Hasegawa S. Safety and Feasibility of Infliximab Therapy in Children With Kawasaki Disease Who Received Live Vaccinations. Pediatr Infect Dis J 2022;41:e388-92. [PMID: 35895884 DOI: 10.1097/INF.0000000000003611] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Masuda M, Fukata N, Sano Y, Nishimon S, Aoi M, Tomiyama T, Fukui T, Omiya M, Okazaki K, Naganuma M. Analysis of the initial dose and reduction rate of corticosteroid for ulcerative colitis in clinical practice. JGH Open 2022;6:612-620. [DOI: 10.1002/jgh3.12796] [Reference Citation Analysis]
118 Haydek JP, Scott FI. Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with IBD. Aliment Pharmacol Ther 2022;56:896-7. [PMID: 35934853 DOI: 10.1111/apt.17137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Chen S, Ji G, Liu X, Yang M, Zhang Y, Cao J, Pan Y. Efficacy of integrated traditional Chinese and Western medicine on ulcerative colitis: A systematic review and meta-analysis. Pharmacological Research - Modern Chinese Medicine 2022;4:100145. [DOI: 10.1016/j.prmcm.2022.100145] [Reference Citation Analysis]
120 Westberg K, Olén O, Söderling J, Bengtsson J, Ludvigsson JF, Everhov ÅH, Myrelid P, Nordenvall C. Primary Versus Staged Reconstruction and Risk of Surgical Failure in Patients With Ulcerative Colitis: a Nation-wide Cohort Study. Inflamm Bowel Dis 2022;28:1301-8. [PMID: 34792582 DOI: 10.1093/ibd/izab263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Alexander JL, Ibraheim H, Richards C, Shum B, Pavlidis P, Hunter N, Teare JP, Wotherspoon A, Furness A, Turajlic S, Pickering L, Larkin J, Speight A, Papa S, Powell N. Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis. J Immunother Cancer 2022;10:e005490. [PMID: 36113896 DOI: 10.1136/jitc-2022-005490] [Reference Citation Analysis]
122 Lee E, Lee S, Adam GO, Yoo Y, Shin H, Ahn D, Jang T, Oh B, Park B, Kim I, Lee SH, Lee JH, Tae H. Anti-Inflammatory Effects of Aralia elata Extract Against Dextran Sodium Sulfate-Induced Colitis in Mice and Raw 264.7 Macrophage Cells Exposed to Lipopolysaccharide: First Report. Natural Product Communications 2022;17:1934578X2211260. [DOI: 10.1177/1934578x221126047] [Reference Citation Analysis]
123 Shao M, Yan Y, Zhu F, Yang X, Qi Q, Yang F, Hao T, Lin Z, He P, Zhou Y, Tang W, He S, Zuo J. Artemisinin analog SM934 alleviates epithelial barrier dysfunction via inhibiting apoptosis and caspase-1-mediated pyroptosis in experimental colitis. Front Pharmacol 2022;13:849014. [DOI: 10.3389/fphar.2022.849014] [Reference Citation Analysis]
124 Marabotto E, Kayali S, Buccilli S, Levo F, Bodini G, Giannini EG, Savarino V, Savarino EV. Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review. Cancers 2022;14:4254. [DOI: 10.3390/cancers14174254] [Reference Citation Analysis]
125 Tucker L, Allen A, Chandler D, Ciurtin C, Dick A, Foulkes A, Gullick N, Helliwell P, Jadon D, Jones G, Kyle S, Madhok V, McHugh N, Parkinson A, Raine T, Siebert S, Smith C, Tillett W, Coates LC. The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology (Oxford) 2022;61:e255-66. [PMID: 35640657 DOI: 10.1093/rheumatology/keac295] [Reference Citation Analysis]
126 Li Q, Sun X, Yu K, Lv J, Miao C, Yang J, Wang S, Fu Z, Sun Y, Zhang H, Zhang ZS, Keller ET, Yao Z, Wang Q. Enterobacter ludwigii protects DSS-induced colitis through choline-mediated immune tolerance. Cell Rep 2022;40:111308. [PMID: 36044853 DOI: 10.1016/j.celrep.2022.111308] [Reference Citation Analysis]
127 Mo J, Ni J, Zhang M, Xu Y, Li Y, Karim N, Chen W. Mulberry Anthocyanins Ameliorate DSS-Induced Ulcerative Colitis by Improving Intestinal Barrier Function and Modulating Gut Microbiota. Antioxidants 2022;11:1674. [DOI: 10.3390/antiox11091674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Matias JN, Lima VM, Nutels GS, Laurindo LF, Barbalho SM, de Alvares Goulart R, Araújo AC, Suzuki RB, Guiguer EL. The use of vitamin D for patients with inflammatory bowel diseases. Int J Vitam Nutr Res 2022. [PMID: 36017738 DOI: 10.1024/0300-9831/a000764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Pu D, Liu L, Wang N, Wang D, Zhang Z, Feng B. Case report: Single-cell mapping of peripheral blood mononuclear cells from a patient with both Crohn’s disease and isolated congenital asplenia. Front Immunol 2022;13:959281. [DOI: 10.3389/fimmu.2022.959281] [Reference Citation Analysis]
130 Hu M, Lian W, Wang F, Yang C, Huang W, Yang J, Chen I, Yang M. Presume Why Probiotics May Not Provide Protection in Inflammatory Bowel Disease through an Azoxymethane and Dextran Sodium Sulfate Murine Model. IJMS 2022;23:9689. [DOI: 10.3390/ijms23179689] [Reference Citation Analysis]
131 Li W, Zhao T, Wu D, Li J, Wang M, Sun Y, Hou S. Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. Current Oncology 2022;29:6091-6114. [DOI: 10.3390/curroncol29090479] [Reference Citation Analysis]
132 Fujimoto R, Harada KH, Minata M. Comment on "Analysis of Microplastics in Human Feces Reveals a Correlation between Fecal Microplastics and Inflammatory Bowel Disease Status". Environ Sci Technol 2022. [PMID: 36001873 DOI: 10.1021/acs.est.2c04391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Farrukh A, Mayberry JF. Surgery for Ulcerative Colitis in the White British and South Asian Populations in Selected Trusts in England 2001–2020: An Absence of Disparate Care and a Need for Specialist Centres. JCM 2022;11:4967. [DOI: 10.3390/jcm11174967] [Reference Citation Analysis]
134 Petric Z, Goncalves J, Paixao P. Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars. Pharmaceutics 2022;14:1766. [DOI: 10.3390/pharmaceutics14091766] [Reference Citation Analysis]
135 Joustra V, Li Yim AY, Hageman I, Levin E, Adams A, Satsangi J, de Jonge WJ, Henneman P, D’haens G. Long-term temporal stability of peripheral blood DNA methylation alterations in patients with inflammatory bowel disease.. [DOI: 10.1101/2022.08.22.504377] [Reference Citation Analysis]
136 Zhu Y, Qin H, Sun C, Shao B, Li G, Qin Y, Kong D, Ren S, Wang H, Wang Z, Zhang J, Wang H, Li XK. Endometrial Regenerative Cell-Derived Exosomes Attenuate Experimental Colitis through Downregulation of Intestine Ferroptosis. Stem Cells International 2022;2022:1-15. [DOI: 10.1155/2022/3014123] [Reference Citation Analysis]
137 Bodecker-Zingmark L, Widbom L, Hultdin J, Eriksson C, Karling P. Anti-Saccharomyces cerevisiae Antibodies Are Only Modestly More Common in Subjects Later Developing Crohn's Disease. Dig Dis Sci 2022. [PMID: 35989383 DOI: 10.1007/s10620-022-07630-5] [Reference Citation Analysis]
138 Xu Y, Liu T, Jiang Y, Zhao X, Meng F, Xu G, Zhao M. Psychosocial Adaptation Among Inflammatory Bowel Disease Patients and Associated Factors: A Cross-Sectional Study. Psychol Res Behav Manag 2022;15:2157-67. [PMID: 35979227 DOI: 10.2147/PRBM.S376254] [Reference Citation Analysis]
139 Puca P, Del Vecchio LE, Ainora ME, Gasbarrini A, Scaldaferri F, Zocco MA. Role of Multiparametric Intestinal Ultrasound in the Evaluation of Response to Biologic Therapy in Adults with Crohn’s Disease. Diagnostics 2022;12:1991. [DOI: 10.3390/diagnostics12081991] [Reference Citation Analysis]
140 Huang C, Huang Z, Ding L, Fu Y, Fan J, Mei Q, Lou L, Wang J, Yin N, Lu Y, Guo S, Zeng Y. Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis. J Transl Med 2022;20:354. [PMID: 35962454 DOI: 10.1186/s12967-022-03569-3] [Reference Citation Analysis]
141 Walker C, Boland A, Carroll A, O’connor A. Concurrent functional gastrointestinal disorders in patients with inflammatory bowel disease. Front Gastroenterol 2022;1. [DOI: 10.3389/fgstr.2022.959082] [Reference Citation Analysis]
142 Kumar S, Pollok R, Goldsmith D. Renal and Urological Disorders Associated With Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac140. [PMID: 35942657 DOI: 10.1093/ibd/izac140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Bouhnik Y, Atreya R, Casey D, Górecki M, Baik D, Yoon SW, Kwon TS, Jang M. Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment. Inflamm Bowel Dis 2022:izac160. [PMID: 35942647 DOI: 10.1093/ibd/izac160] [Reference Citation Analysis]
144 Nishida A, Nishino K, Ohno M, Sakai K, Owaki Y, Noda Y, Imaeda H. Update on gut microbiota in gastrointestinal diseases. WJCC 2022;10:7653-64. [DOI: 10.12998/wjcc.v10.i22.7653] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Zambrano-sánchez R, Alvarez-mena P, Hidalgo D, Liquitay CME, Franco J, Vernooij RW, Simancas-racines D, Viteri-garcía A, Montesinos-guevara C. Quality assessment of Clinical Practice Guidelines (CPG) for the diagnosis and treatment of Inflammatory Bowel Disease using the AGREE II instrument: A Systematic Review.. [DOI: 10.21203/rs.3.rs-1754875/v1] [Reference Citation Analysis]
146 Liu J, Wen Z, Huang S, Zhang X, Ai X, Qian J. XDH genotypes through gene-gene interactions with NUDT15 affect azathioprine-induced leukopenia in Chinese patients. Pharmacogenomics 2022. [PMID: 35916133 DOI: 10.2217/pgs-2022-0063] [Reference Citation Analysis]
147 Rasmussen NF, Green A, Allin KH, Iversen AT, Madsen GI, Pedersen AK, Wolff DL, Jess T, Andersen V. Clinical procedures used to diagnose inflammatory bowel disease: real-world evidence from a Danish nationwide population-based study. BMJ Open Gastroenterol 2022;9:e000958. [PMID: 36028261 DOI: 10.1136/bmjgast-2022-000958] [Reference Citation Analysis]
148 Innocenti T, Roselli J, Taylor A, Dragoni G, Lynch EN, Campani C, Gottin M, Bagnoli S, Macrì G, Rogai F, Milani S, Galli A, Milla M. Pregnancy outcomes in inflammatory bowel disease: Data from a large cohort survey. J Dig Dis 2022;23:473-81. [PMID: 36156857 DOI: 10.1111/1751-2980.13128] [Reference Citation Analysis]
149 Kante B, Vuyyuru SK, Kedia S, Sahu P, Kumar P, Ranjan MK, Virmani S, Sharma R, Madhusudhan KS, Panwar R, Das P, Makharia G, Ahuja V. Monotherapy with thiopurines in stricturing Crohn's disease: A real-life experience from low- and middle-income countries. Indian J Gastroenterol 2022;41:343-51. [PMID: 35997952 DOI: 10.1007/s12664-022-01258-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Giri S, Sundaram S. Low Dose Azathioprine with Allopurinol in IBD: Early Days to Call It a Recipe for Success. Dig Dis Sci 2022;67:4263-5. [PMID: 35244826 DOI: 10.1007/s10620-021-07375-7] [Reference Citation Analysis]
151 Mahadevan U, Naureckas S, Tikhonov I, Wang Y, Lin CB, Geldhof A, van der Woude CJ. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database. Aliment Pharmacol Ther 2022;56:477-90. [PMID: 35560249 DOI: 10.1111/apt.16960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
152 Kii S, Kitamura H, Hashimoto S, Ikeo K, Ichikawa N, Yoshida T, Homma S, Tanino M, Taketomi A. STAT1-mediated induction of Ly6c-expressing macrophages are involved in the pathogenesis of an acute colitis model. Inflamm Res 2022. [PMID: 35913585 DOI: 10.1007/s00011-022-01620-z] [Reference Citation Analysis]
153 Dhar A, Haboubi HN, Attwood SE, Auth MKH, Dunn JM, Sweis R, Morris D, Epstein J, Novelli MR, Hunter H, Cordell A, Hall S, Hayat JO, Kapur K, Moore AR, Read C, Sami SS, Turner PJ, Trudgill NJ. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut 2022;71:1459-87. [PMID: 35606089 DOI: 10.1136/gutjnl-2022-327326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Rosiou K, Carbonell J, Dolby V, Monfared N, Raine T, Selinger CP. Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study. Aliment Pharmacol Ther 2022;56:501-9. [PMID: 35611471 DOI: 10.1111/apt.17039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
155 Hawthorne AB, Glatter J, Blackwell J, Ainley R, Arnott I, Barrett KJ, Bell G, Brookes MJ, Fletcher M, Muhammed R, Nevill AM, Segal J, Selinger CP, St Clair Jones A, Younge L, Lamb CA; IBD UK Board IBD UK Task & Finish Group. Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients. Aliment Pharmacol Ther 2022;56:625-45. [PMID: 35770866 DOI: 10.1111/apt.17042] [Reference Citation Analysis]
156 Bourgonje AR, Alexdottir MS, Otten AT, Loveikyte R, Bay-Jensen AC, Pehrsson M, van Dullemen HM, Visschedijk MC, Festen EAM, Weersma RK, Karsdal MA, Faber KN, Mortensen JH, Dijkstra G. Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease. Aliment Pharmacol Ther 2022;56:675-93. [PMID: 35661188 DOI: 10.1111/apt.17063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Núñez-sánchez MA, Melgar S, O’donoghue K, Martínez-sánchez MA, Fernández-ruiz VE, Ferrer-gómez M, Ruiz-alcaraz AJ, Ramos-molina B. Crohn’s Disease, Host–Microbiota Interactions, and Immunonutrition: Dietary Strategies Targeting Gut Microbiome as Novel Therapeutic Approaches. IJMS 2022;23:8361. [DOI: 10.3390/ijms23158361] [Reference Citation Analysis]
158 Mocci G, Bodini G, Allegretta L, Cazzato AI, Chiri S, Aragona G, Perazzo P, Ferronato A, Graziani MG, Pagnini C, Zampaletta C, Graziosi C, Picchio M, Elisei W, Maconi G, Tursi A. Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. Biomedicines 2022;10:1799. [DOI: 10.3390/biomedicines10081799] [Reference Citation Analysis]
159 Buhl S, Steenholdt C, Brynskov J, Christensen KR, Dorn-rasmussen M, Thomsen OØ, Bendtzen K, Klausen TW, Dahlerup JF, Thorsgaard N, Jahnsen J, Molazahi A, Pedersen N, Kjeldsen J, Almer S, Dahl EE, Vind I, Cannon AG, Marsal J, Sipponen T, Agnholt JS, Kievit HAL, Aure SL, Martinsen L, Meisner S, Hansen JM, Ainsworth MA. Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease. NEJM Evidence 2022;1. [DOI: 10.1056/evidoa2200061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
160 Vorselaars AD, Culver DA. Hit-hard and early versus step-up treatment in severe sarcoidosis. Current Opinion in Pulmonary Medicine 2022;Publish Ahead of Print. [DOI: 10.1097/mcp.0000000000000906] [Reference Citation Analysis]
161 Jucan AE, Gavrilescu O, Dranga M, Popa IV, Mihai BM, Prelipcean CC, Mihai C. Ischemic Heart Disease in Patients with Inflammatory Bowel Disease: Risk Factors, Mechanisms and Prevention. Life (Basel) 2022;12:1113. [PMID: 35892915 DOI: 10.3390/life12081113] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
162 Hamer HM, Mulder AHL, de Boer NK, Crouwel F, van Rheenen PF, Spekle M, Vermeer M, Wagenmakers-huizinga L, Muller Kobold AC. Impact of Preanalytical Factors on Calprotectin Concentration in Stool: A Multiassay Comparison. The Journal of Applied Laboratory Medicine 2022. [DOI: 10.1093/jalm/jfac057] [Reference Citation Analysis]
163 Song Z, Zhang M, Ren Y, Iang B. [Improved Mayo Endoscopic Score has a higher value for evaluating clinical severity of ulcerative colitis]. Nan Fang Yi Ke Da Xue Xue Bao 2022;42:997-1005. [PMID: 35869761 DOI: 10.12122/j.issn.1673-4254.2022.07.05] [Reference Citation Analysis]
164 Murtagh A, Cooney L, Higginbotham C, Heavey P. Dietary practices, beliefs and behaviours of adults with inflammatory bowel disease: a cross-sectional study. Ir J Med Sci 2022. [PMID: 35840827 DOI: 10.1007/s11845-022-03097-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Mousa KH, Nassar AE. Identification of hub genes and potential molecular mechanisms associated with inflammatory bowel diseases using meta-analysis of gene expression data. Highlights in BioScience 2022. [DOI: 10.36462/h.biosci.202202] [Reference Citation Analysis]
166 Bamias G, Zampeli E, Domènech E. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35833363 DOI: 10.1080/17474124.2022.2100759] [Reference Citation Analysis]
167 Blavnsfeldt AG, Parkner T, Knudsen CS. Plasma calprotectin - preanalytical stability and interference from hemolysis. Scand J Clin Lab Invest 2022;:1-7. [PMID: 35822403 DOI: 10.1080/00365513.2022.2092901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Wu X, Liu K, Wu Q, Wang M, Chen X, Li Y, Qian L, Li C, Dai G, Zhang Q, Mu G, Wu J, Shan Z. Biomarkers of Metabolomics in Inflammatory Bowel Disease and Damp-Heat Syndrome: A Preliminary Study. Evid Based Complement Alternat Med 2022;2022:3319646. [PMID: 35815273 DOI: 10.1155/2022/3319646] [Reference Citation Analysis]
169 Nicklason E, Ham Y, Ng D, Glance S, Abel K, Harraka P, Mack H, Colville D, Savige J. Retinal drusen counts are increased in inflammatory bowel disease, and with longer disease duration, more complications and associated IgA glomerulonephritis. Sci Rep 2022;12:11744. [PMID: 35817816 DOI: 10.1038/s41598-022-15232-4] [Reference Citation Analysis]
170 Noor N, Brezina B, Negro JR, Dowling F, Bond S, Whitehead L, Lee J, Lyons P, McKinney E, Smith K, Lee J, Parkes M. Predicting outcomes for Crohn's disease using a molecular biomarker: profile trial. Clin Med (Lond) 2022;22:22-3. [PMID: 36220241 DOI: 10.7861/clinmed.22-4-s22] [Reference Citation Analysis]
171 Mak JWY, Yuen NTK, Yip TCF, Lam RHM, Lam BKH, Cheng CTY, Wong GLH, Chan FKL, Ng SC. No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study. J Gastroenterol Hepatol 2022;37:1284-9. [PMID: 35338526 DOI: 10.1111/jgh.15838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Roblin X, Veyrard P, Bastide L, Berger AE, Barrau M, Paucelle AS, Waeckel L, Kwiatek S, Flourie B, Nancey S, Paul S. Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease. Aliment Pharmacol Ther 2022;56:77-83. [PMID: 35229331 DOI: 10.1111/apt.16852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
173 Khan N, Wang L, Trivedi C, Pernes T, Patel M, Xie D, Yang YX. Efficacy of Recombinant Zoster Vaccine in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2022;20:1570-1578.e1. [PMID: 34274513 DOI: 10.1016/j.cgh.2021.07.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
174 Patel D, Martin S, Luo M, Ursos L, Lirio RA, Kamble P, Wang S. Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review. Crohn's & Colitis 360 2022;4. [DOI: 10.1093/crocol/otac020] [Reference Citation Analysis]
175 Tayyab S, Rual E, Nagari M. Improving compliance to DEXA in IBD population according to BSG guidelines in Morriston Hospital, Swansea. Clin Med (Lond) 2022;22:72-3. [PMID: 36220227 DOI: 10.7861/clinmed.22-4-s72] [Reference Citation Analysis]
176 Wickramasekera N, Coates E, Barr A, Lee MJ, Blackwell S, Bedford H, Dames N, Sebastian S, Probert C, Shackley P, Lobo AJ. Patient preferences for treatment in steroid resistant ulcerative colitis - a discrete-choice experiment. Scand J Gastroenterol 2022;57:797-806. [PMID: 35142585 DOI: 10.1080/00365521.2022.2036808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
177 Hsieh C, Weng M, Tung C, Chen N, Chen H, Chien K, Wei S. Dietary beliefs and information resources of ulcerative colitis patients in clinical remission: A cross-sectional survey in Taiwan. Clinical Nutrition ESPEN 2022. [DOI: 10.1016/j.clnesp.2022.07.005] [Reference Citation Analysis]
178 Gergely M, Prado E, Deepak P. Management of refractory inflammatory bowel disease. Curr Opin Gastroenterol 2022;38:347-57. [PMID: 35762694 DOI: 10.1097/MOG.0000000000000849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
179 Malloy C, Rawl SM, Miller WR. Inflammatory Bowel Disease Self-Management. Gastroenterology Nursing 2022;45:254-266. [DOI: 10.1097/sga.0000000000000657] [Reference Citation Analysis]
180 Hinman SS, Massaro A, Wang Y, Sims CE, Kim R, Allbritton NL. Suspended Collagen Hydrogels to Replicate Human Colonic Epithelial Cell Interactions with Immune Cells. Advanced Biology 2022. [DOI: 10.1002/adbi.202200129] [Reference Citation Analysis]
181 Xie F, You Y, Guan C, Xu J, Yao F. The Qigong of Prolong Life With Nine Turn Method Relieve Fatigue, Sleep, Anxiety and Depression in Patients With Chronic Fatigue Syndrome: A Randomized Controlled Clinical Study. Front Med 2022;9:828414. [DOI: 10.3389/fmed.2022.828414] [Reference Citation Analysis]
182 Ionele CM, Turcu-stiolica A, Subtirelu MS, Ungureanu BS, Cioroianu GO, Rogoveanu I. A Systematic Review and Meta-Analysis on Metabolic Bone Disease in Patients with Primary Sclerosing Cholangitis. JCM 2022;11:3807. [DOI: 10.3390/jcm11133807] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
183 Del Vecchio LE, Fiorani M, Tohumcu E, Bibbò S, Porcari S, Mele MC, Pizzoferrato M, Gasbarrini A, Cammarota G, Ianiro G. Risk Factors, Diagnosis, and Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease. Microorganisms 2022;10:1315. [DOI: 10.3390/microorganisms10071315] [Reference Citation Analysis]
184 Welsh S, Sam Z, Seenan JP, Nicholson GA. The Role of Appendicectomy in Ulcerative Colitis: Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2022:izac127. [PMID: 35766795 DOI: 10.1093/ibd/izac127] [Reference Citation Analysis]
185 Di Vincenzo F, Puca P, Lopetuso LR, Petito V, Masi L, Bartocci B, Murgiano M, De Felice M, Petronio L, Gasbarrini A, Scaldaferri F. Bile Acid-Related Regulation of Mucosal Inflammation and Intestinal Motility: From Pathogenesis to Therapeutic Application in IBD and Microscopic Colitis. Nutrients 2022;14:2664. [DOI: 10.3390/nu14132664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Xiong J, Fu Y, Qiu J, Liao W, Luo L, Chen S. Global research trends of immunotherapy and biotherapy for inflammatory bowel disease: a bibliometric analysis from 2002 to 2021. BioMed Eng OnLine 2022;21. [DOI: 10.1186/s12938-022-01011-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Alghoul Z, Yang C, Merlin D. The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease. Biomedicines 2022;10:1492. [PMID: 35884797 DOI: 10.3390/biomedicines10071492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Elhag DA, Kumar M, Saadaoui M, Akobeng AK, Al-mudahka F, Elawad M, Al Khodor S. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. IJMS 2022;23:6966. [DOI: 10.3390/ijms23136966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
189 Cao Y, Feng J, Duan S, Yang Y, Zhang Y. SARS-CoV-2-inactivated vaccine hesitancy and the safety in inflammatory bowel disease patients: a single-center study. Therap Adv Gastroenterol 2022;15:17562848221101722. [PMID: 35706827 DOI: 10.1177/17562848221101722] [Reference Citation Analysis]
190 Zhang N, Lu Y, Huang Y, Zhang Q, Tan J, Zhang J, Yao M, Luo G. A novel fluorescent probe for real-time imaging of thionitrous acid under inflammatory and oxidative conditions. Redox Biol 2022;54:102372. [PMID: 35728302 DOI: 10.1016/j.redox.2022.102372] [Reference Citation Analysis]
191 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
192 Bak MTJ, Ruiterkamp MFE, van Ruler O, Campmans-Kuijpers MJE, Bongers BC, van Meeteren NLU, van der Woude CJ, Stassen LPS, de Vries AC. Prehabilitation prior to intestinal resection in Crohn’s disease patients: An opinion review. World J Gastroenterol 2022; 28(22): 2403-2416 [DOI: 10.3748/wjg.v28.i22.2403] [Reference Citation Analysis]
193 Landskron G, Dubois-Camacho K, Orellana-Serradell O, De la Fuente M, Parada-Venegas D, Bitrán M, Diaz-Jimenez D, Tang S, Cidlowski JA, Li X, Molina H, Gonzalez CM, Simian D, Lubascher J, Pola V, Montecino M, Blokzijl T, Faber KN, González MJ, Quera R, Hermoso MA. Regulation of the Intestinal Extra-Adrenal Steroidogenic Pathway Component LRH-1 by Glucocorticoids in Ulcerative Colitis. Cells 2022;11:1905. [PMID: 35741034 DOI: 10.3390/cells11121905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
194 Barnes A, Ooi SJ, Lynch KD, Parthasarathy N, Bishara M, Gounder M, Grafton R, Leach P, Bampton P, Sechi A, Ng W, Connor S, van Langenberg D, Mountifield R, Andrews JM. Proactive Metabolite Testing in Patients on Thiopurine May Yield Long-Term Clinical Benefits in Inflammatory Bowel Disease. Dig Dis Sci 2022. [PMID: 35687221 DOI: 10.1007/s10620-022-07556-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Minnis-lyons SE, Aiken Z, Chow S, Din S. Managing IBD in patients with previous cancers. Frontline Gastroenterol 2022;13:e44-50. [DOI: 10.1136/flgastro-2022-102187] [Reference Citation Analysis]
196 Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, Louis E, Lukáš M, Reinisch W, Roblin X, Jang M, Byun HG, Kim DH, Lee SJ, Atreya R. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol 2022;22:291. [PMID: 35676620 DOI: 10.1186/s12876-022-02347-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Chauhan U, Stitt L, Rohatinsky N, Watson M, Currie B, Westin L, McCaw W, Norton C, Nistor I. Patients' Access to Telephone and E-mail Services Provided by IBD Nurses in Canada. J Can Assoc Gastroenterol 2022;5:129-36. [PMID: 35669845 DOI: 10.1093/jcag/gwab041] [Reference Citation Analysis]
198 Ban Q, Liu M, Ding N, Chen Y, Lin Q, Zha J, He W. Nutraceuticals for the Treatment of IBD: Current Progress and Future Directions. Front Nutr 2022;9:794169. [DOI: 10.3389/fnut.2022.794169] [Reference Citation Analysis]
199 Zeng R, Jiang R, Wang J, Yang J, Wu H, Zhuo Z, Yang Q, Li J, Liao S, Tse H, Sha W, Chen H. Investigating Causal Relationships between Inflammatory Bowel Disease and Autism Spectrum Disorder: A Bidirectional Two-sample Mendelian Randomization Study.. [DOI: 10.1101/2022.06.03.22275985] [Reference Citation Analysis]
200 Pestana M, Brito Caldeira M, Cabete J. Comment on: "Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?". Am J Clin Dermatol 2022. [PMID: 35665908 DOI: 10.1007/s40257-022-00694-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Alavi A, Raffals L. Author's Reply to Pestana et al. Comment on: "Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?". Am J Clin Dermatol 2022. [PMID: 35665909 DOI: 10.1007/s40257-022-00695-y] [Reference Citation Analysis]
202 Jedel S, Beck T, Swanson G, Hood MM, Voigt RM, Gorenz A, Jakate S, Raeisi S, Hobfoll S, Keshavarzian A. Mindfulness Intervention Decreases Frequency and Severity of Flares in Inactive Ulcerative Colitis Patients: Results of a Phase II, Randomized, Placebo-Controlled Trial. Inflamm Bowel Dis 2022;28:1872-92. [PMID: 35661212 DOI: 10.1093/ibd/izac036] [Reference Citation Analysis]
203 Xi W, Xu C, Wang L. The Effect of Empowering Education Combined With Mindfulness Meditation Training on Negative Emotion and Quality of Life in Patients With Inflammatory Bowel Disease. Front Behav Neurosci 2022;16:901696. [DOI: 10.3389/fnbeh.2022.901696] [Reference Citation Analysis]
204 Peng L, Hu S, Yu Q, Chen Y. Challenging the Surge of Inflammatory Bowel Disease: The Role of the China Crohn's and Colitis Foundation in the Healthcare Landscape of Inflammatory Bowel Disease. Inflamm Bowel Dis 2022;28:S9-S15. [PMID: 34984463 DOI: 10.1093/ibd/izab344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
205 Barkhodari A, Lee KE, Shen M, Shen B, Yao Q. Inflammatory bowel disease: focus on enteropathic arthritis and therapy. Rheumatology and Immunology Research 2022;3:69-76. [DOI: 10.2478/rir-2022-0012] [Reference Citation Analysis]
206 Ong WC, Lim MS, Chan E, Lim TCT, Lim TG, Chan W. A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol. JGH Open. [DOI: 10.1002/jgh3.12776] [Reference Citation Analysis]
207 Geldof J, Iqbal N, Leblanc J, Anandabaskaran S, Sawyer R, Buskens C, Bemelman W, Gecse K, Lundby L, Lightner AL, Danese S, Spinelli A, Carvello M, Faiz O, Warusavitarne J, Lung P, De Looze D, D'hoore A, Vermeire S, Hart A, Tozer P. Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials. The Lancet Gastroenterology & Hepatology 2022;7:576-84. [DOI: 10.1016/s2468-1253(22)00007-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
208 Rodríguez-lago I, Mesonero F, Hijos-mallada G, Cañas M, Saldaña R, Savini C, Fernández S, Juliá B, Cea-calvo L. Self-medication with analgesics reported by patients with ulcerative colitis: An anonymous survey. Gastroenterología y Hepatología (English Edition) 2022;45:457-463. [DOI: 10.1016/j.gastre.2021.07.005] [Reference Citation Analysis]
209 Watermeyer G, Awuku Y, Fredericks E, Epstein D, Setshedi M, Devani S, Mudombi W, Kassianides C, Katsidzira L. Challenges in the management of inflammatory bowel disease in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00048-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Hanzel J, Ma C, Jairath V; IBD Trial Design Group. Design of Clinical Trials for Mild to Moderate Crohn's Disease. Gastroenterology 2022;162:1800-1814.e1. [PMID: 35240140 DOI: 10.1053/j.gastro.2022.02.036] [Reference Citation Analysis]
211 Achit H, Peyrin-Biroulet L, Ayav C, Guillemin F, Frimat L. Lack of Monitoring Is Associated with Risk of Acute Kidney Events among Patients with Inflammatory Bowel Disease. J Clin Med 2022;11:2954. [PMID: 35683343 DOI: 10.3390/jcm11112954] [Reference Citation Analysis]
212 Shehab M, Alrashed F, Heron V, Restellini S, Bessissow T. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Inflamm Bowel Dis 2022:izac103. [PMID: 35604382 DOI: 10.1093/ibd/izac103] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Dahiya DS, Perisetti A, Kichloo A, Singh A, Goyal H, Rotundo L, Vennikandam M, Shaka H, Singh G, Singh J, Pisipati S, Al-Haddad M, Sanaka MR, Inamdar S. Increasing thirty-day readmissions of Crohn’s disease and ulcerative colitis in the United States: A national dilemma. World J Gastrointest Pathophysiol 2022; 13(3): 85-95 [DOI: 10.4291/wjgp.v13.i3.85] [Reference Citation Analysis]
214 Tomaras S, Keyßer G, Feist E. Curcumin: Useful add-on for Rheumatic Diseases? JCM 2022;11:2908. [DOI: 10.3390/jcm11102908] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Liang C, Chen P, Tang Y, Zhang C, Lei N, Luo Y, Duan S, Zhang Y. Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial. Front Psychiatry 2022;13:880058. [DOI: 10.3389/fpsyt.2022.880058] [Reference Citation Analysis]
216 Freitas M, de Castro FD, Macedo Silva V, Arieira C, Cúrdia Gonçalves T, Leite S, Moreira MJ, Cotter J. Ultrasonographic scores for ileal Crohn's disease assessment: Better, worse or the same as contrast-enhanced ultrasound? BMC Gastroenterol 2022;22:252. [PMID: 35585503 DOI: 10.1186/s12876-022-02326-6] [Reference Citation Analysis]
217 Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Giorgetti G, Graziani MG, Lofano K, Lorenzetti R, Larussa T, Penna A, Pica R, Pranzo G, Rodino' S, Scarcelli A, Zampaletta C, Bassotti G, Cazzato AI, Chiri S, Clemente V, Cocco A, De' Angelis G, Donnarumma L, Faggiani R, Graziosi C, Le Grazie M, Luzza F, Meucci C, Monterubbianesi R, Pagnini C, Perazzo P, Picchio M, Sacco R, Sebkova L, Serio M, Napolitano D, Pugliese D, Scaldaferri F, Schiavoni E, Turchini L, Armuzzi A, Elisei W, Maconi G, Papa A. Comparison of Performances of Adalimumab Biosimilars SB5, APB501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. Inflamm Bowel Dis 2022:izac092. [PMID: 35579320 DOI: 10.1093/ibd/izac092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Chiarello MM, Pepe G, Fico V, Bianchi V, Tropeano G, Altieri G, Brisinda G. Therapeutic strategies in Crohn’s disease in an emergency surgical setting. World J Gastroenterol 2022; 28(18): 1902-1921 [DOI: 10.3748/wjg.v28.i18.1902] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
219 Makarchuk PA, Lomakina EY, Belousova EA, Dubrova SE. Real clinical practice of complicated Crohn’s disease treatment with ustekinumab: clinical case presentation. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-7-116-122] [Reference Citation Analysis]
220 Hart A, D'Haens G, Bereswill M, Finney-Hayward T, Kalabic J, Levy G, Liang H, Seow CH, Loftus EV Jr, Panaccione R, Reinisch W, Satsangi J. Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. United European Gastroenterol J 2022. [PMID: 35560533 DOI: 10.1002/ueg2.12236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 El-Nakeep S, Shawky A, Abbas SF, Abdel Latif O. Stem cell transplantation for induction of remission in medically refractory Crohn's disease. Cochrane Database Syst Rev 2022;5:CD013070. [PMID: 35556242 DOI: 10.1002/14651858.CD013070.pub2] [Reference Citation Analysis]
222 Nasonov EL, Korotaeva TV. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. Naučno-praktičeskaâ revmatologiâ 2022;60:131-148. [DOI: 10.47360/1995-4484-2022-131-148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
223 Gong M, Zhang F, Miao Y, Niu J. Advances of Heat Shock Family in Ulcerative Colitis. Front Pharmacol 2022;13:869930. [DOI: 10.3389/fphar.2022.869930] [Reference Citation Analysis]
224 Luo J, Xu Z, Noordam R, van Heemst D, Li-Gao R. Depression and Inflammatory Bowel Disease: A Bidirectional Two-sample Mendelian Randomization Study. J Crohns Colitis 2022;16:633-42. [PMID: 34739073 DOI: 10.1093/ecco-jcc/jjab191] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
225 Wang S, Zhou P, Li Z. A Case Report and Literature Review of Mesalazine-Induced Kidney Injury in a Pediatric Patient With Ulcerative Colitis. Front Pediatr 2022;10:808472. [DOI: 10.3389/fped.2022.808472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Kubas A, Malecka-Wojciesko E. COVID-19 Vaccination in Inflammatory Bowel Disease (IBD). J Clin Med 2022;11:2676. [PMID: 35566802 DOI: 10.3390/jcm11092676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Argüelles-arias F, Bermejo F, Borrás-blasco J, Domènech E, Sicilia B, Huguet JM, de Arellano AR, Valentine WJ, Hunt B. Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain. Therap Adv Gastroenterol 2022;15:175628482210861. [DOI: 10.1177/17562848221086131] [Reference Citation Analysis]
228 Nie K, Zhang C, Deng M, Luo W, Ma K, Xu J, Wu X, Yang Y, Wang X. A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn's Disease. Front Pharmacol 2022;13:870796. [PMID: 35517818 DOI: 10.3389/fphar.2022.870796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Altemus J, Dadgar N, Li Y, Lightner AL. Adipose tissue-derived mesenchymal stem cells' acellular product extracellular vesicles as a potential therapy for Crohn's disease. J Cell Physiol 2022. [PMID: 35522572 DOI: 10.1002/jcp.30756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Weissman S, Systrom HK, Aziz M, El-Dallal M, Lee-Smith W, Sciarra M, Feuerstein JD. Colorectal Cancer Prevention in Inflammatory Bowel Disease: A Systematic Analysis of the Overall Quality of Guideline Recommendations. Inflamm Bowel Dis 2022;28:745-54. [PMID: 34245270 DOI: 10.1093/ibd/izab164] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
231 Roblin X, Genin C, Nancey S, Williet N, Veyrard P, Boschetti G, Phelip JM, Berger AE, Killian M, Waeckel L, Flourie B, Paul S. Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels. Inflamm Bowel Dis 2022;28:720-7. [PMID: 34405867 DOI: 10.1093/ibd/izab158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
232 Gilca-Blanariu GE, Trifan A, Ciocoiu M, Popa IV, Burlacu A, Balan GG, Olteanu AV, Stefanescu G. Magnesium-A Potential Key Player in Inflammatory Bowel Diseases? Nutrients 2022;14:1914. [PMID: 35565881 DOI: 10.3390/nu14091914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
233 Poo S, Sriranganathan D, Segal JP. Network meta-analysis: efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis. Eur J Gastroenterol Hepatol 2022;34:518-28. [PMID: 35271513 DOI: 10.1097/MEG.0000000000002362] [Reference Citation Analysis]
234 Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG; GALAXI-1 Investigators. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology 2022;162:1650-1664.e8. [PMID: 35134323 DOI: 10.1053/j.gastro.2022.01.047] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
235 Ge C, Lu Y, Shen H, Zhu L. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scand J Gastroenterol 2022;57:513-24. [PMID: 34994661 DOI: 10.1080/00365521.2021.2022193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Drosos AA, Pelechas E, Voulgari PV. Treatment strategies of Covid-19. A rheumatology perspective. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Lovatt J, Selinger CP. Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF therapy. Aliment Pharmacol Ther 2022;55:1346-7. [PMID: 35472183 DOI: 10.1111/apt.16878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Vincent T. Intérêt du suivi immunologique des biothérapies anti-TNF. Revue Francophone des Laboratoires 2022;2022:59-62. [DOI: 10.1016/s1773-035x(22)00178-2] [Reference Citation Analysis]
239 Pontes Azevedo K, Catulio MZDJ, Machado de Souza RG, Ferreira Stringhini ML. Probiotics in Crohn's disease remission: a systematic review. Arch Latinoam Nutr 2022;72:50-59. [DOI: 10.37527/2022.72.1.006] [Reference Citation Analysis]
240 Moss JG, Parry CM, Holt RCL, McWilliam SJ. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review. Eur J Med Res 2022;27:61. [PMID: 35488310 DOI: 10.1186/s40001-022-00687-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
241 Lamberg T, Sipponen T, Valtanen S, Eklund KK, Mälkönen T, Aalto K, Mikola K, Kolho KL, Leinonen S, Isomäki P, Mäkinen H, Vidqvist KL, Kokko A, Huilaja L, Kyllönen M, Keskitalo P, Sard S, Vähäsalo P, Koskela R, Kröger L, Lahtinen P, Haapala AM, Korkatti K, Sokka-Isler T, Jokiranta TS; BLING Research Group. Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases. Autoimmunity 2022;:1-10. [PMID: 35481450 DOI: 10.1080/08916934.2022.2067985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Klang E, Soffer S, Shachar E, Lahat A. Trends in inflammatory bowel disease infections and vaccinations in the past four decades: A high-level text mining analysis of PubMed publications. Hum Vaccin Immunother 2022;:1-6. [PMID: 35471850 DOI: 10.1080/21645515.2022.2065814] [Reference Citation Analysis]
243 Te Groen M, Hoentjen F. Confirming Effectiveness of Endoscopic Colon Cancer Screening in Inflammatory Bowel Disease: The Puzzle Remains Unsolved? Clin Gastroenterol Hepatol 2022:S1542-3565(22)00399-8. [PMID: 35483602 DOI: 10.1016/j.cgh.2022.04.002] [Reference Citation Analysis]
244 Lazarević S, Đanic M, Al-Salami H, Mooranian A, Mikov M. Gut Microbiota Metabolism of Azathioprine: A New Hallmark for Personalized Drug-Targeted Therapy of Chronic Inflammatory Bowel Disease. Front Pharmacol 2022;13:879170. [PMID: 35450035 DOI: 10.3389/fphar.2022.879170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 M’koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina 2022;58:567. [DOI: 10.3390/medicina58050567] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
246 Patel M, Gulati S, Iqbal F, Hayee B. Rapid development of accurate artificial intelligence scoring for colitis disease activity using applied data science techniques. Endosc Int Open 2022;10:E539-43. [DOI: 10.1055/a-1790-6201] [Reference Citation Analysis]
247 Jiang M, Zeng Z, Chen K, Dang Y, Li L, Ma C, Cheng R, Hu K, Li X, Zhang H. Enterogenous Microbiotic Markers in the Differential Diagnosis of Crohn's Disease and Intestinal Tuberculosis. Front Immunol 2022;13:820891. [PMID: 35371004 DOI: 10.3389/fimmu.2022.820891] [Reference Citation Analysis]
248 Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW. Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Database Syst Rev 2022;4:CD007216. [PMID: 35388476 DOI: 10.1002/14651858.CD007216.pub2] [Reference Citation Analysis]
249 Halliday G, Porter RJ, Black CJ, Arends MJ, Din S. c-MET immunohistochemical expression in sporadic and inflammatory bowel disease associated lesions. World J Gastroenterol 2022; 28(13): 1338-1346 [DOI: 10.3748/wjg.v28.i13.1338] [Reference Citation Analysis]
250 West J, Stilwell P, Liu H, Ban L, Bythell M, Card TR, Lanyon P, Nanduri V, Rankin J, Bishton M, Crooks CJ. Temporal trends in the incidence of haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003-2018.. [DOI: 10.1101/2022.03.30.22273090] [Reference Citation Analysis]
251 Fang S, Song Y, Zhang C, Wang L. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatr 2022;22:175. [PMID: 35379216 DOI: 10.1186/s12887-022-03229-x] [Reference Citation Analysis]
252 Loras C, Mañosa M, Andújar X, Sánchiz V, Martí-gallostra M, Zabana Y, Gutiérrez A, Barreiro-de Acosta M. Position Statement. Recommendations of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) on the treatment of strictures in Crohn’s disease. Gastroenterología y Hepatología (English Edition) 2022;45:315-334. [DOI: 10.1016/j.gastre.2022.04.002] [Reference Citation Analysis]
253 Núñez P, Quera R, Flores L, Araya R, Córdova A, Correa I. Role of the multidisciplinary team in pandemics: A new opportunity to achieve greater immunization in patients with inflammatory bowel disease. Dig Liver Dis 2022;54:562-4. [PMID: 35115259 DOI: 10.1016/j.dld.2021.12.013] [Reference Citation Analysis]
254 Wronka KM, Bik E, Milkiewicz P. Outcome of pregnancy in patients with primary sclerosing cholangitis. Dig Liver Dis 2022;54:509-14. [PMID: 34518127 DOI: 10.1016/j.dld.2021.08.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
255 Lamb CA, Saifuddin A, Powell N, Rieder F. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. Gastroenterology 2022;162:1525-42. [PMID: 34995532 DOI: 10.1053/j.gastro.2021.09.077] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
256 Deputy M, Sahnan K, Worley G, Patel K, Balinskaite V, Bottle A, Aylin P, Burns EM, Hart A, Faiz O. The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study. Aliment Pharmacol Ther 2022;55:836-46. [PMID: 35132663 DOI: 10.1111/apt.16800] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
257 Curtius K, Kabir M, Al Bakir I, Choi CHR, Hartono JL, Johnson M, East JE, Lindsay JO, Vega R, Thomas-Gibson S, Warusavitarne J, Wilson A, Graham TA, Hart A; Oxford IBD Cohort Study Investigators. Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool. Gut 2022;71:705-15. [PMID: 33990383 DOI: 10.1136/gutjnl-2020-323546] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
258 Albayrak NE, Polydorides AD. Characteristics and Outcomes of Left-sided Ulcerative Colitis With a Cecal/Periappendiceal Patch of Inflammation. Am J Surg Pathol 2022. [PMID: 35354161 DOI: 10.1097/PAS.0000000000001883] [Reference Citation Analysis]
259 Shut SA, Platoshkin VE, Platoshkina TV, Nikulina NA, Nikolaeva NV. Innovative approaches to colorectal cancer prevention. jour 2022;19:13-20. [DOI: 10.51523/2708-6011.2022-19-1-02] [Reference Citation Analysis]
260 Cassinotti A, Batticciotto A, Parravicini M, Lombardo M, Radice P, Cortelezzi CC, Segato S, Zanzi F, Cappelli A, Segato S. Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications. Therap Adv Gastroenterol 2022;15:17562848221085889. [PMID: 35340755 DOI: 10.1177/17562848221085889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
261 Long X, Yu X, Gong P, Wang X, Tian L. Identification of WT161 as a Potent Agent for the Treatment of Colitis by Targeting the Nucleotide-Binding Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome. Front Pharmacol 2022;13:780179. [PMID: 35330829 DOI: 10.3389/fphar.2022.780179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 Yang D, Li Y, Sun H, He C, Chen G, Zhao Z, Tang T, M'koma A. A Study on Differences between Professional Endoscopists and Gastroenterologists in Endoscopic Detection and Standard Pathological Biopsy of Inflammatory Bowel Diseases. Gastroenterology Research and Practice 2022;2022:1-8. [DOI: 10.1155/2022/7333579] [Reference Citation Analysis]
263 Priadko K, Moretti A, Iolascon G, Gravina AG, Miranda A, Sgambato D, De Musis C, Romano M, Gimigliano F. Bone Alterations in Inflammatory Bowel Diseases: Role of Osteoprotegerin. JCM 2022;11:1840. [DOI: 10.3390/jcm11071840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Sinopoulou V, Gordon M, Limketkai BN, Mullin G, Aali G, Akobeng AK; Cochrane Gut Group. Prebiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd015084] [Reference Citation Analysis]
265 Jones NP. Comment on: Systemic corticosteroid use in UK Uveitis practice: results from the ocular inflammation steroid toxicity risk (OSTRICH) study. Eye (Lond) 2022. [PMID: 35322212 DOI: 10.1038/s41433-022-02031-4] [Reference Citation Analysis]
266 Kumar A, Al-hassi HO, Steed H, Phipps O, Brookes MJ, Nakamura M. Bile Acids and the Microbiome: Making Sense of This Dynamic Relationship in Their Role and Management in Crohn’s Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-12. [DOI: 10.1155/2022/8416578] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
267 Bouazzi M, Bak NF, Agnholt J, Wewer V, Malham M, Bendix M. Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment. GastroHep 2022;2022:1-11. [DOI: 10.1155/2022/9550908] [Reference Citation Analysis]
268 Akbar A, Orchard T, Powell N, Selinger C, tibbatts C. Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101995] [Reference Citation Analysis]
269 Majumder S, Shivaji UN, Kasturi R, Sigamani A, Ghosh S, Iacucci M. Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives. World J Gastrointest Oncol 2022; 14(3): 547-567 [DOI: 10.4251/wjgo.v14.i3.547] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
270 Zand A, Shi S, Nguyen D, Kim B, Esrailian E, Hommes D. Recall of Care Objectives by Patients with Inflammatory Bowel Diseases. Gastrointestinal Disorders 2022;4:49-55. [DOI: 10.3390/gidisord4010006] [Reference Citation Analysis]
271 Kim M, Jeon J. Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases. IJMS 2022;23:2846. [DOI: 10.3390/ijms23052846] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
272 Keung C, Heraud P, Kuk N, Lim R, Sievert W, Moore G, Wood B. Fourier-Transform Infra-Red Microspectroscopy Can Accurately Diagnose Colitis and Assess Severity of Inflammation. IJMS 2022;23:2849. [DOI: 10.3390/ijms23052849] [Reference Citation Analysis]
273 Viscido A, Valvano M, Stefanelli G, Capannolo A, Castellini C, Onori E, Ciccone A, Vernia F, Latella G. Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis. BMC Gastroenterol 2022;22:92. [PMID: 35240984 DOI: 10.1186/s12876-022-02157-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
274 Tun GSZ, Robinson K, Marshall L, Wright A, Thompson L, Wild G, Sargur R, Brooks AJ, Hale MF, Chew TS, Lobo AJ. The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab. Eur J Gastroenterol Hepatol 2022;34:295-301. [PMID: 35100176 DOI: 10.1097/MEG.0000000000002289] [Reference Citation Analysis]
275 Freitas M, Lima Capela T, Macedo Silva V, Arieira C, Cúrdia Gonçalves T, Dias de Castro F, Moreira MJ, Firmino-Machado J, Cotter J. Finding Predictors of Azathioprine-Induced Pancreatitis in Patients With Inflammatory Bowel Disease. Pancreas 2022;51:288-94. [PMID: 35584388 DOI: 10.1097/MPA.0000000000002012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
276 Guillo L, Delanaye P, Flamant M, Figueres L, Karam S, Lemoine S, Benezech A, Pelletier AL, Amiot A, Caron B, Stefanescu C, Boschetti G, Bouguen G, Rahier JF, Gornet JM, Hugot JP, Bonnet J, Vuitton L, Nachury M, Vidon M, Uzzan M, Serrero M, Dib N, Seksik P, Hebuterne X, Bertocchio JP, Mariat C, Peyrin-Biroulet L. Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Dig Liver Dis 2022;54:309-15. [PMID: 34866011 DOI: 10.1016/j.dld.2021.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
277 Unger LW, Schuld GJ, Bergmann M. Bedeutung der Chirurgie bei M. Crohn. J Gastroenterol Hepatol Erkr 2022;20:13-21. [DOI: 10.1007/s41971-022-00121-4] [Reference Citation Analysis]
278 Alhalabi MM, Abbas AJ. Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report. Annals of Medicine and Surgery 2022;75:103456. [DOI: 10.1016/j.amsu.2022.103456] [Reference Citation Analysis]
279 Shah SC, Itzkowitz SH. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology 2022;162:715-730.e3. [PMID: 34757143 DOI: 10.1053/j.gastro.2021.10.035] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 21.0] [Reference Citation Analysis]
280 Yau TO, Vadakekolathu J, Foulds GA, Du G, Dickins B, Polytarchou C, Rutella S. Hyperactive neutrophil chemotaxis contributes to anti-tumor necrosis factor-α treatment resistance in inflammatory bowel disease. J Gastroenterol Hepatol 2022;37:531-41. [PMID: 34931384 DOI: 10.1111/jgh.15764] [Reference Citation Analysis]
281 Wang H, He X, Liang S, Chen X. Role of vitamin D in ulcerative colitis: an update on basic research and therapeutic applications. Expert Rev Gastroenterol Hepatol 2022;16:251-64. [PMID: 35236213 DOI: 10.1080/17474124.2022.2048817] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Rada C, Gheonea D, Ţieranu CG, Popa DE. Diagnosis and Psychotherapeutic Needs by Early Maladaptive Schemas in Patients With Inflammatory Bowel Disease. Front Psychol 2021;12:807107. [PMID: 35222160 DOI: 10.3389/fpsyg.2021.807107] [Reference Citation Analysis]
283 Śledzińska K, Landowski P, Żmijewski MA, Kamińska B, Kowalski K, Liberek A. Diet, Sun, Physical Activity and Vitamin D Status in Children with Inflammatory Bowel Disease. Nutrients 2022;14:1029. [PMID: 35268001 DOI: 10.3390/nu14051029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
284 Núñez F P, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World J Hepatol 2022; 14(2): 319-337 [DOI: 10.4254/wjh.v14.i2.319] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
285 Gadsby J, Hall K, Shah F, Pattni S, Gethins S, Mulla H. Infliximab: a single-centre, prospective, observational evaluation of TDM data in patients with IBD. Eur J Hosp Pharm 2022:ejhpharm-2021-003015. [PMID: 35217509 DOI: 10.1136/ejhpharm-2021-003015] [Reference Citation Analysis]
286 Spinelli A, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, Karmiris K, Katsanos K, Kopylov U, Lakatos PL, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Doherty G, Raine T, Panis Y. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. J Crohns Colitis 2022;16:179-89. [PMID: 34635910 DOI: 10.1093/ecco-jcc/jjab177] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
287 Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482210784. [DOI: 10.1177/17562848221078456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
288 Louis E, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Dignass AU, Magro F, Márquez JR, Moschen AR, Narula N, Rydzewska G, Freddi MJ, Travis SP. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterol 2022;9:e000853. [DOI: 10.1136/bmjgast-2021-000853] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
289 Li X, Liu S, Liu H, Zhu JJ. Acupuncture for gastrointestinal diseases. Anat Rec (Hoboken) 2022. [PMID: 35148031 DOI: 10.1002/ar.24871] [Reference Citation Analysis]
290 Huguet JM, Ferrer-Barceló L, Suárez P, Sanchez E, Prieto JD, Garcia V, Sempere J. Colorectal cancer screening and surveillance in patients with inflammatory bowel disease in 2021. World J Gastroenterol 2022; 28(5): 502-516 [DOI: 10.3748/wjg.v28.i5.502] [Reference Citation Analysis]
291 Akbar A, Arnott I, Kennedy NA, Nolan J, Peake S, Whiteoak SR, Probert C, Fraser A, Cheshire A, Lewis A, Sugrue K, Laird S, Scott G. Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. Gastrointestinal Nursing 2022;20:34-41. [DOI: 10.12968/gasn.2022.20.1.34] [Reference Citation Analysis]
292 Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:447-454.e1. [PMID: 33279779 DOI: 10.1016/j.cgh.2020.11.040] [Reference Citation Analysis]
293 Nayagam JS, Heneghan MA, Samyn M, Joshi D. Editorial: testing for Epstein Barr virus and treating autoimmune hepatitis-still a long way to go! Authors' reply. Aliment Pharmacol Ther 2022;55:366-7. [PMID: 35040167 DOI: 10.1111/apt.16759] [Reference Citation Analysis]
294 Lindhagen S, Karling P. A more frequent disease monitorering but no increased disease activity in patients with inflammatory bowel disease during the first year of the SARS-CoV-2 pandemic. A retrospective study. Scand J Gastroenterol 2022;57:169-74. [PMID: 34699290 DOI: 10.1080/00365521.2021.1993328] [Reference Citation Analysis]
295 Nayagam JS, Heneghan MA, Samyn M, Joshi D. Epstein-Barr virus status and immunosuppression use in paediatric autoimmune liver disease. Aliment Pharmacol Ther 2022;55:455-63. [PMID: 34796537 DOI: 10.1111/apt.16708] [Reference Citation Analysis]
296 Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Kawashima H, Honda T, Ishigami M, Fujishiro M. Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis. Nagoya J Med Sci 2022;84:169-79. [PMID: 35392018 DOI: 10.18999/nagjms.84.1.169] [Reference Citation Analysis]
297 Qazi U. Inflammatory bowel disease in adults. InnovAiT 2022;15:97-105. [DOI: 10.1177/17557380211058758] [Reference Citation Analysis]
298 Iria I, Soares RRG, Brás EJS, Chu V, Gonçalves J, Conde JP. Accurate and rapid microfluidic ELISA to monitor Infliximab titers in patients with inflammatory bowel diseases. Analyst 2022;147:480-8. [PMID: 35023516 DOI: 10.1039/d1an01810h] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Sebastian S, Patel KV, Segal JP, Subramanian S, Conley TE, Gonzalez HA, Kent AJ, Saifuddin A, Hicks L, Mehta S, Bhala N, Brookes MJ, Lamb CA, Kennedy NA, Walker GJ; PROTECT ASUC collaborators. Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study. BMJ Open Gastroenterol 2022;9:e000763. [DOI: 10.1136/bmjgast-2021-000763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
300 Watanabe S, Hibiya S, Katsukura N, Kitagawa S, Sato A, Okamoto R, Watanabe M, Tsuchiya K. Importance of Telomere Shortening in the Pathogenesis of Ulcerative Colitis: A New Treatment From the Aspect of Telomeres in Intestinal Epithelial Cells. J Crohns Colitis 2022;16:109-21. [PMID: 34180971 DOI: 10.1093/ecco-jcc/jjab115] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
301 Alhalabi M, Eddin KA, Ali F, Abbas A. SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report. Medicine (Baltimore) 2022;101:e28722. [PMID: 35089243 DOI: 10.1097/MD.0000000000028722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
302 Yu S, Li H, Li Y, Xu H, Tan B, Tian B, Dai Y, Tian F, Qian J. Development and validation of novel models for the prediction of intravenous corticosteroid resistance in acute severe ulcerative colitis using logistic regression and machine learning. Gastroenterology Report 2022;10. [DOI: 10.1093/gastro/goac053] [Reference Citation Analysis]
303 Labriola F, Marcato C, Zarbo C, Betti L, Catelli A, Valerii MC, Spisni E, Alvisi P. Dietary Habits of a Group of Children with Crohn’s Disease Compared to Healthy Subjects: Assessment of Risk of Nutritional Deficiencies through a Bromatological Analysis. Nutrients 2022;14:499. [DOI: 10.3390/nu14030499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Jena A, Mishra S, Singh AK, Sekar A, Sharma V. Cytomegalovirus in ulcerative colitis: An evidence-based approach to diagnosis and treatment. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2032662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Mahendra G, Hewavisenthi J. The Role of the Pathologist in Ulcerative Colitis. Ulcerative Colitis [Working Title] 2022. [DOI: 10.5772/intechopen.102072] [Reference Citation Analysis]
306 Radford SJ, Taylor S, Moran G. Ultrasound use to assess Crohn's disease in the UK: a survey of British Society of Gastroenterology Inflammatory Bowel Disease Group members. Frontline Gastroenterol 2022;13:471-6. [PMID: 36250164 DOI: 10.1136/flgastro-2021-102065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
307 Zhao Z, Yuan X, Cui Y, Liu J, Shen J, Jin B, Feng B, Zhai Y, Zheng M, Kou G, Zhou R, Li L, Zuo X, Li S, Li Y. Melatonin Mitigates Oxazolone-Induced Colitis in Microbiota-Dependent Manner. Front Immunol 2022;12:783806. [DOI: 10.3389/fimmu.2021.783806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
308 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:32-43. [PMID: 35069028 DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
309 Nevejan L, Strypens T, Van Nieuwenhove M, Boel A, Cattoir L, Meeus P, Bossuyt X, De Neve N, Van Hoovels L. Prognostic value of circulating calprotectin levels on the clinical course of COVID-19 differs between serum, heparin, EDTA and citrate sample types. Clin Chim Acta 2022;525:54-61. [PMID: 34919937 DOI: 10.1016/j.cca.2021.12.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
310 Rieker L, Hofer J, Petzold G, Ellenrieder V, Amanzada A. Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report. BMC Gastroenterol 2022;22:22. [PMID: 35033015 DOI: 10.1186/s12876-022-02094-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
311 Williams I, Pandey S, Haller W, Huynh HQ, Chan A, Düeker G, Bettels R, Peyrin-biroulet L, Dike CR, Degeeter C, Smith D, Al Eisa N, Platt N, Marquardt T, Schwerd T, Platt FM, Uhlig HH. Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C. Wellcome Open Res 2022;7:11. [DOI: 10.12688/wellcomeopenres.16986.1] [Reference Citation Analysis]
312 Halder W, Laskaratos F, El-mileik H, Coda S, Fox S, Banerjee S, Epstein O. Review: Colon Capsule Endoscopy in Inflammatory Bowel Disease. Diagnostics 2022;12:149. [DOI: 10.3390/diagnostics12010149] [Reference Citation Analysis]
313 Wu Z, Bi Y. Potential role of MALT1 as a candidate biomarker of disease surveillance and treatment response prediction in inflammatory bowel disease patients. J Clin Lab Anal 2022;:e24130. [PMID: 34997981 DOI: 10.1002/jcla.24130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
314 Liso M, Sila A, Verna G, Scarano A, Donghia R, Castellana F, Cavalcanti E, Pesole PL, Sommella EM, Lippolis A, Armentano R, Giudetti AM, Vergara D, Campiglia P, Sardone R, Curlo M, Mastronardi M, Petroni K, Tonelli C, Santino A, Chieppa M. Nutritional Regimes Enriched with Antioxidants as an Efficient Adjuvant for IBD Patients under Infliximab Administration, a Pilot Study. Antioxidants 2022;11:138. [DOI: 10.3390/antiox11010138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
315 Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne) 2021;8:765474. [PMID: 34988090 DOI: 10.3389/fmed.2021.765474] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
316 Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, Kłopocka M, Małecka-Wojciesko E, Radwan P, Reguła J, Zagórowicz E, Rydzewska G. Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Prz Gastroenterol 2021;16:257-96. [PMID: 34976235 DOI: 10.5114/pg.2021.110914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-κB signaling in inflammation and cancer. MedComm (2020) 2021;2:618-53. [PMID: 34977871 DOI: 10.1002/mco2.104] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 30.0] [Reference Citation Analysis]
318 Kienle P. Chronisch-entzündliche Darmerkrankungen: Morbus Crohn und Colitis ulcerosa. Allgemein- und Viszeralchirurgie II 2022. [DOI: 10.1016/b978-3-437-24812-2.00011-1] [Reference Citation Analysis]
319 Huynh L, Hass S, Peyrin-biroulet L, Duh MS, Sipsma H, Cheng M, Lax A, Nag A. Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe. Crohn's & Colitis 360 2022;4. [DOI: 10.1093/crocol/otac001] [Reference Citation Analysis]
320 李 彦. Application of Infliximab in Inflammatory Bowel Disease: Current Status and Prospects. ACM 2022;12:952-958. [DOI: 10.12677/acm.2022.122139] [Reference Citation Analysis]
321 Archuleta C, Wright M, Kennedy AM, Despain S. Diseases of the Small and Large Bowel. Family Medicine 2022. [DOI: 10.1007/978-3-030-54441-6_181] [Reference Citation Analysis]
322 Zhong LL, Lam WC, Cheung HLH, Lyu A. Integrative medicine in allergy and immunology. Allergic and Immunologic Diseases 2022. [DOI: 10.1016/b978-0-323-95061-9.00047-3] [Reference Citation Analysis]
323 Aslam N, Lo SW, Sikafi R, Barnes T, Segal J, Smith PJ, Limdi JK. A review of the therapeutic management of ulcerative colitis. Therap Adv Gastroenterol 2022;15:175628482211381. [DOI: 10.1177/17562848221138160] [Reference Citation Analysis]
324 Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022;20:74-87.e3. [PMID: 32931960 DOI: 10.1016/j.cgh.2020.09.021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 25.0] [Reference Citation Analysis]
325 van Liere ELSA, Bayoumy AB, Mulder CJJ, Warner B, Hayee B, Mateen BA, Nolan JD, de Boer NKH, Anderson SHC, Ansari AR. Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases. Dig Dis Sci 2022;67:4008-19. [PMID: 34729677 DOI: 10.1007/s10620-021-07273-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
326 Egloff C, Mergui J, Uzan C, Canlorbe G. Prise en charge des lésions cervicales HPV induites chez les patientes immunodéprimées – Revue de la littérature. Gynécologie Obstétrique Fertilité & Sénologie 2022;50:82-92. [DOI: 10.1016/j.gofs.2021.10.012] [Reference Citation Analysis]
327 Wark G, Samocha-bonet D, Ghaly S, Danta M. The role of nutrition in inflammatory bowel disease: disease associations, management of active disease and maintenance of remission. Reference Module in Food Science 2022. [DOI: 10.1016/b978-0-12-821848-8.00104-9] [Reference Citation Analysis]
328 Radhakrishnan ST, Alexander JL, Mullish BH, Gallagher KI, Powell N, Hicks LC, Hart AL, Li JV, Marchesi JR, Williams HRT. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2022;55:26-48. [PMID: 34751954 DOI: 10.1111/apt.16656] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
329 Shinzaki S, Sakagami K, Matsumoto M, Takehara T, Ito H. Nurse-Provided Medication Guidance for Improving Drug Adherence to Thiopurines in Outpatients With Inflammatory Bowel Disease: A Single-Center Prospective Study. Crohn's & Colitis 360 2022;4. [DOI: 10.1093/crocol/otab081] [Reference Citation Analysis]
330 Rabinowitz LG, Kumta NA, Marion JF. Beyond the SCENIC route: updates in chromoendoscopy and dysplasia screening in patients with inflammatory bowel disease. Gastrointest Endosc 2022;95:30-7. [PMID: 34363806 DOI: 10.1016/j.gie.2021.07.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
331 Nazar C, San Martín J, Garretón R, Muñoz A. Cytomegalovirus retinitis in Crohn's disease treated with anti-tumor necrosis factor-alpha antibody. Pan Am J Ophthalmol 2022;4:1. [DOI: 10.4103/pajo.pajo_116_21] [Reference Citation Analysis]
332 Zafer M, Zhang H, Dwadasi S, Goens D, Paknikar R, Dalal S, Cohen RD, Pekow J, Rubin DT, Sakuraba A, Micic D. A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. Crohn's & Colitis 360 2022;4. [DOI: 10.1093/crocol/otab082] [Reference Citation Analysis]
333 Iacucci M, Cannatelli R. Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2022. [DOI: 10.1007/978-3-030-56993-8_29] [Reference Citation Analysis]
334 Orieux A, Brunier J, Rigothier C, Pinson B, Dabernat S, Bats ML. Plasma creatinine below limit of quantification in a patient with acute kidney injury. Clin Chim Acta 2022;524:101-5. [PMID: 34883091 DOI: 10.1016/j.cca.2021.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
335 Brar MS, Macrae H. IBD Diagnosis and Evaluation. The ASCRS Textbook of Colon and Rectal Surgery 2022. [DOI: 10.1007/978-3-030-66049-9_44] [Reference Citation Analysis]
336 Armuzzi A, Bortoli A, Castiglione F, Contaldo A, Daperno M, D'Incà R, Labarile N, Mazzuoli S, Onali S, Milla M, Orlando A, Principi M, Pugliese D, Renna S, Rizzello F, Scribano ML, Todeschini A; Italian Group for the Study of Inflammatory Bowel Disease Working Group:. Female reproductive health and inflammatory bowel disease: A practice-based review. Dig Liver Dis 2022;54:19-29. [PMID: 34120858 DOI: 10.1016/j.dld.2021.05.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
337 Ayroldi E, Migliorati G, Riccardi C. Immunomodulatory and Anti-Inflammatory Properties of Glucocorticoids. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00052-9] [Reference Citation Analysis]
338 Catalán-serra I, Ricanek P, Grimstad T. "Out of the box� new therapeutic strategies for Crohn�s disease: moving beyond biologics. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.9010/2022] [Reference Citation Analysis]
339 Boldovjakova D, Scrimgeour DSG, Parnaby CN, Ramsay G. Improved outcomes for patients undergoing colectomy for acute severe inflammatory colitis by adopting a multi-disciplinary care bundle. J Gastrointest Surg 2022;26:218-20. [PMID: 34282524 DOI: 10.1007/s11605-021-05082-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
340 Conley TE, Fiske J, Subramanian S. How to manage: acute severe colitis. Frontline Gastroenterol 2022;13:64-72. [PMID: 34970430 DOI: 10.1136/flgastro-2020-101710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 El-sahhar S, Varga-weisz P. The gut microbiome in health and disease: Inflammatory bowel diseases. Advances in Ecological Research 2022. [DOI: 10.1016/bs.aecr.2022.09.005] [Reference Citation Analysis]
342 Chen W, Sui J, Wang C. Magnetically Actuated Capsule Robots: A Review. IEEE Access 2022;10:88398-420. [DOI: 10.1109/access.2022.3197632] [Reference Citation Analysis]
343 Kumar A, Saran K, Gupta R. Sleep Disturbances and Functional Gastrointestinal Diseases. Sleep and Neuropsychiatric Disorders 2022. [DOI: 10.1007/978-981-16-0123-1_29] [Reference Citation Analysis]
344 Din S, Gaya D, Kammermeier J, Lamb CA, Macdonald J, Moran G, Parkes G, Pollok R, Sebastian S, Segal J, Selinger C, Smith PJ, Steed H, Arnott ID. Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterol 2022;13:77-81. [PMID: 34966535 DOI: 10.1136/flgastro-2021-101805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
345 Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021; 13(12): 1828-1849 [DOI: 10.4254/wjh.v13.i12.1828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
346 Volynets GV, Khavkin AI. Inflammatory bowel disease and drug-induced liver damage. jour 2021. [DOI: 10.31146/1682-8658-ecg-194-10-138-146] [Reference Citation Analysis]
347 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Papa A, Rapaccini GL, Gasbarrini A, Armuzzi A. Orphan patients with inflammatory bowel disease - when we treat beyond evidence. World J Gastroenterol 2021; 27(47): 8047-8057 [DOI: 10.3748/wjg.v27.i47.8047] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
348 Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM, Strand EK, Mielnik P, Torp R, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA 2021;326:2375-84. [PMID: 34932077 DOI: 10.1001/jama.2021.21316] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
349 Knyazev OV, Belousova EA, Abdulganieva DI, Gubonina IV, Kaibullayeva JA, Marakhouski YK, Chashkova EY, Shapina MV, Shchukina OB, Gegenava BB, Oliferuk NS. Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study. Alʹm klin med 2021;49:443-454. [DOI: 10.18786/2072-0505-2021-49-061] [Reference Citation Analysis]
350 Pagnini C, Di Paolo MC, Graziani MG, Delle Fave G. Probiotics and Vitamin D/Vitamin D Receptor Pathway Interaction: Potential Therapeutic Implications in Inflammatory Bowel Disease. Front Pharmacol 2021;12:747856. [PMID: 34899302 DOI: 10.3389/fphar.2021.747856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
351 Dhaliwal A, Williams FR, Quinlan JI, Allen SL, Greig C, Filer A, Raza K, Ghosh S, Lavery GG, Newsome PN, Choudhary S, Breen L, Armstrong MJ, Elsharkawy AM, Lord JM. Evaluation of the mechanisms of sarcopenia in chronic inflammatory disease: protocol for a prospective cohort study. Skelet Muscle 2021;11:27. [PMID: 34895316 DOI: 10.1186/s13395-021-00282-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
352 Shariff S, Moran G, Grimes C, Cooney RM. Current Use of EEN in Pre-Operative Optimisation in Crohn's Disease. Nutrients 2021;13:4389. [PMID: 34959941 DOI: 10.3390/nu13124389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
353 Golusda L, Kühl AA, Siegmund B, Paclik D. Reducing Pain in Experimental Models of Intestinal Inflammation Affects the Immune Response. Inflamm Bowel Dis 2022;28:801-7. [PMID: 34871378 DOI: 10.1093/ibd/izab290] [Reference Citation Analysis]
354 Mokros Ł, Domżał-Magrowska D, Pietras T, Sipowicz K, Talar-Wojnarowska R. The Association between Temperament, Chronotype, Depressive Symptoms, and Disease Activity among Patients with Inflammatory Bowel Disease-A Cross-Sectional Pilot Study. Life (Basel) 2021;11:1347. [PMID: 34947878 DOI: 10.3390/life11121347] [Reference Citation Analysis]
355 Almuntashri F, Binyaseen K, Alkhotani A. Chronic Inflammatory Demyelinating Polyneuropathy in Patients With Crohn's Disease on Infliximab Therapy. Cureus 2021;13:e19041. [PMID: 34858738 DOI: 10.7759/cureus.19041] [Reference Citation Analysis]
356 Harvey PR, Slater J, Algieder A, Jones J, Bates B, De Silva S. Nurse-led early evaluation following corticosteroid prescription in patients with inflammatory bowel disease. Journal of Prescribing Practice 2021;3:500-506. [DOI: 10.12968/jprp.2021.3.12.500] [Reference Citation Analysis]
357 Gatopoulou A, Christodoulou DK, Katsanos KH, Bakos D, Mouzas I, Tzouvala M, Theodoropoulou A, Paspatis G, Theocharis G, Thomopoulos K, Giouleme O, Kourikou A, Manolakopoulos S, Zampeli E, Michopoulos S, Karatzas P, Katsaros M, Moschovis D, Orfanoudaki E, Livieratos A, Petrikkou E, Mantzaris GJ. Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece. Eur J Gastroenterol Hepatol 2021;33:e615-24. [PMID: 34034278 DOI: 10.1097/MEG.0000000000002182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
358 Razanskaite V, Kallis C, Young B, Williamson PR, Bodger K. Heterogeneity in outcome assessment for inflammatory bowel disease in routine clinical practice: a mixed-methods study in a sample of English hospitals. BMJ Open 2021;11:e056413. [DOI: 10.1136/bmjopen-2021-056413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
359 Yang D. Recent Advance in the Management of Dysplasia in the Ulcerative Colitis. JDCR 2021;9:50-56. [DOI: 10.52927/jdcr.2021.9.2.50] [Reference Citation Analysis]
360 Macaluso FS, Liguori G, Galli M. Vaccinations in patients with inflammatory bowel disease. Dig Liver Dis 2021;53:1539-45. [PMID: 34116972 DOI: 10.1016/j.dld.2021.05.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
361 Crooks B, Misra R, Arebi N, Kok K, Brookes MJ, McLaughlin J, Limdi JK. The dietary practices and beliefs of people living with older-onset inflammatory bowel disease. Eur J Gastroenterol Hepatol 2021;33:e442-8. [PMID: 34357746 DOI: 10.1097/MEG.0000000000002130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
362 Hoy SM. Subcutaneous vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a profile of its use. Drugs Ther Perspect 2021;37:563-572. [DOI: 10.1007/s40267-021-00873-8] [Reference Citation Analysis]
363 Pouw RE, Bisschops R, Gecse KB, de Hertogh G, Iacucci M, Rutter M, Barret M, Biermann K, Czakó L, Hucl T, Jansen M, Savarino E, Spaander MCW, Schmidt PT, Dinis-Ribeiro M, Vieth M, van Hooft JE. Endoscopic tissue sampling - Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021;53:1261-73. [PMID: 34715702 DOI: 10.1055/a-1671-6336] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
364 Ali A, Kumaravel Kanagavelu AS, Rahimi A, Mehmood Z, Tariq AB, Das T, Elmdaah A. A Rare Case of Mesalazine-Induced Acute Myocarditis in a 19-Year-Old Female With Ulcerative Colitis. Cureus 2021. [DOI: 10.7759/cureus.20036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
365 Na SY, Lim YJ. Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom? Diagnostics (Basel) 2021;11:2240. [PMID: 34943477 DOI: 10.3390/diagnostics11122240] [Reference Citation Analysis]
366 Losurdo G, Brescia IV, Lillo C, Mezzapesa M, Barone M, Principi M, Ierardi E, Di Leo A, Rendina M. Liver involvement in inflammatory bowel disease: What should the clinician know? World J Hepatol 2021; 13(11): 1534-1551 [PMID: 34904028 DOI: 10.4254/wjh.v13.i11.1534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
367 Chen S, Zhang C, He B, He R, Xu L, Zhang S. The Role of lncRNAs in Regulating the Intestinal Mucosal Mechanical Barrier. Biomed Res Int 2021;2021:2294942. [PMID: 34820453 DOI: 10.1155/2021/2294942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
368 Iyer N, Corr SC. Gut Microbial Metabolite-Mediated Regulation of the Intestinal Barrier in the Pathogenesis of Inflammatory Bowel Disease. Nutrients 2021;13:4259. [PMID: 34959809 DOI: 10.3390/nu13124259] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
369 Frigerio S, Lartey DA, D'Haens GR, Grootjans J. The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms. Int J Mol Sci 2021;22:12739. [PMID: 34884543 DOI: 10.3390/ijms222312739] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
370 Toçoglu A, Dheir H, Demirci T, Kurt R, Salihi S, Yaylaci S, Çakar GÇ, Toptan H, Karabay O, Sipahi S. The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19. Rev Assoc Med Bras (1992) 2021;67:1299-304. [PMID: 34816924 DOI: 10.1590/1806-9282.20210600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
371 Kjeldsen S, Nielsen J, Mertz Nørgård B, Kjeldsen J. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data. Inflamm Bowel Dis 2022;28:1513-9. [PMID: 34849917 DOI: 10.1093/ibd/izab299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
372 Simpson N, Seenan JP, Patel R, Kipgen D. Acute interstitial nephritis secondary to vedolizumab. BMJ Case Rep 2021;14:e243568. [PMID: 34799387 DOI: 10.1136/bcr-2021-243568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
373 Yang Q, Chen L, Feng L, Liu C, Fang L, Liu Z, Sun X. Success of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Severe Steroid-refractory Ulcerative Colitis. Inflamm Bowel Dis 2021;27:e157-8. [PMID: 34398196 DOI: 10.1093/ibd/izab181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
374 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:2010-22. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
375 Malesza IJ, Malesza M, Walkowiak J, Mussin N, Walkowiak D, Aringazina R, Bartkowiak-Wieczorek J, Mądry E. High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review. Cells 2021;10:3164. [PMID: 34831387 DOI: 10.3390/cells10113164] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 11.5] [Reference Citation Analysis]
376 Beute J, Boermans P, KleinJan A. Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report. Can Respir J 2021;2021:7456208. [PMID: 34760031 DOI: 10.1155/2021/7456208] [Reference Citation Analysis]
377 Ratajczak AE, Szymczak-Tomczak A, Rychter AM, Zawada A, Dobrowolska A, Krela-Kaźmierczak I. Does Folic Acid Protect Patients with Inflammatory Bowel Disease from Complications? Nutrients 2021;13:4036. [PMID: 34836291 DOI: 10.3390/nu13114036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
378 Kim MJ, Ko JS, Shin M, Hahn JW, Moon SY, Kim HY, Moon JS. Colorectal Cancer associated with pediatric inflammatory bowel disease: a case series. BMC Pediatr 2021;21:504. [PMID: 34763671 DOI: 10.1186/s12887-021-02966-9] [Reference Citation Analysis]
379 Jones JL, Benchimol EI, Bernstein CN, Huang JG, Marshall JK, Mukhtar MS, Murthy SK, Nguyen GC, Kaplan GG, Kuenzig ME, Tandon P, Targownik LE, Windsor JW, Bitton A. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. J Can Assoc Gastroenterol 2021;4:S61-7. [PMID: 34755041 DOI: 10.1093/jcag/gwab034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
380 Xia SL, Min QJ, Shao XX, Lin DP, Ma GL, Wu H, Cao SG, Jiang Y. Influence of Vitamin D3 Supplementation on Infliximab Effectiveness in Chinese Patients With Crohn's Disease: A Retrospective Cohort Study. Front Nutr 2021;8:739285. [PMID: 34746207 DOI: 10.3389/fnut.2021.739285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
381 Brar MS, de Buck van Overstraeten A, Baxter NN. Rectal Cancer Incidence is Low Following Rectal Diversion or Subtotal Colectomy for IBD: Results of a Population-based Study. J Crohns Colitis 2021;15:1787-98. [PMID: 34165532 DOI: 10.1093/ecco-jcc/jjab090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Kichloo A, Dahiya DS, Shaka H, Jamal S, Khan MZ, Wani F, Mehboob A, Kanjwal K. Impact of atrial fibrillation on inflammatory bowel disease hospitalizations-a nationwide retrospective study. Proc (Bayl Univ Med Cent) 2021;34:673-7. [PMID: 34732983 DOI: 10.1080/08998280.2021.1951071] [Reference Citation Analysis]
383 Sagar R, Lenti MV, Clark T, Rafferty HJ, Gracie DJ, Ford AC, O'Connor A, Ahmad T, Hamlin PJ, Selinger CP. Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. Inflamm Intest Dis 2021;6:132-9. [PMID: 34722643 DOI: 10.1159/000515593] [Reference Citation Analysis]
384 Walsh C. Microscopic colitis and the role of the specialist inflammatory bowel disease nurse: a clinical review. Gastrointestinal Nursing 2021;19:20-26. [DOI: 10.12968/gasn.2021.19.9.20] [Reference Citation Analysis]
385 Cao Y, Wang Z, Yan Y, Ji L, He J, Xuan B, Shen C, Ma Y, Jiang S, Ma D, Tong T, Zhang X, Gao Z, Zhu X, Fang JY, Chen H, Hong J. Enterotoxigenic Bacteroidesfragilis Promotes Intestinal Inflammation and Malignancy by Inhibiting Exosome-Packaged miR-149-3p. Gastroenterology 2021;161:1552-1566.e12. [PMID: 34371001 DOI: 10.1053/j.gastro.2021.08.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
386 Quera R, Simian D, Núñez P, Flores L. Immunization in patients with inflammatory bowel disease: Still far from standards. Dig Liver Dis 2021;53:1519-20. [PMID: 34148863 DOI: 10.1016/j.dld.2021.05.030] [Reference Citation Analysis]
387 Snook J, Bhala N, Beales ILP, Cannings D, Kightley C, Logan RP, Pritchard DM, Sidhu R, Surgenor S, Thomas W, Verma AM, Goddard AF. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut 2021;70:2030-51. [PMID: 34497146 DOI: 10.1136/gutjnl-2021-325210] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
388 Claytor JD, Viramontes O, Conner S, Wen KW, Beck K, Chin-Hong PV, Henrich TJ, Peluso MJ. TNF-α inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines. AIDS 2021;35:2163-8. [PMID: 34115645 DOI: 10.1097/QAD.0000000000002985] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
389 Cassinotti A, Corona A, Duca P, Nebuloni M, Maconi G, Fociani P, Ardizzone S. Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission. Clin Gastroenterol Hepatol 2021;19:2293-2301.e1. [PMID: 34139332 DOI: 10.1016/j.cgh.2021.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
390 Popa IV, Burlacu A, Gavrilescu O, Dranga M, Prelipcean CC, Mihai C. A new approach to predict ulcerative colitis activity through standard clinical–biological parameters using a robust neural network model. Neural Comput & Applic 2021;33:14133-14146. [DOI: 10.1007/s00521-021-06055-x] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
391 Doherty J, Fennessy S, Stack R, O' Morain N, Cullen G, Ryan EJ, De Gascun C, Doherty GA. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. Aliment Pharmacol Ther 2021;54:1110-23. [PMID: 34472643 DOI: 10.1111/apt.16590] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
392 Hegner J, Patel J, Fong S, Jeffs S. THE ROLE OF A SPECIALIST PHARMACIST IN THE MANAGEMENT OF ADALIMUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Int J Pharm Pharm Sci 2021. [DOI: 10.22159/ijpps.2021v13i11.42451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
393 Mateen BA, Patel M, Akobeng AK, Gordon M, Hayee B. 6-thioguanine nucleotide monitoring in azathioprine and mercaptopurine monotherapy for the treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews 2021;2022. [DOI: 10.1002/14651858.cd014795] [Reference Citation Analysis]
394 Li S, Li P, Sun H, Hu W, Hu S, Chen Y, Lv M. Medication Belief is Associated with Improved Adherence to Exclusive Enteral Nutrition in Patients with Crohn's Disease. Patient Prefer Adherence 2021;15:2327-34. [PMID: 34703215 DOI: 10.2147/PPA.S330842] [Reference Citation Analysis]
395 Zhang T, Xu Y, Yao Y, Jin L, Liu H, Zhou Y, Gu L, Ji Q, Zhu W, Gong J. Randomized Controlled Trial: Perioperative Dexamethasone Reduces Excessive Postoperative Inflammatory Response and Ileus After Surgery for Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1756-65. [PMID: 33749741 DOI: 10.1093/ibd/izab065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
396 Fasoulas K, Stergiou E, Soufleris K. Ustekinumab for Crohn Disease With Severe Gastroduodenal Involvement. Inflamm Bowel Dis 2021;27:e123. [PMID: 33999143 DOI: 10.1093/ibd/izab128] [Reference Citation Analysis]
397 Chiba M, Morita N, Nakamura A, Tsuji K, Harashima E. Increased Incidence of Inflammatory Bowel Disease in Association with Dietary Transition (Westernization) in Japan. JMA J 2021;4:347-57. [PMID: 34796289 DOI: 10.31662/jmaj.2021-0038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
398 Shen Z, Huang W, Liu J, Tian J, Wang S, Rui K. Effects of Mesenchymal Stem Cell-Derived Exosomes on Autoimmune Diseases. Front Immunol 2021;12:749192. [PMID: 34646275 DOI: 10.3389/fimmu.2021.749192] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
399 Basson AR, Rodriguez-Palacios A, Cominelli F. Artificial Sweeteners: History and New Concepts on Inflammation. Front Nutr 2021;8:746247. [PMID: 34631773 DOI: 10.3389/fnut.2021.746247] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
400 Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247 [PMID: 34712029 DOI: 10.3748/wjg.v27.i37.6231] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
401 Fumery M, Yzet C, Chatelain D, Yzet T, Brazier F, LeMouel JP, Laharie D, Sabbagh C. Colonic Strictures in Inflammatory Bowel Disease: Epidemiology, Complications, and Management. J Crohns Colitis 2021;15:1766-73. [PMID: 33844013 DOI: 10.1093/ecco-jcc/jjab068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
402 Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. BioDrugs 2021;35:473-503. [PMID: 34613592 DOI: 10.1007/s40259-021-00496-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Texler B, Zollner A, Reinstadler V, Reider SJ, Macheiner S, Jelusic B, Pfister A, Watschinger C, Przysiecki N, Tilg H, Oberacher H, Moschen AR. Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics. Cell Mol Gastroenterol Hepatol 2022;13:383-404. [PMID: 34624526 DOI: 10.1016/j.jcmgh.2021.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
404 Akbar A, Arnott I, Kennedy NA, Nolan J, Peake S, Whiteoak SR, Probert C, Fraser A, Cheshire A, Lewis A, Sugrue K, Laird S, Scott G. Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. Br J Hosp Med (Lond) 2021;82:1-11. [PMID: 34726945 DOI: 10.12968/hmed.2021.0399] [Reference Citation Analysis]
405 Harvey PR, Slater J, Algieder A, Jones J, Bates B, De Silva S. Nurse-led early evaluation following corticosteroid prescription in patients with inflammatory bowel disease. Gastrointestinal Nursing 2021;19:36-41. [DOI: 10.12968/gasn.2021.19.8.36] [Reference Citation Analysis]
406 Aardoom MA, Klomberg RCW, Kemos P, Ruemmele FM, van Ommen CHH, de Ridder L, Croft NM; PIBD-VTE Group, PIBD-SETQuality Consortium. The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry. J Crohns Colitis 2022;16:695-707. [PMID: 34599822 DOI: 10.1093/ecco-jcc/jjab171] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
407 Suzuki K, Fujii H, Yamauchi T, Kato‐hayashi H, Ishihara M, Iihara H, Hirose C, Nishida S, Funato M, Kobayashi R, Yasuda K, Ino Y, Tamaki H, Yamashita S, Iguchi K, Noguchi Y, Teramachi H, Takada J, Kubota M, Ibuka T, Araki H, Shimizu M, Suzuki A. Questionnaire survey to identify meal habits which influence adherence to oral 5‐aminosalicylic acid regimens in patients with ulcerative colitis. J Pharm Pract Res 2021;51:374-380. [DOI: 10.1002/jppr.1712] [Reference Citation Analysis]
408 Nguyen ALH, Sparrow MP. Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules. Dig Dis Sci 2021;66:3250-62. [PMID: 33073334 DOI: 10.1007/s10620-020-06662-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
409 Bakshi N, Hart AL, Lee MC, Williams ACC, Lackner JM, Norton C, Croft P. Chronic pain in patients with inflammatory bowel disease. Pain 2021;162:2466-71. [PMID: 34534174 DOI: 10.1097/j.pain.0000000000002304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
410 Bali AS, Picco MF, Hashash JG, Farraye FA, Kröner PT. Time to Flexible Sigmoidoscopy or Colonoscopy in Patients Admitted With Ulcerative Colitis Has Decreased From 2012 to 2018. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab080] [Reference Citation Analysis]
411 Schauer C, Avery V, Seleq S, Garg P, Wang MTM, Chieng M, Rowan C, Sekra A, Lane M, Walmsley R. A comparison of intravenous methylprednisolone and hydrocortisone for the treatment of acute inflammatory bowel disease. J Gastroenterol Hepatol 2021;36:2762-8. [PMID: 33939853 DOI: 10.1111/jgh.15535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
412 Takahashi K, Khwaja IG, Schreyer JR, Bulmer D, Peiris M, Terai S, Aziz Q. Post-inflammatory Abdominal Pain in Patients with Inflammatory Bowel Disease During Remission: A Comprehensive Review. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab073] [Reference Citation Analysis]
413 Lundgren D, Widbom L, Hultdin J, Karling P. Preclinical Markers in Inflammatory Bowel Disease. A Nested Case–Control Study. Crohn's & Colitis 360 2021;3:otab072. [DOI: 10.1093/crocol/otab072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
414 Roberts KJ, Cubitt MF, Carlton TM, Rodrigues-Duarte L, Maggiore L, Chai R, Clare S, Harcourt K, MacDonald TT, Ray KP, Vossenkämper A, West MR, Crowe JS. Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Sci Rep 2021;11:19422. [PMID: 34593832 DOI: 10.1038/s41598-021-97236-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
415 Mitrev N, Huang H, Hannah B, Kariyawasam VC. Review of exclusive enteral therapy in adult Crohn's disease. BMJ Open Gastroenterol 2021;8:e000745. [PMID: 34580154 DOI: 10.1136/bmjgast-2021-000745] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
416 Byrne LW, McKay D. Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic review. Surgeon 2021;19:e153-67. [PMID: 34581275 DOI: 10.1016/j.surge.2020.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
417 Shields VE, Cooper J. Use of helminth therapy for management of ulcerative colitis and Crohn's disease: a systematic review. Parasitology 2021;:1-10. [PMID: 34579797 DOI: 10.1017/S0031182021001670] [Reference Citation Analysis]
418 Vrdoljak J, Kumric M, Ticinovic Kurir T, Males I, Martinovic D, Vilovic M, Bozic J. Effects of Wine Components in Inflammatory Bowel Diseases. Molecules 2021;26:5891. [PMID: 34641434 DOI: 10.3390/molecules26195891] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
419 Hagihara K, Mori R, Sekido Y, Ogino T, Hata T, Takahashi H, Miyoshi N, Uemura M, Doki Y, Eguchi H, Mizushima T. Defecation Function After Laparo-Assisted Restorative Proctocolectomy with Ileal Pouch Anal Anastomosis for Ulcerative Colitis. J Laparoendosc Adv Surg Tech A 2021. [PMID: 34569880 DOI: 10.1089/lap.2021.0465] [Reference Citation Analysis]
420 Watanabe S, Nishimura R, Shirasaki T, Katsukura N, Hibiya S, Kirimura S, Negi M, Okamoto R, Matsumoto Y, Nakamura T, Watanabe M, Tsuchiya K. Schlafen 11 Is a Novel Target for Mucosal Regeneration in Ulcerative Colitis. J Crohns Colitis 2021;15:1558-72. [PMID: 33596306 DOI: 10.1093/ecco-jcc/jjab032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
421 Rosiou K, Ong Ming San E, Kumar A, Esquivel K, Almas S, Stokes D, Ng T, Jayasooriya N, Ranasinghe I, Pollok R, Brookes M, Selinger CP. Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study. J Clin Med 2021;10:4329. [PMID: 34640345 DOI: 10.3390/jcm10194329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
422 Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, Bryant R, Begun J, Ward MG, Lewindon PJ, Connor SJ, Ghaly S, Christensen B. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 2021;3:212-28. [PMID: 34539248 DOI: 10.1002/ygh2.473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
423 Sienkiewicz M, Szymańska P, Maciejewska O, Niewiadomska J, Wiśniewska‐jarosińska M, Fichna J. Assessment of dietary habits in inflammatory bowel disease patients: A cross‐sectional study from Poland. Nutr Bull 2021;46:432-42. [DOI: 10.1111/nbu.12525] [Reference Citation Analysis]
424 Cohan JN, Ozanne EM, Hofer RK, Kelly YM, Kata A, Larsen C, Finlayson E. Ileostomy or ileal pouch-anal anastomosis for ulcerative colitis: patient participation and decisional needs. BMC Gastroenterol 2021;21:347. [PMID: 34538236 DOI: 10.1186/s12876-021-01916-0] [Reference Citation Analysis]
425 Okobi OE, Udoete IO, Fasehun OO, Okobi T, Evbayekha EO, Ekabua JJ, Elukeme H, Ebong IL, Ajayi OO, Olateju IV, Taiwo A, Anaya IC, Omole JA, Nkongho MB, Ojinnaka U, Ajibowo AO, Ogbeifun OE, Ugbo OO, Okorare O, Akinsola Z, Olusoji RA, Amanze IO, Nwafor JN, Ukoha NA, Elimihele TA. A Review of Four Practice Guidelines of Inflammatory Bowel Disease. Cureus 2021;13:e16859. [PMID: 34513436 DOI: 10.7759/cureus.16859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
426 Wijnands AM, Mahmoud R, Lutgens MWMD, Oldenburg B. Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectives. Eur J Intern Med 2021;93:35-41. [PMID: 34481721 DOI: 10.1016/j.ejim.2021.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
427 Rocha R, de J Santos G, Santana G. Influence of nutritional status in the postoperative period of patients with inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2021; 12(5): 90-99 [PMID: 34616585 DOI: 10.4292/wjgpt.v12.i5.90] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
428 Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis 2022;28:1254-64. [PMID: 34480558 DOI: 10.1093/ibd/izab228] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
429 Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary Osteoporosis. Endocr Rev 2021:bnab028. [PMID: 34476488 DOI: 10.1210/endrev/bnab028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
430 Taylor J. Patient access to biological medications for ulcerative colitis. Gastrointestinal Nursing 2021;19:32-39. [DOI: 10.12968/gasn.2021.19.7.32] [Reference Citation Analysis]
431 Scott R, Parker H, Mccartney S, Harrow P, Williams D, Giles I. Outcomes following biosimilar TNF inhibitors use for inflammatory-mediated immune disorders in pregnancy. Obstet Med. [DOI: 10.1177/1753495x211028779] [Reference Citation Analysis]
432 Saikaly E, Saad MK. Postcolonoscopy Colorectal Cancer: An Overview and Future Directions. Journal of Coloproctology 2021;41:301-307. [DOI: 10.1055/s-0041-1730014] [Reference Citation Analysis]
433 Gatenby G, Glyn T, Pearson J, Gearry R, Eglinton T. The long-term incidence of dysplasia and colorectal cancer in a Crohn's colitis population-based cohort. Colorectal Dis 2021;23:2399-406. [PMID: 34041848 DOI: 10.1111/codi.15756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
434 Li Z, Wang Y, Liu J, Rawding P, Bu J, Hong S, Hu Q. Chemically and Biologically Engineered Bacteria-Based Delivery Systems for Emerging Diagnosis and Advanced Therapy. Adv Mater 2021;33:e2102580. [PMID: 34347325 DOI: 10.1002/adma.202102580] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
435 da Silva ISM, Cambi MPC, Magro DO, Kotze PG. Perioperative Nutritional Optimization in Inflammatory Bowel Diseases: When and How? Journal of Coloproctology 2021;41:295-300. [DOI: 10.1055/s-0041-1730369] [Reference Citation Analysis]
436 Ye TY, Mei Y, Bao DN, Zhu YF, Xu XH, Zhu LF. Maternal anti-tumour necrosis factor-α drug use during pregnancy and risk of infection in the offspring: A systematic review and meta-analysis. Dig Liver Dis 2021;53:1112-7. [PMID: 33376073 DOI: 10.1016/j.dld.2020.11.033] [Reference Citation Analysis]
437 Sanderson J, Escudier MP. Diseases of the Gastrointestinal Tract. Burket's Oral Medicine 2021. [DOI: 10.1002/9781119597797.ch15] [Reference Citation Analysis]
438 Yong HM, Park SJ, Jeon SR, Park H, Kim HG, Lee TH, Park J, Kim JO, Lee JS, Ko BM, Goong HJ, Park S. Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis. Medicine (Baltimore) 2021;100:e27065. [PMID: 34449501 DOI: 10.1097/MD.0000000000027065] [Reference Citation Analysis]
439 Larussa T, Basile A, Palleria C, Iannelli C, Vero A, Giubilei L, De Sarro C, Suraci E, Marasco R, Imeneo M, Russo E, Abenavoli L, De Sarro G, Luzza F. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. Med Pharm Rep 2021;94:289-97. [PMID: 34430850 DOI: 10.15386/mpr-1897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
440 Huang H, Liu B, Qu N, Zhang S, Bai X, Handley M, Shan F. Research progress of opioid growth factor in immune-related diseases and cancer diseases. Int Immunopharmacol 2021;99:107713. [PMID: 34426103 DOI: 10.1016/j.intimp.2021.107713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
441 Zhou YF, Sun N, Cheng SR, Deng XD, Ye XY, Li ZJ, Zhou J, Xu GX, Qu YZ, Huang LY, Sun RR, Liang FR. Effectiveness and safety of acupuncture therapy for inflammatory bowel disease: a protocol of systematic review and meta-analysis. BMJ Open 2021;11:e045090. [PMID: 34429304 DOI: 10.1136/bmjopen-2020-045090] [Reference Citation Analysis]
442 O'Hagan P, Limdi J, Akbar A, Tucknott S, Kahol DN. Ulcerative colitis: understanding the impact of ulcerative colitis on everyday life and exploring the unmet needs of patients. Curr Med Res Opin 2021;37:1901-11. [PMID: 34420463 DOI: 10.1080/03007995.2021.1971180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
443 Paridaens K, Fullarton JR, Travis SPL. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Curr Med Res Opin 2021;37:1891-900. [PMID: 34404286 DOI: 10.1080/03007995.2021.1968813] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
444 Ahmed S, Newton PD, Ojo O, Dibley L. Experiences of ethnic minority patients who are living with a primary chronic bowel condition: a systematic scoping review with narrative synthesis. BMC Gastroenterol 2021;21:322. [PMID: 34407752 DOI: 10.1186/s12876-021-01857-8] [Reference Citation Analysis]
445 Yau TO, Vadakekolathu J, Foulds GA, Du G, Polytarchou C, Dickins B, Rutella S. Hyperactive chemotaxis contributes to anti-TNFα treatment resistance in inflammatory bowel disease.. [DOI: 10.1101/2021.08.15.456400] [Reference Citation Analysis]
446 Bower JAJ, O'Flynn L, Kakad R, Aldulaimi D. Effect of inflammatory bowel disease treatments on patients with diabetes mellitus. World J Diabetes 2021; 12(8): 1248-1254 [PMID: 34512890 DOI: 10.4239/wjd.v12.i8.1248] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
447 Rodríguez-Lago I, Mesonero F, Hijos-Mallada G, Cañas M, Saldaña R, Savini C, Fernández S, Juliá B, Cea-Calvo L; ACCU, GETECCU, GETEII. Self-medication with analgesics reported by patients with ulcerative colitis: An anonymous survey. Gastroenterol Hepatol 2021:S0210-5705(21)00227-2. [PMID: 34400189 DOI: 10.1016/j.gastrohep.2021.07.009] [Reference Citation Analysis]
448 Day AS, Yao CK, Costello SP, Andrews JM, Bryant RV. Food avoidance, restrictive eating behaviour and association with quality of life in adults with inflammatory bowel disease: A systematic scoping review. Appetite 2021;167:105650. [PMID: 34391842 DOI: 10.1016/j.appet.2021.105650] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
449 Su L, Su Y, An Z, Zhang P, Yue Q, Zhao C, Sun X, Zhang S, Liu X, Li K, Zhao L. Fermentation products of Danshen relieved dextran sulfate sodium-induced experimental ulcerative colitis in mice. Sci Rep 2021;11:16210. [PMID: 34376708 DOI: 10.1038/s41598-021-94594-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
450 Antunes JC, Seabra CL, Domingues JM, Teixeira MO, Nunes C, Costa-Lima SA, Homem NC, Reis S, Amorim MTP, Felgueiras HP. Drug Targeting of Inflammatory Bowel Diseases by Biomolecules. Nanomaterials (Basel) 2021;11:2035. [PMID: 34443866 DOI: 10.3390/nano11082035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
451 Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
452 Alipour O, Gualti A, Shao L, Zhang B. Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease. BMC Gastroenterol 2021;21:312. [PMID: 34344314 DOI: 10.1186/s12876-021-01883-6] [Reference Citation Analysis]
453 Kim JM, Kang JG, Kim S, Cheon JH. Deep-learning system for real-time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis. J Gastroenterol Hepatol 2021;36:2141-8. [PMID: 33554375 DOI: 10.1111/jgh.15433] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
454 Zielińska AK, Sałaga M, Siwiński P, Włodarczyk M, Dziki A, Fichna J. Oxidative Stress Does Not Influence Subjective Pain Sensation in Inflammatory Bowel Disease Patients. Antioxidants (Basel) 2021;10:1237. [PMID: 34439485 DOI: 10.3390/antiox10081237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
455 Yang QY, Liu YJ, Xu Y, Zhang L, Wang CD. Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease. J Dig Dis 2021;22:473-80. [PMID: 34240823 DOI: 10.1111/1751-2980.13032] [Reference Citation Analysis]
456 Mohamed DZ, Ghoneim MES, Abu-Risha SES, Abdelsalam RA, Farag MA. Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management. World J Gastroenterol 2021; 27(28): 4504-4535 [PMID: 34366621 DOI: 10.3748/wjg.v27.i28.4504] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
457 Iliopoulou L, Kollias G. Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment. Mucosal Immunol 2021. [PMID: 34316007 DOI: 10.1038/s41385-021-00433-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
458 Fernández-Sánchez M, Ribes-Artero H, Romá-Sánchez E, Gómez-Portero MR, Guerrero-Hurtado E, García-Pellicer J, Poveda-Andrés JL. Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report. Birth Defects Res 2021. [PMID: 34309233 DOI: 10.1002/bdr2.1942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
459 Meijboom RW, Gardarsdottir H, Becker ML, de Groot MCH, Movig KLL, Kuijvenhoven J, Egberts TCG, Leufkens HGM, Giezen TJ. Switching TNFα inhibitors: Patterns and determinants. Pharmacol Res Perspect 2021;9:e00843. [PMID: 34302442 DOI: 10.1002/prp2.843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
460 Dowdell AS, Colgan SP. Metabolic Host-Microbiota Interactions in Autophagy and the Pathogenesis of Inflammatory Bowel Disease (IBD). Pharmaceuticals (Basel) 2021;14:708. [PMID: 34451805 DOI: 10.3390/ph14080708] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
461 Sinopoulou V, Gordon M, Dovey TM, Akobeng AK. Interventions for the management of abdominal pain in ulcerative colitis. Cochrane Database Syst Rev 2021;7:CD013589. [PMID: 34291816 DOI: 10.1002/14651858.CD013589.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
462 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
463 Gargallo-Puyuelo CJ, Laredo V, Gomollón F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907. [PMID: 34336887 DOI: 10.3389/fmed.2021.681907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
464 Loras C, Mañosa M, Andújar X, Sánchiz V, Martí-Gallostra M, Zabana Y, Gutiérrez A, Barreiro-de Acosta M; en representación de GETECCU. Position Statement. Recommendations of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of strictures in Crohn's disease. Gastroenterol Hepatol 2021:S0210-5705(21)00219-3. [PMID: 34274357 DOI: 10.1016/j.gastrohep.2021.07.001] [Reference Citation Analysis]
465 Adams A, Gupta V, Mohsen W, Chapman TP, Subhaharan D, Ramaswamy PK, Vuyyuru SK, Kedia S, Mcgregor CG, Ambrose T, George BD, Palmer R, Brain O, Walsh A, Ahuja V, Travis S, Satsangi J. Optimising Early Management of Acute Severe Ulcerative Colitis in the Biologics Era: Admission Model for Intensification of Therapy in Acute Severe Colitis (ADMIT–ASC).. [DOI: 10.1101/2021.07.14.21260477] [Reference Citation Analysis]
466 Park SH, Park SH, Ye BD. Interpretation of Enterography in Patients with Crohn’s Disease. Korean J Abdom Radiol 2021;5:1-16. [DOI: 10.52668/kjar.2021.00017] [Reference Citation Analysis]
467 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
468 Deng F, Xia P, Wu Z, Zhou H, Wang X. Perianal and Luminal Relapse Following Perianal Surgical Intervention in Crohn's Disease. Int J Gen Med 2021;14:3387-96. [PMID: 34285563 DOI: 10.2147/IJGM.S315505] [Reference Citation Analysis]
469 de Bock E, Filipe MD, Meij V, Oldenburg B, van Schaik FDM, Bastian OW, Fidder HF, Vriens MR, Richir MC. Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands. BMJ Open Gastroenterol 2021;8:e000670. [PMID: 34215570 DOI: 10.1136/bmjgast-2021-000670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
470 Alexander JL, Ibraheim H, Sheth B, Little J, Khan MS, Richards C, Hunter N, Chauhan D, Ratnakumaran R, McHugh K, Pinato DJ, Nathan P, Choy J, Crusz SM, Furness A, Turajlic S, Pickering L, Larkin J, Teare JP, Papa S, Speight A, Sharma A, Powell N. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. J Immunother Cancer 2021;9:e002742. [PMID: 34233964 DOI: 10.1136/jitc-2021-002742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
471 Verburgt CM, Heutink WP, Kuilboer LIM, Dickmann JD, van Etten-Jamaludin FS, Benninga MA, de Jonge WJ, Van Limbergen JE, Tabbers MM. Antibiotics in pediatric inflammatory bowel diseases: a systematic review. Expert Rev Gastroenterol Hepatol 2021;15:891-908. [PMID: 34148466 DOI: 10.1080/17474124.2021.1940956] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
472 Adamina M, Feakins R, Iacucci M, Spinelli A, Cannatelli R, D'Hoore A, Driessen A, Katsanos K, Mookhoek A, Myrelid P, Pellino G, Peros G, Tontini GE, Tripathi M, Yanai H, Svrcek M. ECCO Topical Review Optimising Reporting in Surgery, Endoscopy, and Histopathology. J Crohns Colitis 2021;15:1089-105. [PMID: 33428711 DOI: 10.1093/ecco-jcc/jjab011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
473 Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. J Crohns Colitis 2021;15:1184-96. [PMID: 33433562 DOI: 10.1093/ecco-jcc/jjab010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
474 Stansfield C. Vedolizumab (Entyvio) in Crohn's disease. Gastrointestinal Nursing 2021;19:20-28. [DOI: 10.12968/gasn.2021.19.6.20] [Reference Citation Analysis]
475 Schnitzler F, Seitz T, Tillack-schreiber C, Lange S, Waggershauser C, Ochsenkühn T. Early Start of Infliximab in Crohn’s Disease Increases Rates of Endoscopic Remission and Decreases Stenosis Formation: Experiences From a Single Center Cohort. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab060] [Reference Citation Analysis]
476 Rodriguez-Palacios A, Basson AR, Cominelli F. Artificial Sweeteners and Whole-Food Science: Could Mice Help Clinicians Make Diet Recommendations for IBD Patients? Gastroenterology 2021;161:8-14. [PMID: 33798527 DOI: 10.1053/j.gastro.2021.03.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
477 Jain SR, Ow ZGW, Chin YH, Lim WH, Kong G, Tham HY, Wong NW, Chong CS, Foo FJ, Chan WPW. Quantifying the rate of recurrence of postoperative Crohn's disease with biological therapy. A meta-analysis. J Dig Dis 2021;22:399-407. [PMID: 34048153 DOI: 10.1111/1751-2980.13025] [Reference Citation Analysis]
478 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
479 . Inflammatory bowel disease. Colorectal Surgery 2021. [DOI: 10.1093/med/9780192896247.003.0004] [Reference Citation Analysis]
480 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
481 López-Serrano A, Suárez MJ, Besó P, Algarra A, Latorre P, Barrachina MM, Paredes JM. Virtual chromoendoscopy with iSCAN as an alternative method to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammatory bowel disease: a case-control study. Scand J Gastroenterol 2021;56:820-8. [PMID: 34043920 DOI: 10.1080/00365521.2021.1925339] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
482 Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M. Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals (Basel) 2021;14:637. [PMID: 34209234 DOI: 10.3390/ph14070637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
483 Fossmark R, Olaisen M, Martinsen TC, Melberg HO. Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study. Therap Adv Gastroenterol 2021;14:17562848211021760. [PMID: 34262610 DOI: 10.1177/17562848211021760] [Reference Citation Analysis]
484 Sninsky J, Barnes EL. Medical Management of Aggressive Inflammatory Bowel Disease: When Is the Time to Cut Your (and the Patient's) Losses? J Laparoendosc Adv Surg Tech A 2021;31:905-10. [PMID: 34171979 DOI: 10.1089/lap.2021.0338] [Reference Citation Analysis]
485 Chien TH, Puig A, Khuong T, Kouhkamari MH, Che S, Huang TH. An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn's Disease. Biologics 2021;15:237-45. [PMID: 34163137 DOI: 10.2147/BTT.S310076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
486 Stange EF. Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. Z Gastroenterol 2021. [PMID: 34161990 DOI: 10.1055/a-1482-9273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
487 Radford SJ, Clarke C, Shinkins B, Leighton P, Taylor S, Moran G. Clinical utility of small bowel ultrasound assessment of Crohn’s disease in adults: a systematic scoping review. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
488 Johnson LE, Lee MJ, Turner-Moore T, Grinsted Tate LR, Brooks AJ, Tattersall RS, Jones GL, Lobo AJ. Systematic Review of Factors Affecting Transition Readiness Skills in Patients with Inflammatory Bowel Disease. J Crohns Colitis 2021;15:1049-59. [PMID: 33252669 DOI: 10.1093/ecco-jcc/jjaa245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
489 Kabir M, Thomas-Gibson S, Hart AL, Wilson A. Perception of Cancer Risk and Management Practice for Colitis-associated Dysplasia Is Influenced by Colonoscopy Experience and Workplace Affiliation: Results of an International Clinician Survey. J Crohns Colitis 2022;16:39-48. [PMID: 34155511 DOI: 10.1093/ecco-jcc/jjab110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
490 Bqain M, Efimov A, Baker D, Kang AS. Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review. Hum Antibodies 2021. [PMID: 34151784 DOI: 10.3233/HAB-210449] [Reference Citation Analysis]
491 Udomkarnjananun S, Francke MI, De Winter BCM, Mulder MB, Baan CC, Metselaar HJ, den Hoed CM, Hesselink DA. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101756. [PMID: 34874840 DOI: 10.1016/j.bpg.2021.101756] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
492 Si Y, Shao L, Gao S, Wen H. Suppository treatment in ulcerative proctitis. Eur J Inflamm 2021;19:205873922110151. [DOI: 10.1177/20587392211015108] [Reference Citation Analysis]
493 Xiang BJ, Huang YH, Dai C. A Rare Autoinflammatory Syndrome Involving Acute Severe Ulcerative Colitis Combined With Iritis. Inflamm Bowel Dis 2021;27:e83-6. [PMID: 33694367 DOI: 10.1093/ibd/izab043] [Reference Citation Analysis]
494 Barenbrug L, Groen MT, Hoentjen F, van Drongelen J, Reek JMPAVD, Joosten I, de Jong EMGJ, van der Molen RG. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis. J Autoimmun 2021;122:102676. [PMID: 34126302 DOI: 10.1016/j.jaut.2021.102676] [Reference Citation Analysis]
495 Tontini GE, Rimondi A, Vernero M, Neumann H, Vecchi M, Bezzio C, Cavallaro F. Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons. Therap Adv Gastroenterol 2021;14:17562848211017730. [PMID: 34178115 DOI: 10.1177/17562848211017730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
496 Yalchin M, Baker AM, Graham TA, Hart A. Predicting Colorectal Cancer Occurrence in IBD. Cancers (Basel) 2021;13:2908. [PMID: 34200768 DOI: 10.3390/cancers13122908] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
497 Edwards K, Yearsley K. Unusual presentation of Crohn's disease. BMJ Case Rep 2021;14:e242703. [PMID: 34108157 DOI: 10.1136/bcr-2021-242703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
498 Moradi S, Zobeiri M, Feizi A, Clark CCT, Entezari MH. The effects of spirulina (Arthrospira platensis) supplementation on anthropometric indices, blood pressure, sleep quality, mental health, fatigue status and quality of life in patients with ulcerative colitis: A randomised, double-blinded, placebo-controlled trial. Int J Clin Pract 2021;:e14472. [PMID: 34107141 DOI: 10.1111/ijcp.14472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
499 Gordon-Dixon A, Hampal R, Miah A, Webb-Butler S, Lewis W, Ross R, Ghosh N, Grimes C. Does exclusive enteral nutrition reduce the rate of stoma formation in patients requiring ileocolic resection for Crohn's disease? A single center experience. Clin Nutr ESPEN 2021;44:282-6. [PMID: 34330480 DOI: 10.1016/j.clnesp.2021.05.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
500 Torun A, Hupalowska A, Trzonkowski P, Kierkus J, Pyrzynska B. Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children. Front Immunol 2021;12:642166. [PMID: 34163468 DOI: 10.3389/fimmu.2021.642166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
501 Chandwe K, Kelly P. Colostrum Therapy for Human Gastrointestinal Health and Disease. Nutrients 2021;13:1956. [PMID: 34200282 DOI: 10.3390/nu13061956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
502 Bruscoli S, Febo M, Riccardi C, Migliorati G. Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice. Front Immunol 2021;12:691480. [DOI: 10.3389/fimmu.2021.691480] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
503 Zhang W, Michalowski CB, Beloqui A. Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment. Front Bioeng Biotechnol 2021;9:675194. [PMID: 34150733 DOI: 10.3389/fbioe.2021.675194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
504 Chaparro M, Donday MG, Abad-Santos F, Martín de Carpi FJ, Maciá-Martínez MÁ, Montero D, Acosta D, Brenes Y, Gisbert JP. The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. Therap Adv Gastroenterol 2021;14:17562848211018097. [PMID: 34158835 DOI: 10.1177/17562848211018097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
505 Park S, Kim H. Focus on Rectal Mass. JDCR 2021;9:40-41. [DOI: 10.52927/jdcr.2021.9.1.40] [Reference Citation Analysis]
506 Guillo L, D'Amico F, Achit H, Ayav C, Guillemin F, Danese S, Frimat L, Peyrin-Biroulet L. Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. Dig Liver Dis 2021;53:691-6. [PMID: 33563584 DOI: 10.1016/j.dld.2021.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
507 Sicilia B, Vicente R, Arias L, Echarri A, Zabana Y, Mañosa M, Beltrán B, Barreiro-de Acosta M. Recommendations of the Spanish Working Group on Crohn’s disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa — GETECCU) on dysplasia screening in inflammatory bowel disease patients. Gastroenterología y Hepatología (English Edition) 2021;44:435-447. [DOI: 10.1016/j.gastre.2020.12.002] [Reference Citation Analysis]
508 Guan Y, Hao Y, Guan Y, Bu H, Wang H. Effects of vitamin D supplementation on blood markers in ulcerative colitis patients: a systematic review and meta-analysis. Eur J Nutr 2021. [PMID: 34075433 DOI: 10.1007/s00394-021-02603-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
509 Meier JL. Viral Acute Gastroenteritis in Special Populations. Gastroenterol Clin North Am 2021;50:305-22. [PMID: 34024443 DOI: 10.1016/j.gtc.2021.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
510 Roblin X, Nancey S, Paul S. Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply. Aliment Pharmacol Ther 2021;53:1319-20. [PMID: 34029416 DOI: 10.1111/apt.16399] [Reference Citation Analysis]
511 Mathur A, McLean MH, Cao H, Vickers MA. Hyposplenism and Gastrointestinal Diseases: Significance and Mechanisms. Dig Dis 2022;40:290-8. [PMID: 34034254 DOI: 10.1159/000517338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
512 Gu Z, Zhu Y, Mei F, Dong X, Xia G, Shen X. Tilapia head glycolipids protect mice against dextran sulfate sodium-induced colitis by ameliorating the gut barrier and suppressing NF-kappa B signaling pathway. Int Immunopharmacol 2021;96:107802. [PMID: 34162163 DOI: 10.1016/j.intimp.2021.107802] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
513 Huang X, Liu F, Guan H, Jiang Z, Wei P, Luo Y, Jia Q. Effects of endoscopic submucosal dissection on post-operative early treatment effectiveness and serum TAT-2 and GP73 expression levels in patients with early gastric cancer. Exp Ther Med 2021;22:806. [PMID: 34093762 DOI: 10.3892/etm.2021.10238] [Reference Citation Analysis]
514 Blackwell J, Alexakis C, Saxena S, Creese H, Bottle A, Petersen I, Hotopf M, Pollok RCG. Association between antidepressant medication use and steroid dependency in patients with ulcerative colitis: a population-based study. BMJ Open Gastroenterol 2021;8:e000588. [PMID: 34045238 DOI: 10.1136/bmjgast-2020-000588] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
515 Gerasimidis K, Godny L, Sigall-boneh R, Svolos V, Wall C, Halmos E. Current recommendations on the role of diet in the aetiology and management of IBD. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2020-101429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
516 Shaffer SR, Erondu AI, Traboulsi C, Rai V, Krugliak Cleveland N, Israel A, Christensen B, Rubin DT. Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. Inflamm Bowel Dis 2022;28:553-9. [PMID: 34037230 DOI: 10.1093/ibd/izab130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
517 Anasseri M. Effect of Cognitive-Behavioral Group Therapy on the Anxiety and Depression of War-Handicapped. J Arch Mil Med 2021;9. [DOI: 10.5812/jamm.114085] [Reference Citation Analysis]
518 Khan F, Person H, Dekio F, Ogawa M, Ho HE, Dunkin D, Secord E, Cunningham-Rundles C, Ward SC. Crohn's-like Enteritis in X-Linked Agammaglobulinemia: A Case Series and Systematic Review. J Allergy Clin Immunol Pract 2021:S2213-2198(21)00579-1. [PMID: 34029777 DOI: 10.1016/j.jaip.2021.04.070] [Reference Citation Analysis]
519 Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond) 2021;21:135-9. [PMID: 33762374 DOI: 10.7861/clinmed.2021-0080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
520 Garcia KS, Facas BP, Machado MB, Teixeira FV, Avedano L, Lönnfors S, Hossne RS, Peyrin-Biroulet L, Queiroz NSF. Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients. Therap Adv Gastroenterol 2021;14:17562848211013249. [PMID: 34046083 DOI: 10.1177/17562848211013249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
521 Huang Q, Zhang X, Hu Z. Application of Artificial Intelligence Modeling Technology Based on Multi-Omics in Noninvasive Diagnosis of Inflammatory Bowel Disease. J Inflamm Res 2021;14:1933-43. [PMID: 34017190 DOI: 10.2147/JIR.S306816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
522 De Simone B, Davies J, Chouillard E, Di Saverio S, Hoentjen F, Tarasconi A, Sartelli M, Biffl WL, Ansaloni L, Coccolini F, Chiarugi M, De'Angelis N, Moore EE, Kluger Y, Abu-Zidan F, Sakakushev B, Coimbra R, Celentano V, Wani I, Pintar T, Sganga G, Di Carlo I, Tartaglia D, Pikoulis M, Cardi M, De Moya MA, Leppaniemi A, Kirkpatrick A, Agnoletti V, Poggioli G, Carcoforo P, Baiocchi GL, Catena F. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. World J Emerg Surg 2021;16:23. [PMID: 33971899 DOI: 10.1186/s13017-021-00362-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
523 Dernoncourt A, Schmidt J, Duhaut P, Liabeuf S, Gras-Champel V, Masmoudi K, Bennis Y, Batteux B. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database. Fundam Clin Pharmacol 2021. [PMID: 33973280 DOI: 10.1111/fcp.12695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
524 Moon SY, Kim KD, Yoo J, Lee JH, Hwangbo C. Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models. Molecules 2021;26:2824. [PMID: 34068714 DOI: 10.3390/molecules26092824] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
525 Rathore AS, Stevenson JG, Chhabra H, Maharana C. The global landscape on interchangeability of biosimilars. Expert Opin Biol Ther 2021;:1-16. [PMID: 33567923 DOI: 10.1080/14712598.2021.1889511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
526 Iqbal N, Sackitey C, Reza L, Warusavitarne J, Tozer P, Hart A. Patient perceptions of joint medical-surgical assessment in a tertiary referral clinic for inflammatory bowel disease. British Journal of Healthcare Management 2021;27:146-151. [DOI: 10.12968/bjhc.2020.0121] [Reference Citation Analysis]
527 Deputy M, Segal J, Reza L, Worley G, Costello S, Burns E, Faiz O, Clark S, Hart A. The pouch behaving badly: management of morbidity after ileal pouch-anal anastomosis. Colorectal Dis 2021;23:1193-204. [PMID: 33523546 DOI: 10.1111/codi.15553] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
528 Napolitano D, Scaldaferri F, Fiorino G, Spagnuolo R, Leonetti A, Lopetuso LR, Cocchieri A. Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey. Gastroenterol Nurs 2021;44:E59-66. [PMID: 34037573 DOI: 10.1097/SGA.0000000000000593] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
529 Fantini MC, Guadagni I. From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies. Dig Liver Dis 2021;53:558-65. [PMID: 33541800 DOI: 10.1016/j.dld.2021.01.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
530 Pérez-Garza DM, Chavez-Alvarez S, Ocampo-Candiani J, Gomez-Flores M. Erythema Nodosum: A Practical Approach and Diagnostic Algorithm. Am J Clin Dermatol 2021;22:367-78. [PMID: 33683567 DOI: 10.1007/s40257-021-00592-w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
531 Waked B, Holvoet T, Geldof J, Baert F, Pattyn P, Lobatón T, Hindryckx P. Conservative management of spontaneous intra-abdominal abscess in Crohn's disease: Outcome and prognostic factors. J Dig Dis 2021;22:263-70. [PMID: 33742782 DOI: 10.1111/1751-2980.12984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
532 Colombo A, Giuffrè M, Crocè LS, Venturini S, Sablich R. Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test. Pathogens 2021;10:535. [PMID: 33946817 DOI: 10.3390/pathogens10050535] [Reference Citation Analysis]
533 Le Fevre ER, McGrath KH, Fitzgerald DA. Pulmonary Manifestations of Gastrointestinal, Pancreatic, and Liver Diseases in Children. Pediatr Clin North Am 2021;68:41-60. [PMID: 33228942 DOI: 10.1016/j.pcl.2020.09.002] [Reference Citation Analysis]
534 Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol 2020;32:371-9. [PMID: 32412995 DOI: 10.1097/BOR.0000000000000713] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
535 Hawthorne TZ, Shellien R, Chambers L, Devereux G. CMV pneumonitis in a patient with Crohn's disease taking azathioprine. BMJ Case Rep 2021;14:e241256. [PMID: 33893128 DOI: 10.1136/bcr-2020-241256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
536 Liu X, Li Y, Wu K, Shi Y, Chen M. Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2021;2021:6612970. [PMID: 33981340 DOI: 10.1155/2021/6612970] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
537 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 29.0] [Reference Citation Analysis]
538 Albishi AM, Chakik R, Bazeed M. Renal Cell Carcinoma in Fistulizing Crohn's Disease Patient Who Received Anti-TNF α Therapy. Case Rep Gastrointest Med 2021;2021:5593067. [PMID: 33968453 DOI: 10.1155/2021/5593067] [Reference Citation Analysis]
539 Lovatt J, Gascoyne-Binzi D, Hussey T, Garside M, McGill F, Selinger CP. Screening for TB in Hospitalised Patients with Inflammatory Bowel Disease before Anti-TNF Therapy: Is QuantiFERON® Gold Testing Useful? J Clin Med 2021;10:1816. [PMID: 33919426 DOI: 10.3390/jcm10091816] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
540 Bertani L, Ribaldone DG, Bellini M, Mumolo MG, Costa F. Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions? Nutrients 2021;13:1387. [PMID: 33924119 DOI: 10.3390/nu13041387] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
541 Pepe M, Carulli E, Forleo C, Moscarelli M, Di Cillo O, Bortone AS, Nestola PL, Biondi-Zoccai G, Giordano A, Favale S. Inflammatory Bowel Disease and Acute Coronary Syndromes: From Pathogenesis to the Fine Line Between Bleeding and Ischemic Risk. Inflamm Bowel Dis 2021;27:725-31. [PMID: 32592478 DOI: 10.1093/ibd/izaa160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
542 Wang Z, Chen J, Chen Z, Xie L, Wang W. Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora. Saudi J Gastroenterol 2021;27:149-57. [PMID: 33835051 DOI: 10.4103/sjg.SJG_462_20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
543 Maconi G, Camatta D, Cannatelli R, Ferretti F, Carvalhas Gabrielli A, Ardizzone S. Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. Ther Clin Risk Manag 2021;17:285-92. [PMID: 33854320 DOI: 10.2147/TCRM.S263835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
544 Uchino M, Ikeuchi H, Hata K, Minagawa T, Horio Y, Kuwahara R, Nakamura S, Watanabe K, Saruta M, Fujii T, Kobayashi T, Sugimoto K, Hirai F, Esaki M, Hiraoka S, Matsuoka K, Shinzaki S, Matsuura M, Inoue N, Nakase H, Watanabe M. Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:864-72. [PMID: 33002235 DOI: 10.1111/jgh.15288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
545 Kennedy NA. Integrating a treat to target approach into clinical practice in 2020. J Gastroenterol Hepatol 2021;36 Suppl 1:6-7. [PMID: 33817849 DOI: 10.1111/jgh.15446] [Reference Citation Analysis]
546 Mountifield R. Anti-tumor necrosis factors (TNFs) are outdated-It's time to move on: Session three summary. J Gastroenterol Hepatol 2021;36 Suppl 1:25-6. [PMID: 33817852 DOI: 10.1111/jgh.15455] [Reference Citation Analysis]
547 An YK. Common mistakes with steroids. J Gastroenterol Hepatol 2021;36 Suppl 1:30-1. [PMID: 33817842 DOI: 10.1111/jgh.15458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
548 Nuñez F. P, Quera R, Simian D, Flores L, Figueroa C, Ibañez P, Kronberg U, Lubascher J, Pizarro G. Infliximab in inflammatory bowel disease. Is premedication necessary? Gastroenterología y Hepatología (English Edition) 2021. [DOI: 10.1016/j.gastre.2020.07.012] [Reference Citation Analysis]
549 Husam Al-Ani A, Christensen B. Endoscopic and histologic endpoints as treatment targets: Are we there yet? J Gastroenterol Hepatol 2021;36 Suppl 1:8-9. [PMID: 33817841 DOI: 10.1111/jgh.15447] [Reference Citation Analysis]
550 Stournaras E, Qian W, Pappas A, Hong YY, Shawky R, Raine T, Parkes M; UK IBD BioResource Investigators, UK IBD Bioresource Investigators. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. Gut 2021;70:677-86. [PMID: 33004550 DOI: 10.1136/gutjnl-2019-320185] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
551 Correia JP, Ponte AI, Silva JC, Gomes AC, Afecto E. Mesalazine-induced acute pancreatitis: a rare adverse reaction but with important therapeutic implications in ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:595. [PMID: 33657605 DOI: 10.1097/MEG.0000000000001901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
552 Tokuyama M, Dhingra S, Polydorides AD. Clinicopathologic Features and Diagnostic Implications of Pyloric Gland Metaplasia in Intestinal Specimens. Am J Surg Pathol 2021;45:365-73. [PMID: 33105158 DOI: 10.1097/PAS.0000000000001608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
553 Joustra V, Duijvestein M, Mookhoek A, Bemelman W, Buskens C, Koželj M, Novak G, Hindryckx P, Mostafavi N, D'Haens G. Natural History and Risk Stratification of Recurrent Crohn's Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study. Inflamm Bowel Dis 2022;28:1-8. [PMID: 33783507 DOI: 10.1093/ibd/izab044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
554 Kim KU, Kim J, Kim WH, Min H, Choi CH. Treatments of inflammatory bowel disease toward personalized medicine. Arch Pharm Res 2021;44:293-309. [PMID: 33763844 DOI: 10.1007/s12272-021-01318-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
555 Takeyama E, Wada H, Sato S, Tomooka K, Ikeda A, Tanigawa T. Association of diagnostic delay with medical cost for patients with Crohn's disease: A Japanese claims-based cohort study. JGH Open 2021;5:568-72. [PMID: 34013056 DOI: 10.1002/jgh3.12534] [Reference Citation Analysis]
556 Garrido I, Lopes S, Macedo G. Endoscopy in Small Bowel Crohn’s Disease. Endoscopy in Small Bowel Diseases 2021. [DOI: 10.5772/intechopen.95925] [Reference Citation Analysis]
557 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
558 Zielińska A, Sobolewska-Włodarczyk A, Wiśniewska-Jarosińska M, Gąsiorowska A, Fichna J, Sałaga M. The 25(OH)D3, but Not 1,25(OH)2D3 Levels Are Elevated in IBD Patients Regardless of Vitamin D Supplementation and Do Not Associate with Pain Severity or Frequency. Pharmaceuticals (Basel) 2021;14:284. [PMID: 33809912 DOI: 10.3390/ph14030284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
559 Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol 2021;14:71-81. [PMID: 33727846 DOI: 10.2147/CEG.S197719] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
560 Grant RK, Jones GR, Plevris N, Lynch RW, Jenkinson PW, Lees CW, Manship TA, Jagger FAM, Brindle WM, Shivakumar M, Satsangi J, Arnott IDR. The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis. Inflamm Bowel Dis 2021;27:451-7. [PMID: 32572468 DOI: 10.1093/ibd/izaa088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
561 Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding. Int J Mol Sci 2021;22:2922. [PMID: 33805757 DOI: 10.3390/ijms22062922] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
562 Singhi AD, Waters KM, Makhoul EP, Parian A, Lazarev MG, Proksell SS, Dueker JM, Schwartz MB, Wald AI, Nikiforova MN, Montgomery EA. Targeted next-generation sequencing supports serrated epithelial change as an early precursor to inflammatory bowel disease-associated colorectal neoplasia. Hum Pathol 2021;112:9-19. [PMID: 33727167 DOI: 10.1016/j.humpath.2021.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
563 Papa A, Scaldaferri F, Vetrone LM, Neri M, Gasbarrini A, Lopetuso LR. How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. Vaccines (Basel) 2021;9:248. [PMID: 33808983 DOI: 10.3390/vaccines9030248] [Reference Citation Analysis]
564 Arkteg CB, Wergeland Sørbye S, Buhl Riis L, Dalen SM, Florholmen J, Goll R. Real-life evaluation of histologic scores for Ulcerative Colitis in remission. PLoS One 2021;16:e0248224. [PMID: 33684168 DOI: 10.1371/journal.pone.0248224] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
565 Lamot L, Miler M, Vukojević R, Vidović M, Lamot M, Trutin I, Gabaj NN, Harjaček M. The Increased Levels of Fecal Calprotectin in Children With Active Enthesitis Related Arthritis and MRI Signs of Sacroiliitis: The Results of a Single Center Cross-Sectional Exploratory Study in Juvenile Idiopathic Arthritis Patients. Front Med (Lausanne) 2021;8:650619. [PMID: 33763437 DOI: 10.3389/fmed.2021.650619] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
566 Chen QL, Yin HR, He QY, Wang Y. Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease. Biomed Pharmacother 2021;138:111442. [PMID: 33667791 DOI: 10.1016/j.biopha.2021.111442] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
567 Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. J Crohns Colitis 2021;15:462-70. [PMID: 32931556 DOI: 10.1093/ecco-jcc/jjaa189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
568 Denesh D, Carbonell J, Kane JS, Gracie D, Selinger CP. Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration. Expert Rev Gastroenterol Hepatol 2021;15:1091-6. [PMID: 33653185 DOI: 10.1080/17474124.2021.1898944] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
569 Wellens J, Vermeire S, Sabino J. Let Food Be Thy Medicine-Its Role in Crohn's Disease. Nutrients 2021;13:832. [PMID: 33802429 DOI: 10.3390/nu13030832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
570 Häuser W, Morlion B, Vowles KE, Bannister K, Buchser E, Casale R, Chenot JF, Chumbley G, Drewes AM, Dom G, Jutila L, O'Brien T, Pogatzki-Zahn E, Rakusa M, Suarez-Serrano C, Tölle T, Krčevski Škvarč N. European* clinical practice recommendations on opioids for chronic noncancer pain - Part 1: Role of opioids in the management of chronic noncancer pain. Eur J Pain 2021;25:949-68. [PMID: 33655607 DOI: 10.1002/ejp.1736] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 11.5] [Reference Citation Analysis]
571 Quera R, Simian D, Núñez P, Flores L, Figueroa C, Ibáñez P, Kronberg U, Lubascher J, Pizarro G. Are patients with inflammatory bowel disease receiving adequate immunisation? Gastroenterología y Hepatología (English Edition) 2021;44:198-205. [DOI: 10.1016/j.gastre.2020.06.018] [Reference Citation Analysis]
572 Brynza M, V. N. Karazin Kharkiv National University, Uvarova K, V. N. Karazin Kharkiv National University. Issues of inflammatory bowel disease management in primary care. Shidnoevr z vnutr simejnoi med 2021;2021:109-115. [DOI: 10.15407/internalmed2021.01.109] [Reference Citation Analysis]
573 Abdalla T, Lowes MA, Kaur N, Micheletti RG, Steinhart AH, Alavi A. Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors? Am J Clin Dermatol 2021;22:139-47. [PMID: 33398848 DOI: 10.1007/s40257-020-00579-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
574 Nigam GB, Bhandare AP, Antoniou GA, Limdi JK. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2021;33:346-57. [PMID: 32889976 DOI: 10.1097/MEG.0000000000001917] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
575 Raine T, Gkini MA, Irving PM, Kaul A, Korendowych E, Laws P, Foulkes AC. Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists. BioDrugs 2021;35:187-99. [PMID: 33635522 DOI: 10.1007/s40259-020-00464-5] [Reference Citation Analysis]
576 Irving PM, de Lusignan S, Tang D, Nijher M, Barrett K. Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study. BMJ Open Gastroenterol 2021;8:e000573. [PMID: 33597152 DOI: 10.1136/bmjgast-2020-000573] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
577 Dhaliwal A, Quinlan JI, Overthrow K, Greig C, Lord JM, Armstrong MJ, Cooper SC. Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview. Nutrients 2021;13:656. [PMID: 33671473 DOI: 10.3390/nu13020656] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
578 Niriella MA, Liyanage IK, Kodisinghe SK, De Silva AP, Jayatissa AVGAM, Navarathne NMM, Peiris RK, Kalubovila UP, Kumarasena SR, Jayasekara RW, de Silva HJ. Changing phenotype, early clinical course and clinical predictors of inflammatory bowel disease in Sri Lanka: a retrospective, tertiary care-based, multi-centre study. BMC Gastroenterol 2021;21:71. [PMID: 33593289 DOI: 10.1186/s12876-021-01644-5] [Reference Citation Analysis]
579 Sicilia B, Vicente R, Arias L, Echarri A, Zabana Y, Mañosa M, Beltrán B, Barreiro-de Acosta M; en nombre de GETECCU. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients. Gastroenterol Hepatol 2021;44:435-47. [PMID: 33592179 DOI: 10.1016/j.gastrohep.2020.12.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
580 Di Ruscio M, Tinazzi I, Variola A, Geccherle A, Marchetta A, McGonagle D. Prevalence and Real-World Management of Vedolizumab Associated Enthesitis in Successfully Treated IBD Patients. Rheumatology (Oxford) 2021:keab135. [PMID: 33580246 DOI: 10.1093/rheumatology/keab135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
581 Bertani L, Tricò D, Zanzi F, Baiano Svizzero G, Coppini F, de Bortoli N, Bellini M, Antonioli L, Blandizzi C, Marchi S. Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis. Nutrients 2021;13:608. [PMID: 33673371 DOI: 10.3390/nu13020608] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
582 Carriss-Wright J. Running a one-stop clinic for patients with inflammatory bowel disease. Br J Nurs 2021;30:190-1. [PMID: 33565929 DOI: 10.12968/bjon.2021.30.3.190] [Reference Citation Analysis]
583 Kim H, Alten R, Cummings F, Danese S, D'Haens G, Emery P, Ghosh S, Gilletta de Saint Joseph C, Lee J, Lindsay JO, Nikiphorou E, Parker B, Schreiber S, Simoens S, Westhovens R, Jeong JH, Peyrin-Biroulet L. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs 2021;13:1868078. [PMID: 33557682 DOI: 10.1080/19420862.2020.1868078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
584 Spencer NJ, Fryer AA, Farmer AD, Duff CJ. Blood test monitoring of immunomodulatory therapy in inflammatory disease. BMJ. [DOI: 10.1136/bmj.n159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
585 Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opin Drug Saf 2021;20:275-92. [PMID: 33412078 DOI: 10.1080/14740338.2021.1873948] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
586 Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA;  PROTECT-ASUC Study Group. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterol Hepatol. 2021;6:271-281. [PMID: 33545083 DOI: 10.1016/s2468-1253(21)00016-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
587 Dore MP, Fanciulli G, Manca A, Cocco V, Nieddu A, Murgia M, Pes GM. Clinically relevant thyroid disorders and inflammatory bowel disease are inversely related: a retrospective case-control study. Scand J Gastroenterol 2021;56:171-6. [PMID: 33327797 DOI: 10.1080/00365521.2020.1861323] [Reference Citation Analysis]
588 Gill SK, Rossi M, Bajka B, Whelan K. Dietary fibre in gastrointestinal health and disease. Nat Rev Gastroenterol Hepatol 2021;18:101-16. [PMID: 33208922 DOI: 10.1038/s41575-020-00375-4] [Cited by in Crossref: 163] [Cited by in F6Publishing: 163] [Article Influence: 81.5] [Reference Citation Analysis]
589 Oudman E, Wijnia JW, Oey MJ, van Dam M, Postma A. Wernicke's encephalopathy in Crohn's disease and ulcerative colitis. Nutrition 2021;86:111182. [PMID: 33611107 DOI: 10.1016/j.nut.2021.111182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
590 Erdman KA, Jones KW, Madden RF, Gammack N, Parnell JA. Dietary Patterns in Runners with Gastrointestinal Disorders. Nutrients 2021;13:448. [PMID: 33572891 DOI: 10.3390/nu13020448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
591 Tominaga K, Sugaya T, Tanaka T, Kanazawa M, Iijima M, Irisawa A. Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:582291. [PMID: 33584261 DOI: 10.3389/fphar.2020.582291] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
592 Wong NACS, Wallage MJ, Virgo P, Lowes H. Sampling endoscopically normal large bowel mucosa from patients presenting with elevated faecal calprotectin levels is not clinically justified. J Clin Pathol 2021:jclinpath-2020-207343. [PMID: 33509947 DOI: 10.1136/jclinpath-2020-207343] [Reference Citation Analysis]
593 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
594 MacFarlane H, Baldock TE, McLean RC, Brown LR. Patient Outcomes Following Emergency Bowel Resection for Inflammatory Bowel Disease and the Impact of Surgical Subspecialisation in the North of England: A Retrospective Cohort Study. World J Surg 2021;45:1376-89. [PMID: 33506292 DOI: 10.1007/s00268-020-05947-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
595 Smith PJ. Moving house-moving medical teams: keeping control of my IBD. Frontline Gastroenterol 2021;12:3-4. [PMID: 33493245 DOI: 10.1136/flgastro-2019-101378] [Reference Citation Analysis]
596 Na S. Therapeutic Approach to Inflammatory Bowel Disease Using Human Microbial Modification. Korean J Gastroenterol 2021;77:1-3. [DOI: 10.4166/kjg.2021.012] [Reference Citation Analysis]
597 Malnick SDH, Abdullah A, Neuman MG. Checkpoint Inhibitors and Hepatotoxicity. Biomedicines 2021;9:101. [PMID: 33494227 DOI: 10.3390/biomedicines9020101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
598 Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, Iqbal T, Allen P, Hoque S, Engineer J, Akobeng AK. Interventions for treating iron deficiency anaemia in inflammatory bowel disease. Cochrane Database Syst Rev 2021;1:CD013529. [PMID: 33471939 DOI: 10.1002/14651858.CD013529.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
599 Yao J, Jiang X, You JHS. A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy. Inflamm Bowel Dis 2021;27:275-82. [PMID: 32311018 DOI: 10.1093/ibd/izaa073] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
600 Ala M, Kheyri Z. The rationale for selenium supplementation in inflammatory bowel disease: A mechanism-based point of view. Nutrition 2021;85:111153. [PMID: 33578241 DOI: 10.1016/j.nut.2021.111153] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
601 D'Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. J Crohns Colitis 2021;15:152-61. [PMID: 32392336 DOI: 10.1093/ecco-jcc/jjaa093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
602 Wan Q, Zhao R, Xia L, Wu Y, Zhou Y, Wang Y, Cui Y, Shen X, Wu XT. Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: a meta-analysis of 26 observational studies. J Cancer Res Clin Oncol 2021;147:1077-87. [PMID: 33433655 DOI: 10.1007/s00432-020-03496-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
603 Richards T, Breymann C, Brookes MJ, Lindgren S, Macdougall IC, McMahon LP, Munro MG, Nemeth E, Rosano GMC, Schiefke I, Weiss G. Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice. Ann Med 2021;53:274-85. [PMID: 33426933 DOI: 10.1080/07853890.2020.1867323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
604 Krusiński A, Grzywa-Celińska A, Szewczyk K, Grzycka-Kowalczyk L, Emeryk-Maksymiuk J, Milanowski J. Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents. Int J Inflam 2021;2021:6284987. [PMID: 33489084 DOI: 10.1155/2021/6284987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
605 Gupta V, Mohsen W, Chapman TP, Satsangi J. Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021. J Crohns Colitis 2021;15:1211-21. [PMID: 33388777 DOI: 10.1093/ecco-jcc/jjaa265] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
606 A A, S D, M S, G T. A Complex Case of Adalimumab Induced Pleuropericarditis in a Patient with Underlying Ulcerative Colitis. Asp Biomed Clin Case Rep 2021;4:16-21. [DOI: 10.36502/2021/asjbccr.6223] [Reference Citation Analysis]
607 Siddique O, Vaziri H, Anderson JC. Colon Cancer Screening and Surveillance in the IBD Patient. Clinical Gastroenterology 2021. [DOI: 10.1007/978-3-030-81780-0_10] [Reference Citation Analysis]
608 Archuleta C, Wright M, Kennedy AM, Despain S. Diseases of the Small and Large Bowel. Family Medicine 2021. [DOI: 10.1007/978-1-4939-0779-3_181-1] [Reference Citation Analysis]
609 Gordon C, Chee D, Hamilton B, Heerasing NM, Hendy P, Chanchlani N, Lin S, Wesley E, Daniels IR, Silva N, Osborne M, Kennedy NA, Goodhand JR, Ahmad T. Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2021;53:291-301. [PMID: 33159472 DOI: 10.1111/apt.16155] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
610 Yusuf F, Kamarlis RK, Muhsin M. Ulcerative Colitis in Hemophilia A Patient: Case Report. Mater Sociomed 2021;33:75-7. [PMID: 34012356 DOI: 10.5455/msm.2021.33.75-77] [Reference Citation Analysis]
611 Sacks OA, Goldwag JL, Eid MA, Shaw RD, Williams TJ, Ivatury SJ. Poor Baseline Health of IBD Patients at Presentation to a Surgeon: Results From a Patient-Reported Outcomes Database. Crohn's & Colitis 360 2021;3:otaa096. [DOI: 10.1093/crocol/otaa096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
612 Östlund I, Werner M, Karling P. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease. Scand J Gastroenterol 2021;56:38-45. [PMID: 33284639 DOI: 10.1080/00365521.2020.1854342] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
613 Iacucci M, Cannatelli R. Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2021. [DOI: 10.1007/978-3-030-29964-4_29-1] [Reference Citation Analysis]
614 Abdulganieva DI, Bakulev AL, Belousova EA, Veselov AV, Korotaeva TV, Lila AM, Loginova EY, Sokolovskiy EV, Khobeysh MM, Shapina MV, Shchukina OB. Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion. Alʹm klin med 2020;48:422-436. [DOI: 10.18786/2072-0505-2020-48-050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
615 Lang-Schwarz C, Agaimy A, Atreya R, Becker C, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Tilg H, Villanacci V, Westerhoff M, Vieth M. Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. Virchows Arch 2021;478:581-94. [PMID: 33373023 DOI: 10.1007/s00428-020-02982-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
616 Pitman S, Jones C, Polyak S, Taylor A, Cerven-jenn D, Reist D. Exploring Cost Savings with Specialty Biologic Drugs Administered to Adult Inpatients with Inflammatory Bowel Disease. Hosp Pharm. [DOI: 10.1177/0018578720985430] [Reference Citation Analysis]
617 Shivaji UN, Bazarova A, Critchlow T, Smith SCL, Nardone OM, Love M, Davis J, Ghosh S, Iacucci M. Clinical outcomes, predictors of prognosis and health economics consequences in IBD patients after discontinuation of the first biological therapy. Therap Adv Gastroenterol 2020;13:1756284820981216. [PMID: 34104206 DOI: 10.1177/1756284820981216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
618 Comeche JM, Gutierrez-Hervás A, Tuells J, Altavilla C, Caballero P. Predefined Diets in Patients with Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Nutrients 2020;13:E52. [PMID: 33375314 DOI: 10.3390/nu13010052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
619 Hou S, Yang X, Tong Y, Yang Y, Chen Q, Wan B, Wei R, Wang Y, Zhang Y, Kong B, Huang J, Chen Y, Lu T, Hu Q, Du D. Structure-based discovery of 1H-indole-2-carboxamide derivatives as potent ASK1 inhibitors for potential treatment of ulcerative colitis. Eur J Med Chem 2021;211:113114. [PMID: 33360793 DOI: 10.1016/j.ejmech.2020.113114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
620 Crooks B, Mclaughlin J, Limdi J. Dietary beliefs and recommendations in inflammatory bowel disease: a national survey of healthcare professionals in the UK. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2020-101723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
621 Wu Y, Zhang L, Cao J, Wang H, Ye C, Zhuoma D, Yang P, Wang X. Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820976923. [PMID: 33425009 DOI: 10.1177/1756284820976923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
622 Tang-Fichaux M, Chagneau CV, Bossuet-Greif N, Nougayrède JP, Oswald É, Branchu P. The Polyphosphate Kinase of Escherichia coli Is Required for Full Production of the Genotoxin Colibactin. mSphere 2020;5:e01195-20. [PMID: 33328353 DOI: 10.1128/mSphere.01195-20] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
623 Hicks A, Hamlin PJ, Selinger CP. The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment. Inflamm Intest Dis 2020;5:191-9. [PMID: 33313071 DOI: 10.1159/000509907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
624 Cainzos-Achirica M, Glassner K, Zawahir HS, Dey AK, Agrawal T, Quigley EMM, Abraham BP, Acquah I, Yahya T, Mehta NN, Nasir K. Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2020;76:2895-905. [PMID: 33303079 DOI: 10.1016/j.jacc.2020.10.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
625 Zuluaga Arbeláez N, Sierra Vargas EC, Díaz Coronado JC, Guevara Casallas LG. Colitis ulcerativa para no gastroenterólogos. CES Med 2020;34:188-197. [DOI: 10.21615/cesmedicina.34.3.2] [Reference Citation Analysis]
626 Giráldez-Montero JM, Gonzalez-Lopez J, Campos-Toimil M, Lamas-Díaz MJ. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements. Br J Clin Pharmacol 2021;87:2216-27. [PMID: 33197071 DOI: 10.1111/bcp.14654] [Reference Citation Analysis]
627 Gioxari A, Amerikanou C, Papada E, Zioga E, Georgoulis AD, Bamias G, Kaliora AC. Serum Vitamins D, B9 and B12 in Greek Patients with Inflammatory Bowel Diseases. Nutrients 2020;12:E3734. [PMID: 33291539 DOI: 10.3390/nu12123734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
628 Svatkova OA, Sheptulin AA. Sources of Bias in Common Diagnosis of Chronic Inflammatory Bowel Diseases. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2020;30:26-29. [DOI: 10.22416/1382-4376-2020-30-5-26-29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
629 Gethins S. Access to secondary care services for patients with established inflammatory bowel disease. Gastrointestinal Nursing 2020;18:20-25. [DOI: 10.12968/gasn.2020.18.10.20] [Reference Citation Analysis]
630 Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:689-704. [PMID: 33121689 DOI: 10.1016/j.gtc.2020.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
631 Clark-Snustad K, Butnariu M, Afzali A. Women's Health and Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:769-89. [PMID: 33121695 DOI: 10.1016/j.gtc.2020.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
632 Heo Y. Tofacitinib in ulcerative colitis: a profile of its use. Drugs Ther Perspect 2020;36:553-563. [DOI: 10.1007/s40267-020-00789-9] [Reference Citation Analysis]
633 Hernandez-rocha C, Vande Casteele N. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. Current Opinion in Pharmacology 2020;55:99-109. [DOI: 10.1016/j.coph.2020.10.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
634 Grammatikopoulou MG, Goulis DG, Gkiouras K, Nigdelis MP, Papageorgiou ST, Papamitsou T, Forbes A, Bogdanos DP. Low FODMAP Diet for Functional Gastrointestinal Symptoms in Quiescent Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials. Nutrients 2020;12:E3648. [PMID: 33260902 DOI: 10.3390/nu12123648] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
635 Yan ZX, Liu YM, Ma T, Xu MJ, Zhang XB, Zha XJ, Yang JH, Jiang P, Chen X, Lin ZW, Wu YH, Zu RZ, Lin WR, Lin XY. Efficacy and safety of retention enema with traditional Chinese medicine for ulcerative colitis: A meta-analysis of randomized controlled trials. Complement Ther Clin Pract 2021;42:101278. [PMID: 33276227 DOI: 10.1016/j.ctcp.2020.101278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
636 Polidano K, Chew-Graham CA, Farmer AD, Saunders B. Access to Psychological Support for Young People Following Stoma Surgery: Exploring Patients' and Clinicians' Perspectives. Qual Health Res 2021;31:535-49. [PMID: 33228473 DOI: 10.1177/1049732320972338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
637 Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodriguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. CMAJ 2020;192:E295-301. [PMID: 32392512 DOI: 10.1503/cmaj.191012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
638 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
639 Popa IV, Burlacu A, Mihai C, Prelipcean CC. A Machine Learning Model Accurately Predicts Ulcerative Colitis Activity at One Year in Patients Treated with Anti-Tumour Necrosis Factor α Agents. Medicina (Kaunas) 2020;56:E628. [PMID: 33233514 DOI: 10.3390/medicina56110628] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
640 Ferenczi S, Solymosi N, Horváth I, Szeőcs N, Grózer Z, Kuti D, Juhász B, Winkler Z, Pankotai T, Sükösd F, Stágel A, Paholcsek M, Dóra D, Nagy N, Kovács KJ, Zanoni I, Szallasi Z. Efficient treatment of a preclinical inflammatory bowel disease model with engineered bacteria. Mol Ther Methods Clin Dev 2021;20:218-26. [PMID: 33426148 DOI: 10.1016/j.omtm.2020.11.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
641 Guzman-Prado Y, Samson O, Segal JP, Limdi JK, Hayee B. Vitamin D Therapy in Adults With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2020;26:1819-30. [PMID: 32385487 DOI: 10.1093/ibd/izaa087] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
642 Ramírez-Sánchez AD, Tan IL, Gonera-de Jong BC, Visschedijk MC, Jonkers I, Withoff S. Molecular Biomarkers for Celiac Disease: Past, Present and Future. Int J Mol Sci 2020;21:E8528. [PMID: 33198309 DOI: 10.3390/ijms21228528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
643 Richard L, Noller G, Derrett S, Sullivan T, Doolan-Noble F, McCombie A, Schultz M, Ho C, Stokes T. Patients' accounts of living with and managing inflammatory bowel disease in rural Southern New Zealand: a qualitative study. BMJ Open 2020;10:e041789. [PMID: 33184085 DOI: 10.1136/bmjopen-2020-041789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
644 Rosano G, Schiefke I, Göhring UM, Fabien V, Bonassi S, Stein J. A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose. J Clin Med 2020;9:E3587. [PMID: 33172157 DOI: 10.3390/jcm9113587] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
645 Dolman GE, Kennedy PTF. Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel disease. Gut 2020;69:2053-4. [PMID: 32001552 DOI: 10.1136/gutjnl-2019-319480] [Reference Citation Analysis]
646 Zingone F, Buda A, Savarino E. Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre. Dig Liver Dis 2020;52:1248-9. [PMID: 32811778 DOI: 10.1016/j.dld.2020.07.021] [Reference Citation Analysis]
647 Quera R, Simian D, Núñez P, Flores L, Figueroa C, Ibáñez P, Kronberg U, Lubascher J, Pizarro G. Are patients with inflammatory bowel disease receiving adequate immunisation? Gastroenterol Hepatol 2021;44:198-205. [PMID: 33131901 DOI: 10.1016/j.gastrohep.2020.06.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
648 Nelson A, Stewart CJ, Kennedy NA, Lodge JK, Tremelling M, Probert CS, Parkes M, Mansfield JC, Smith DL, Hold GL, Lees CW, Bridge SH, Lamb CA; UK IBD Genetics Consortium. The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation. J Crohns Colitis 2021;15:800-12. [PMID: 33119074 DOI: 10.1093/ecco-jcc/jjaa220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
649 Naseer M, Poola S, Dailey FE, Akin H, Tahan V. Implications of COVID-19 for inflammatory bowel disease: Opportunities and challenges amidst the pandemic. World J Meta-Anal 2020; 8(5): 383-399 [DOI: 10.13105/wjma.v8.i5.383] [Reference Citation Analysis]
650 Fiske J, Conley T, Sebastian S, Subramanian S. Infliximab in acute severe colitis: getting the right dose. Frontline Gastroenterol 2020;11:427-9. [PMID: 33104078 DOI: 10.1136/flgastro-2020-101407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
651 Gibson DJ, Doherty J, McNally M, Campion J, Keegan D, Keogh A, Kennedy U, Byrne K, Egan LJ, McKiernan S, MacCarthy F, Sengupta S, Sheridan J, Mulcahy HE, Cullen G, Slattery E, Kevans D, Doherty GA. Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. Frontline Gastroenterol 2020;11:441-7. [PMID: 33104766 DOI: 10.1136/flgastro-2019-101335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
652 Watanabe K. Clinical management for small bowel of Crohn's disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion. Intest Res. 2020;18:347-354. [PMID: 33131231 DOI: 10.5217/ir.2020.00032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
653 Corridoni D, Chapman T, Antanaviciute A, Satsangi J, Simmons A. Inflammatory Bowel Disease Through the Lens of Single-cell RNA-seq Technologies. Inflamm Bowel Dis 2020;26:1658-68. [PMID: 32386055 DOI: 10.1093/ibd/izaa089] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
654 Barszczewska O, Medical University of Lodz, Poland, Piechota A, Suchecka J, University of Lodz, Poland, University of Lodz, Poland. Management of the National Drug Administration Through the Use of Biosimilar Medicines. Expenditures, Numbers of Reimbursed Packages and Shares of Biosimilar Products in the Infliximab Market a Year Prior to and a Year after the Introduction of the National Drug Policy 2018–2022. PZ 2020;2/2020:121-138. [DOI: 10.7172/1644-9584.89.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
655 Nuñez F P, Quera R, Simian D, Flores L, Figueroa C, Ibañez P, Kronberg U, Lubascher J, Pizarro G. Infliximab in inflammatory bowel disease. Is premedication necessary? Gastroenterol Hepatol 2021;44:321-9. [PMID: 33386199 DOI: 10.1016/j.gastrohep.2020.07.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
656 Harmand PO, Solassol J. Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT. Genes (Basel) 2020;11:E1212. [PMID: 33081236 DOI: 10.3390/genes11101212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
657 Terjung B, Schmelz R, Ehehalt R, Klaus J, Knop J, Schwind S, Wilke T, Stallmach A. Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review. Therap Adv Gastroenterol 2020;13:1756284820952592. [PMID: 33149762 DOI: 10.1177/1756284820952592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
658 Haider SA, Yadav A, Perry C, Su L, Akanbi O, Kudaravalli P, Tripathi N, Hashim MA, Abdelsalam M, Hussein M, Elkheshen A, Patel V, Ali SE, Lamb L, Ingram K, Mayne C, Stuffelbeam AB, Flomenhoft D, Stromberg A, Barrett TA. Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820959245. [PMID: 33133239 DOI: 10.1177/1756284820959245] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
659 Gajendran M, Perisetti A, Aziz M, Raghavapuram S, Bansal P, Tharian B, Goyal H. Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned. Ann Gastroenterol. 2020;33:591-602. [PMID: 33162736 DOI: 10.20524/aog.2020.0547] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
660 Maclean A, Ashton JJ, Garrick V, Beattie RM, Hansen R. Impact of COVID-19 on the diagnosis, assessment and management of children with inflammatory bowel disease in the UK: implications for practice. BMJ Paediatr Open 2020;4:e000786. [PMID: 34192173 DOI: 10.1136/bmjpo-2020-000786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
661 Hunt RH, East JE, Lanas A, Malfertheiner P, Satsangi J, Scarpignato C, Webb GJ. COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. Dig Dis 2021;39:119-39. [PMID: 33040064 DOI: 10.1159/000512152] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 15.0] [Reference Citation Analysis]
662 Lemay JA, Yamamoto M, Kroezen Z, Shanmuganathan M, Ly R, Hart L, Pai N, Britz-McKibbin P. Lyophilized fecal short-chain fatty acid and electrolyte determination by capillary electrophoresis with indirect UV detection for assessment of pediatric inflammatory bowel disease. J Pharm Biomed Anal 2021;192:113658. [PMID: 33091761 DOI: 10.1016/j.jpba.2020.113658] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
663 Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F, Cooney R, Dart RJ, Galloway J, Gaya DR, Ghosh S, Griffiths M, Hancock L, Hansen R, Hart A, Lamb CA, Lees CW, Limdi JK, Lindsay JO, Patel K, Powell N, Murray CD, Probert C, Raine T, Selinger C, Sebastian S, Smith PJ, Tozer P, Ustianowski A, Younge L, Samaan MA, Irving PM. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut 2020;69:1769-77. [PMID: 32513653 DOI: 10.1136/gutjnl-2020-321927] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
664 Nyabanga CT, Axelrad JE, Zhang X, Barnes EL, Chang S. Adjunctive Pharmacotherapy Use in Patients With Ileal Pouch-Anal Anastomosis (IPAA). Crohn's & Colitis 360 2020;2. [DOI: 10.1093/crocol/otaa091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
665 Silva JC, Fernandes C, Rodrigues J, Fernandes S, Ponte A, Rodrigues A, Silva AP, Gomes AC, Afecto E, Correia J, Carvalho J. Endoscopic and histologic activity assessment considering disease extent and prediction of treatment failure in ulcerative colitis. Scand J Gastroenterol 2020;55:1157-62. [PMID: 32772587 DOI: 10.1080/00365521.2020.1803397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
666 Braithwaite E, Carbonell J, Kane JS, Gracie D, Selinger CP. Patients' perception of colonoscopy and acceptance of colonoscopy based IBD related colorectal cancer surveillance. Expert Rev Gastroenterol Hepatol 2021;15:211-6. [PMID: 32981385 DOI: 10.1080/17474124.2021.1829971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
667 Ahmedy OA, Ibrahim SM, Salem HH, Kandil EA. Antiulcerogenic effect of melittin via mitigating TLR4/TRAF6 mediated NF-κB and p38MAPK pathways in acetic acid-induced ulcerative colitis in mice. Chem Biol Interact 2020;331:109276. [PMID: 33002459 DOI: 10.1016/j.cbi.2020.109276] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
668 Marotto D, Atzeni F, Ardizzone S, Monteleone G, Giorgi V, Sarzi-Puttini P. Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacol Res 2020;161:105206. [PMID: 32998068 DOI: 10.1016/j.phrs.2020.105206] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
669 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
670 Kim SY, An S, Park DK, Kwon KA, Kim KO, Chung JW, Kim JH, Kim YJ. Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents. Therap Adv Gastroenterol 2020;13:1756284820961302. [PMID: 33029199 DOI: 10.1177/1756284820961302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
671 Greer MC, Cytter-Kuint R, Pratt LT, Soboleski D, Focht G, Castro DA. Clinical-stage Approaches for Imaging Chronic Inflammation and Fibrosis in Crohn's Disease. Inflamm Bowel Dis 2020;26:1509-23. [PMID: 32946578 DOI: 10.1093/ibd/izaa218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
672 Bourchany A, Gilletta De Saint-Joseph C, Breton A, Barreau F, Mas E. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases. Curr Opin Pharmacol 2020;54:51-8. [PMID: 32947075 DOI: 10.1016/j.coph.2020.07.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
673 Mourad FH, Hashash JG, Kariyawasam VC, Leong RW. Ulcerative Colitis and Cytomegalovirus Infection: From A to Z. J Crohns Colitis 2020;14:1162-71. [PMID: 32103246 DOI: 10.1093/ecco-jcc/jjaa036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
674 Hart A, Ng SC, Watkins J, Paridaens K, Edwards JO, Fullarton JR, Sonderegger YLY, Ghatnekar O, Ghosh S. The use of 5-aminosalicylates in Crohn's disease: a retrospective study using the UK Clinical Practice Research Datalink. Ann Gastroenterol 2020;33:500-7. [PMID: 32879597 DOI: 10.20524/aog.2020.0521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
675 Harrison H. Back pain in inflammatory bowel disease: could it be axial spondyloarthritis? Gastrointestinal Nursing 2020;18:34-41. [DOI: 10.12968/gasn.2020.18.7.34] [Reference Citation Analysis]
676 Hansen R, Meade S, Beattie RM, Auth MK, Croft N, Davies P, Devadason D, Doherty C, Epstein J, Howarth L, Kiparissi F, Muhammed R, Shivamurthy V, Spray C, Stanton MP, Torrente F, Urs A, Wilson D, Irving PM, Samaan M, Kammermeier J. Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut 2021;70:1044-52. [PMID: 32873696 DOI: 10.1136/gutjnl-2020-322449] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
677 Klapheke RW, Bortniker E. Obscure Gastrointestinal Bleeding Due to Colonic Source. Curr Treat Options Gastro 2020;18:394-407. [DOI: 10.1007/s11938-020-00296-w] [Reference Citation Analysis]
678 Jones K, Baker K, Speight RA, Thompson NP, Tew GA. Randomised clinical trial: combined impact and resistance training in adults with stable Crohn's disease. Aliment Pharmacol Ther 2020;52:964-75. [PMID: 33119156 DOI: 10.1111/apt.16002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
679 Anikhindi SA, Kumar A, Arora A. COVID-19 in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2020;14:1187-93. [PMID: 32856955 DOI: 10.1080/17474124.2020.1816822] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
680 Miller C, Emmanuel A, Zarate-Lopez N, Taylor S, Bloom S. Constipation in ulcerative colitis: pathophysiology and practical management. Frontline Gastroenterol 2021;12:493-9. [PMID: 34712467 DOI: 10.1136/flgastro-2020-101566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
681 Eskander A, Saadah OI, Abdelrazek AA, Mosli M, Alsufyani HA, Meshaal S, Hasnoon AM, Tarek S, Abdelgalil A. Prevalence of Celiac Disease in Children and Adolescents With Inflammatory Bowel Disease. Cureus 2020;12:e9977. [PMID: 32983679 DOI: 10.7759/cureus.9977] [Reference Citation Analysis]
682 Zanelli J, Chandrapalan S, Patel A, Arasaradnam RP. The impact of pre-operative biologic therapy on post-operative surgical outcomes in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2020;13:1756284820937089. [PMID: 33281933 DOI: 10.1177/1756284820937089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
683 Yue B, Yu ZL, Lv C, Geng XL, Wang ZT, Dou W. Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease. World J Gastroenterol 2020; 26(30): 4378-4393 [PMID: 32874052 DOI: 10.3748/wjg.v26.i30.4378] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
684 Adegbola SO, Sahnan K, Twum-Barima C, Iqbal N, Reza L, Lung P, Warusavitarne J, Tozer P, Hart A. Current review of the management of fistulising perianal Crohn's disease. Frontline Gastroenterol 2021;12:515-23. [PMID: 34712470 DOI: 10.1136/flgastro-2020-101489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
685 Phisalprapa P, Kositamongkol C, Limsrivilai J, Aniwan S, Charatcharoenwitthaya P, Pisespongsa P, Kitiyakara T, Treepongkaruna S, Chaiyakunapruk N. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand. J Med Econ 2020;23:1302-10. [PMID: 32729347 DOI: 10.1080/13696998.2020.1803889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
686 Matsuda K, Hashiguchi Y, Asako K, Okada Y, Ohno K, Tsukamoto M, Fukushima Y, Shimada R, Ozawa T, Hayama T, Nozawa K, Fukagawa T, Kikuchi Y, Sasajima Y. A young woman who developed ascending colon cancer 2 years after the onset of ulcerative colitis. Clin J Gastroenterol 2020;13:1189-95. [PMID: 32780275 DOI: 10.1007/s12328-020-01207-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
687 Naganuma M. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis. J Gastroenterol 2020;55:1013-22. [PMID: 32778960 DOI: 10.1007/s00535-020-01713-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
688 Vespa E, Furfaro F, Allocca M, Fiorino G, Correale C, Gilardi D, Argollo M, Zilli A, Zacharopoulou E, Loy L, Danese S. Endoscopy after surgery in inflammatory bowel disease: Crohn's disease recurrence and pouch surveillance. Expert Rev Gastroenterol Hepatol 2020;14:829-41. [PMID: 32758015 DOI: 10.1080/17474124.2020.1807325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
689 Candia R, Bravo-Soto GA, Monrroy H, Hernandez C, Nguyen GC. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2020;8:CD012328. [PMID: 32746500 DOI: 10.1002/14651858.CD012328.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
690 Arieira C, Dias de Castro F, Cúrdia Gonçalves T, Moreira MJ, Cotter J. Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine? Scand J Gastroenterol 2020;55:920-3. [PMID: 32689833 DOI: 10.1080/00365521.2020.1792543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
691 Segal JP, Smith PJ. Editorial: quality improvement project to identify factors associated with a delay in IBD diagnosis. Aliment Pharmacol Ther 2020;52:733-4. [PMID: 33545748 DOI: 10.1111/apt.15949] [Reference Citation Analysis]
692 Scheffe N, Schreiner R, Thomann A, Findeisen P. Development of a Mass Spectrometry-Based Method for Quantification of Ustekinumab in Serum Specimens. Therapeutic Drug Monitoring 2020;42:572-577. [DOI: 10.1097/ftd.0000000000000734] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
693 Garrido I, Lopes S, Macedo G. Inflammatory Bowel Disease Management in a Major Referral Center During COVID-19 Pandemic. Inflamm Bowel Dis 2020;26:e114-5. [PMID: 32737966 DOI: 10.1093/ibd/izaa204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
694 Larussa T, Flauti D, Abenavoli L, Boccuto L, Suraci E, Marasco R, Imeneo M, Luzza F. The Reality of Patient-Reported Outcomes of Health-Related Quality of Life in an Italian Cohort of Patients with Inflammatory Bowel Disease: Results from a Cross-Sectional Study. J Clin Med 2020;9:E2416. [PMID: 32731482 DOI: 10.3390/jcm9082416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
695 Long Y, Zhao X, Liu C, Xia C, Liu C. Activated inducible co-stimulator-positive programmed cell death 1-positive follicular helper T cells indicate disease activity and severity in ulcerative colitis patients. Clin Exp Immunol 2020;202:106-18. [PMID: 32621310 DOI: 10.1111/cei.13485] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
696 Burisch J, Bergemalm D, Halfvarson J, Domislovic V, Krznaric Z, Goldis A, Dahlerup JF, Oksanen P, Collin P, de Castro L, Hernandez V, Turcan S, Belousova E, D'Incà R, Sartini A, Valpiani D, Giannotta M, Misra R, Arebi N, Duricova D, Bortlik M, Gatt K, Ellul P, Pedersen N, Kjeldsen J, Andersen KW, Andersen V, Katsanos KH, Christodoulou DK, Sebastian S, Barros L, Magro F, Midjord JM, Nielsen KR, Salupere R, Kievit HA, Kiudelis G, Kupčinskas J, Fumery M, Gower-Rousseau C, Kaimakliotis IP, Schwartz D, Odes S, Lakatos L, Lakatos PL, Langholz E, Munkholm P; Epi-IBD group. The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study. United European Gastroenterol J 2020;8:949-60. [PMID: 32715989 DOI: 10.1177/2050640620945949] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
697 Malesza IJ, Malesza M, Krela-Kaźmierczak I, Zielińska A, Souto EB, Dobrowolska A, Eder P. Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. Int J Mol Sci 2020;21:E5223. [PMID: 32718006 DOI: 10.3390/ijms21155223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
698 Naeck-Boolauky P, Adio J, Burch J. Review of normal gastrointestinal tract, ulcerative colitis, proctitis and rectal medication adherence. Br J Nurs 2020;29:805-11. [PMID: 32697644 DOI: 10.12968/bjon.2020.29.14.805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
699 Jentzer A, Veyrard P, Roblin X, Saint-Sardos P, Rochereau N, Paul S, Bourlet T, Pozzetto B, Pillet S. Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). Microorganisms 2020;8:E1078. [PMID: 32698383 DOI: 10.3390/microorganisms8071078] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
700 Gorrepati VS, Soriano C, Johri A, Dalessio S, Stuart A, Koltun W, Tinsley A, Clarke K, Williams E, Coates M. Abdominal Pain and Anxious or Depressed State Are Independently Associated With Weight Loss in Inflammatory Bowel Disease. Crohns Colitis 360 2020;2:otaa047. [PMID: 32671337 DOI: 10.1093/crocol/otaa047] [Reference Citation Analysis]
701 Palchaudhuri S, Albenberg L, Lewis JD. Diet Recommendations for Hospitalized Patients With Inflammatory Bowel Disease: Better Options Than Nil Per Os. Crohns Colitis 360 2020;2:otaa059. [PMID: 33954288 DOI: 10.1093/crocol/otaa059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
702 Barnhill MS, Steinberg JM, Jennings JJ, Lewis JH. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Curr Gastroenterol Rep 2020;22:47. [PMID: 32671616 DOI: 10.1007/s11894-020-00781-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
703 Zhang Z, Hyun JE, Thiesen A, Park H, Hotte N, Watanabe H, Higashiyama T, Madsen KL. Sex-Specific Differences in the Gut Microbiome in Response to Dietary Fiber Supplementation in IL-10-Deficient Mice. Nutrients 2020;12:E2088. [PMID: 32679670 DOI: 10.3390/nu12072088] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
704 Snell A, Segal J, Limdi J, Banerjee R. Inflammatory bowel disease in India: challenges and opportunities. Frontline Gastroenterol 2021;12:390-6. [DOI: 10.1136/flgastro-2020-101500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
705 Wall CL, McCombie A, Mulder R, Day AS, Gearry RB. Adherence to exclusive enteral nutrition by adults with active Crohn's disease is associated with conscientiousness personality trait: a sub-study. J Hum Nutr Diet 2020;33:752-7. [PMID: 32627898 DOI: 10.1111/jhn.12787] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
706 Finucci A, Ditto MC, Parisi S, Borrelli R, Priora M, Realmuto C, Fusaro E. Rheumatic manifestations in inflammatory bowel disease. Minerva Gastroenterol (Torino) 2021;67:79-90. [PMID: 32623869 DOI: 10.23736/S2724-5985.20.02726-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
707 Yu M, Ye Z, Chen Y, Qin T, Kou J, Tian D, Xiao F. Questionnaire assessment helps the self-management of patients with inflammatory bowel disease during the outbreak of Coronavirus Disease 2019. Aging (Albany NY) 2020;12:12468-78. [PMID: 32628131 DOI: 10.18632/aging.103525] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
708 Kabir M, Fofaria R, Arebi N, Bassett P, Tozer PJ, Hart AL, Thomas-Gibson S, Humphries A, Suzuki N, Saunders B, Warusavitarne J, Faiz O, Wilson A. Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present). Aliment Pharmacol Ther 2020;52:5-19. [PMID: 32432797 DOI: 10.1111/apt.15778] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
709 Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA, Spain L, Yousaf N, Hunter N, Eldridge L, Pavlidis P, Irving P, Hayee B, Turajlic S, Larkin J, Lindsay JO, Gore M. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol 2020;5:679-97. [PMID: 32553146 DOI: 10.1016/S2468-1253(20)30014-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
710 Neumann H, Emura F, Bokemeyer B, Guda N, Tajiri H, Matsumoto T, Rubin DT. Practical advice for management of inflammatory bowel diseases patients during the COVID-19 pandemic: World Endoscopy Organization Statement. Dig Endosc 2020;32:658-62. [PMID: 32369646 DOI: 10.1111/den.13712] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
711 Chapman TP, Frias Gomes C, Louis E, Colombel JF, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:73-84. [PMID: 32452591 DOI: 10.1111/apt.15771] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
712 Liu S, Zhao W, Lan P, Mou X. The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. Protein Cell 2021;12:331-45. [PMID: 32601832 DOI: 10.1007/s13238-020-00745-3] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 19.7] [Reference Citation Analysis]
713 Schreiner P, Mueller NJ, Fehr J, Maillard MH, Brand S, Michetti P, Schoepfer A, Restellini S, Vulliemoz M, Vavricka SR, Juillerat P, Rogler G, Biedermann L. Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. J Crohns Colitis 2020:jjaa132. [PMID: 32592587 DOI: 10.1093/ecco-jcc/jjaa132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
714 Richard L, Noller G, Derrett S, Sullivan T, Doolan-noble F, Mccombie A, Schultz M, Ho C, Stokes T. Patients’ accounts of living with and managing Inflammatory Bowel Disease in rural Southern New Zealand: a qualitative study.. [DOI: 10.1101/2020.06.25.20133421] [Reference Citation Analysis]
715 Premjeyanth V, Shipman AR, Shipman KE. Faecal calprotectin in dermatology practice. Clin Exp Dermatol 2020;45:831-5. [DOI: 10.1111/ced.14307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
716 Hamilton B, Green H, Heerasing N, Hendy P, Moore L, Chanchlani N, Walker G, Bewshea C, Kennedy NA, Ahmad T, Goodhand J. Incidence and prevalence of inflammatory bowel disease in Devon, UK. Frontline Gastroenterol 2021;12:461-70. [PMID: 34712463 DOI: 10.1136/flgastro-2019-101369] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
717 D'Amico F, Baumann C, Rousseau H, Danese S, Peyrin-Biroulet L. Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. J Crohns Colitis 2020;14:710-8. [PMID: 31901097 DOI: 10.1093/ecco-jcc/jjz214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
718 Su S, Shen J, Zhu L, Qiu Y, He JS, Tan JY, Iacucci M, Ng SC, Ghosh S, Mao R, Liang J. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therap Adv Gastroenterol 2020;13:1756284820934626. [PMID: 32595762 DOI: 10.1177/1756284820934626] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
719 Toyonaga T, Steinbach EC, Keith BP, Barrow JB, Schaner MR, Wolber EA, Beasley C, Huling J, Wang Y, Allbritton NL, Chaumont N, Sadiq TS, Koruda MJ, Jain A, Long MD, Barnes EL, Herfarth HH, Isaacs KL, Hansen JJ, Shanahan MT, Rahbar R, Furey TS, Sethupathy P, Sheikh SZ. Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier Integrity in Patients With Crohn's Disease. Cell Mol Gastroenterol Hepatol 2020;10:779-96. [PMID: 32561494 DOI: 10.1016/j.jcmgh.2020.06.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
720 Kousgaard SJ, Nielsen HL, Kirk KF, Thorlacius-Ussing O. Consumption of yoghurt favours remission after faecal microbiota transplantation for chronic pouchitis. Int J Colorectal Dis 2020;35:1955-8. [PMID: 32504332 DOI: 10.1007/s00384-020-03648-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
721 Matsuoka K. NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease. Intest Res 2020;18:275-81. [PMID: 32482022 DOI: 10.5217/ir.2020.00002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
722 Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, Vetrano S, Vande Casteele N. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:323-37. [PMID: 32203403 DOI: 10.1038/s41575-020-0273-0] [Cited by in Crossref: 188] [Cited by in F6Publishing: 179] [Article Influence: 62.7] [Reference Citation Analysis]
723 Wen Y, Niu J, Zhang F, Wu J, Li M, Sun Y, Wang W, Xia S, Tan Y, Wang K, Miao Y. Heat shock transcription factor 2 predicts mucosal healing and promotes mucosal repair of ulcerative colitis. Scand J Gastroenterol 2020;55:677-86. [PMID: 32538201 DOI: 10.1080/00365521.2020.1774924] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
724 Soop M. Challenges in Crohn's disease: Intestinal failure and short bowel syndrome in Crohn's disease. Seminars in Colon and Rectal Surgery 2020;31:100749. [DOI: 10.1016/j.scrs.2020.100749] [Reference Citation Analysis]
725 Gibson DJ, Doherty GA. Fast and Curious: An Algorithmic Approach to Infliximab Dosing in Acute Severe Ulcerative Colitis. Dig Dis Sci 2020;65:1584-5. [PMID: 31970607 DOI: 10.1007/s10620-020-06084-x] [Reference Citation Analysis]
726 Zingone F, Buda A, Savarino EV. Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak. Dig Liver Dis 2020;52:604-5. [PMID: 32360133 DOI: 10.1016/j.dld.2020.04.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
727 Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, Parkes M, Patel K, Pollok RC, Powell N, Probert CS, Raine T, Sebastian S, Selinger C, Smith PJ, Stansfield C, Younge L, Lindsay JO, Irving PM, Lees CW. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2020;69:984-90. [PMID: 32303607 DOI: 10.1136/gutjnl-2020-321244] [Cited by in Crossref: 183] [Cited by in F6Publishing: 160] [Article Influence: 61.0] [Reference Citation Analysis]
728 Soulakova JN, Su L, Crockett LJ. Smokers’ reports on receiving a doctor’s advice to quit smoking; receiving the advice is more prevalent among smokers with Crohn’s Disease relative to smokers with Ulcerative Colitis. Preventive Medicine Reports 2020;18:101091. [DOI: 10.1016/j.pmedr.2020.101091] [Reference Citation Analysis]
729 Crespo J, Andrade R, Alberca de las Parras F, Balaguer F, Barreiro-de Acosta M, Bujanda L, Gutiérrez A, Jorquera F, Iglesias-garcía J, Sánchez-yagüe A, Calleja JL. Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. Gastroenterología y Hepatología (English Edition) 2020;43:332-347. [DOI: 10.1016/j.gastre.2020.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
730 Sulz MC, Duetschler J, Seibold F. Therapiealgorithmen für die Behandlung des Morbus Crohn im klinischen Alltag. Schweiz Gastroenterol 2020;1:51-64. [DOI: 10.1007/s43472-020-00009-9] [Reference Citation Analysis]
731 Mintz MJ, Ananthakrishnan AN. Phenotype and Natural History of Inflammatory Bowel Disease in Patients With Concomitant Eosinophilic Esophagitis. Inflamm Bowel Dis 2021;27:469-75. [PMID: 32430501 DOI: 10.1093/ibd/izaa094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
732 Inagaki Y, Azuma K, Nakamura Y, Kouno S, Matsuda Y, Atagi S. Meaningful Symptoms of Immune Checkpoint Inhibitor Therapy-Related Gastrointestinal Adverse Events in Patients With Inflammatory Bowel Disease. J Clin Oncol 2020;38:1748-9. [PMID: 32250716 DOI: 10.1200/JCO.20.00033] [Reference Citation Analysis]
733 Hsieh PC, Cheng CF, Wu CW, Tzeng IS, Kuo CY, Hsu PS, Lee CT, Yu MC, Lan CC. Combination of Acupoints in Treating Patients with Chronic Obstructive Pulmonary Disease: An Apriori Algorithm-Based Association Rule Analysis. Evid Based Complement Alternat Med 2020;2020:8165296. [PMID: 32595739 DOI: 10.1155/2020/8165296] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
734 D'Amico F, Fiorino G, Furfaro F, Allocca M, Roda G, Loy L, Zilli A, Solitano V, Peyrin-Biroulet L, Danese S. Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Rev Gastroenterol Hepatol 2020;14:765-73. [PMID: 32427002 DOI: 10.1080/17474124.2020.1772057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
735 Selinger CP, Nelson-Piercy C, Fraser A, Hall V, Limdi J, Smith L, Smith M, Nasur R, Gunn M, King A, Mohan A, Mulgabal K, Kent A, Kok KB, Glanville T. IBD in pregnancy: recent advances, practical management. Frontline Gastroenterol 2021;12:214-24. [PMID: 33912333 DOI: 10.1136/flgastro-2019-101371] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
736 Jiang P, Lai S, Wu S, Zhao XM, Chen WH. Host DNA contents in fecal metagenomics as a biomarker for intestinal diseases and effective treatment. BMC Genomics 2020;21:348. [PMID: 32393180 DOI: 10.1186/s12864-020-6749-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
737 Arslan F, Vahaboğlu H. Cytomegalovirus and inflammatory bowel disease; reconsidering a 'result or reason dilemma' in terms of viral pathogenesis and medical ethics. Expert Rev Gastroenterol Hepatol 2020;14:307-9. [PMID: 32228242 DOI: 10.1080/17474124.2020.1745631] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
738 Pülat H, Yalaki S. Can red blood cell distribution width (RDW) predict clinical and endoscopic activity in ulcerative colitis patients? Journal of Surgery and Medicine 2020. [DOI: 10.28982/josam.712289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
739 Martínez V, Iriondo De-Hond A, Borrelli F, Capasso R, Del Castillo MD, Abalo R. Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals? Int J Mol Sci 2020;21:E3067. [PMID: 32357565 DOI: 10.3390/ijms21093067] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 23.0] [Reference Citation Analysis]
740 Crespo J, Andrade R, Alberca de Las Parras F, Balaguer F, Barreiro-de Acosta M, Bujanda L, Gutiérrez A, Jorquera F, Iglesias-García J, Sánchez-Yagüe A, Calleja JL. Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. Gastroenterol Hepatol 2020;43:332-47. [PMID: 32409107 DOI: 10.1016/j.gastrohep.2020.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
741 Prasad SS, Keely S, Talley NJ, Kairuz T, Walker MM. Pharmacists' Confidence in Managing Patients with Inflammatory Bowel Disease. Pharmacy (Basel) 2020;8:E68. [PMID: 32316504 DOI: 10.3390/pharmacy8020068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
742 Łodyga M, Eder P, Dobrowolska A, Reguła J, Rydzewska G. The position statement of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic. Prz Gastroenterol 2020;15:85-8. [PMID: 32550938 DOI: 10.5114/pg.2020.94544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
743 Queiroz NSF, Barros LL, Azevedo MFC, Oba J, Sobrado CW, Carlos AS, Milani LR, Sipahi AM, Damião AOMC. Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance. Clinics (Sao Paulo) 2020;75:e1909. [PMID: 32321117 DOI: 10.6061/clinics/2020/e1909] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
744 Iacucci M, Cannatelli R, Labarile N, Mao R, Panaccione R, Danese S, Kochhar GS, Ghosh S, Shen B. Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. Lancet Gastroenterol Hepatol 2020;5:598-606. [PMID: 32305075 DOI: 10.1016/S2468-1253(20)30119-9] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 20.7] [Reference Citation Analysis]
745 Choi YI, Kim YJ, Chung JW, Kim KO, Kim H, Park RW, Park DK. Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study. JMIR Med Inform 2020;8:e15124. [PMID: 32293578 DOI: 10.2196/15124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
746 Curtius K, Kabir M, Bakir IA, Choi CR, Hartono J, Johnson M, East JE, Lindsay JO, Vega R, Thomas-gibson S, Wilson A, Graham TA, Hart A, Oxford IBD Cohort Study Investigators. Multi-centre derivation and validation of a colitis-associated colorectal cancer risk prediction web-tool.. [DOI: 10.1101/2020.04.10.20057869] [Reference Citation Analysis]
747 Mehta P, Manson JJ. What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis? Front Immunol 2020;11:589. [PMID: 32318070 DOI: 10.3389/fimmu.2020.00589] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
748 Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease.Nat Rev Dis Primers. 2020;6:22. [PMID: 32242028 DOI: 10.1038/s41572-020-0156-2] [Cited by in Crossref: 162] [Cited by in F6Publishing: 172] [Article Influence: 54.0] [Reference Citation Analysis]
749 Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol 2021;12:207-13. [PMID: 33907617 DOI: 10.1136/flgastro-2019-101288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
750 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointest Endosc 2020;91:733-45. [PMID: 31786161 DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
751 Younge L, Mason I, Kapasi R. Specialist inflammatory bowel disease nursing in the UK: current situation and future proofing. Frontline Gastroenterol 2021;12:169-74. [PMID: 33907615 DOI: 10.1136/flgastro-2019-101354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
752 Harris RE, Duncan H, Buchanan E, Cardigan T, Garrick V, Curtis L, Gervais L, Barclay A, Haddock G, Hansen R, Tayler R, Walker G, Russell RK. Prehabilitation: The Impact of Preoperative Exclusive Enteral Nutrition on Paediatric Patients With Crohn Disease. J Pediatr Gastroenterol Nutr 2020;70:503-7. [PMID: 31880668 DOI: 10.1097/MPG.0000000000002595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
753 D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. Review article: faecal calprotectin and histologic remission in ulcerative colitis. Aliment Pharmacol Ther 2020;51:689-98. [PMID: 32048751 DOI: 10.1111/apt.15662] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
754 Yu M, Ye Z, Chen Y, Qin T, Kou J, Tian D, Xiao F. Questionnaire assessment helps the self-management of patients with inflammatory bowel disease during the outbreak of Coronavirus Disease 2019.. [DOI: 10.1101/2020.03.25.20043364] [Reference Citation Analysis]
755 Soop M, Khan H, Nixon E, Teubner A, Abraham A, Carlson G, Lal S. Causes and Prognosis of Intestinal Failure in Crohn's Disease: An 18-year Experience From a National Centre. J Crohns Colitis 2020;14:1558-64. [PMID: 32215559 DOI: 10.1093/ecco-jcc/jjaa060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
756 Zingone F, Savarino EV. Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. Lancet Gastroenterol Hepatol. 2020;5:525. [PMID: 32220656 DOI: 10.1016/s2468-1253(20)30085-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
757 Avery P. Developments and challenges of e-health strategies for people with inflammatory bowel disease. British Journal of Healthcare Management 2020;26:73-6. [DOI: 10.12968/bjhc.2020.0010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
758 Sebastian S, Myers S. Letter: infliximab induction regimens in steroid-refractory acute severe colitis-a propensity score analysis. Authors' reply. Aliment Pharmacol Ther 2020;51:666-7. [PMID: 32100353 DOI: 10.1111/apt.15647] [Reference Citation Analysis]
759 Sanderson J, Irving P. Ulcerative colitis. Oxford Textbook of Medicine 2020. [DOI: 10.1093/med/9780198746690.003.0307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
760 Parkes M, Raine T. Crohn’s disease. Oxford Textbook of Medicine 2020. [DOI: 10.1093/med/9780198746690.003.0306] [Reference Citation Analysis]
761 Gibson DJ, Ward MG, Rentsch C, Friedman AB, Taylor KM, Sparrow MP, Gibson PR. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:612-28. [PMID: 31961001 DOI: 10.1111/apt.15643] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
762 Toyonaga T, Keith BP, Barrow JB, Schaner MS, Wolber EA, Beasley C, Huling J, Wang Y, Allbritton NL, Chaumont N, Sadiq TS, Koruda MJ, Rahbar R, Furey TS, Sethupathy P, Sheikh SZ. Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier integrity and is associated with a poor clinical outcome in Crohn’s disease.. [DOI: 10.1101/2020.02.21.960070] [Reference Citation Analysis]
763 Selinger CP. Biologicals are the main contributor to cost of care for IBD: a European perspective. Lancet Gastroenterol Hepatol 2020;5:421-2. [PMID: 32061323 DOI: 10.1016/S2468-1253(20)30042-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
764 Mullish BH, Quraishi MN, Segal JP, Ianiro G, Iqbal TH. The gut microbiome: what every gastroenterologist needs to know. Frontline Gastroenterol 2021;12:118-27. [PMID: 33613943 DOI: 10.1136/flgastro-2019-101376] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
765 Arkteg CB, Goll R, Gundersen MD, Anderssen E, Fenton C, Florholmen J. Mucosal gene transcription of ulcerative colitis in endoscopic remission. Scand J Gastroenterol 2020;55:139-47. [PMID: 31918598 DOI: 10.1080/00365521.2019.1710245] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
766 Nigam GB, Nayeemuddin S, Kontopantelis E, Hayee B, Limdi JK. UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Frontline Gastroenterol 2021;12:22-9. [PMID: 33493247 DOI: 10.1136/flgastro-2019-101372] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
767 Shen B. Inflammatory bowel disease–associated neoplasia. Atlas of Endoscopy Imaging in Inflammatory Bowel Disease 2020. [DOI: 10.1016/b978-0-12-814811-2.00012-8] [Reference Citation Analysis]
768 Patel RN, Nigam GB, Jatale RG, Desai D, Makharia G, Ahuja V, Limdi JK. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. Indian J Gastroenterol 2020;39:176-85. [PMID: 32483692 DOI: 10.1007/s12664-020-01047-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
769 Hart A. Commentary: safety of anti-TNF use in pregnancy. Aliment Pharmacol Ther 2020;51:205-6. [PMID: 31850565 DOI: 10.1111/apt.15548] [Reference Citation Analysis]
770 Sebastian S. Letter: should we intensify infliximab in acute severe ulcerative colitis? Author's reply. Aliment Pharmacol Ther 2020;51:188. [PMID: 31850578 DOI: 10.1111/apt.15569] [Reference Citation Analysis]
771 Gill N, Pietrosanu M, Gniadecki R. Risk of Inflammatory Bowel Disease in Psoriasis Patients Treated with Anti-Interleukin-17 Agents: A Bayesian Metaanalysis.. [DOI: 10.1101/19012179] [Reference Citation Analysis]
772 Segal JP, Htet HMT, Limdi J, Hayee B. How to manage IBD in the 'elderly'. Frontline Gastroenterol 2020;11:468-77. [PMID: 33101625 DOI: 10.1136/flgastro-2019-101218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
773 Sebastian S, Kennedy NA, Subramanian S, Raine T. Editorial: accelerated infliximab induction-it's time to settle the debate! Authors' reply. Aliment Pharmacol Ther 2019;50:1061-2. [PMID: 31625193 DOI: 10.1111/apt.15498] [Reference Citation Analysis]
774 Sebastian S, Lisle J, Subramanian S, Dhar A, Shenoy A, Limdi J, Butterworth J, Allen PB, Samuel S, Moran G, Shenderey R, Parkes G, Raine T, Lobo AJ, Kennedy NA. Practice pattern variability in the management of acute severe colitis: a UK provider survey. Frontline Gastroenterol 2020;11:272-9. [PMID: 32587670 DOI: 10.1136/flgastro-2019-101277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
775 Kapasi R, Glatter J, Lamb CA, Acheson AG, Andrews C, Arnott ID, Barrett KJ, Bell G, Bhatnagar G, Bloom S, Brookes MJ, Brown SR, Burch N, Burman A, Crook K, Cummings JF, Davies J, Demick A, Epstein J, Faiz O, Feakins R, Fletcher M, Garrick V, Jaffray B, Johnson M, Keetarut K, Limdi J, Meade U, Muhammed R, Murdock A, Posford N, Rowse G, Shaw I, St Clair Jones A, Taylor S, Weaver S, Younge L, Hawthorne AB. Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK. Frontline Gastroenterol 2020;11:178-87. [PMID: 32419908 DOI: 10.1136/flgastro-2019-101260] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
776 Na S. Asian Physician's Perspectives on Biosimilars in Inflammatory Bowel Disease: Are We Ready to Use? Korean J Gastroenterol 2019;74:301. [DOI: 10.4166/kjg.2019.74.6.301] [Reference Citation Analysis]